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Title: TMC Biodesign: The Design and Implementation of a Product Development
Framework for Successful Innovation in the Healthcare Industry.
Major Professor: Eric Nauman, School of Mechanical Engineering
It is not uncommon to see both academic and industry institutions speed through, or even
outright skip, the different stages of innovation. Industry often considers early stages of
innovation, such as needs identification, to be too risky, or a waste of time and resources.
They tend to focus more on improving validated solutions and creating incremental
changes, resulting in products that lack innovation. Academia often considers aspects of
the innovation process to be too commercial to consider during their research initiatives,
which often results in the development of great technologies that cannot be implemented
due to their lack of commercial viability, resulting in a great deal of wasted time and capital.
There is a stark need to train everyone involved in the product development process to
properly appreciate and implement all stages of the innovation cycle. Engineers,
physicians, and business-minded people need to be taught how to come together to solve
healthcare’s biggest problems. They need to learn how to turn technological developments
into commercially viable products that solve customer needs. In partnership with the Texas
Medical center, I present in this research a framework for providing future medical
technology leaders the experience required to create transformational solutions to
healthcare’s biggest challenges. I provide a structured process for innovating in the
complex healthcare industry, beginning with first-hand observations of clinical needs and
ending with a plan for commercializing a medical product. This thesis is intended to
describe the proposed framework for medical device innovation and evaluate its potential
for success through participation in the inaugural fellowship.

1

CHAPTER 1: INTRODUCTION

Healthcare product development is simply defined as the development of a drug or a
biologic or medical device. However, this process is anything but simple. It is a long and
complex undertaking that requires significant understanding of the stakeholders involved,
of which there are often many. It also requires access to large amounts of capital and a
strong understanding of how to navigate the complex regulations in place for medical
devices. Due to the complex nature of the industry, there is an increasing need for
innovation and a change in the way that product development is led and implemented.
Innovation can be defined as “the design, invention, development, and/or
implementation of new or altered products, services, processes, systems, organizational
structures, or business models for the purpose of creating new value for customers and
financial returns for the firm” [1]. Typically, there are two types of innovations, as
categorized by their impact on the stakeholders involved: incremental innovation and
disruptive innovation. Over the past few decades, there have been many advancements
made in healthcare thanks to advances in technology and pharmaceuticals. However, the
majority of those innovations have focused on developing more targeted drugs or more
precise surgical tools and diagnostic devices. While these inventions have been successful
in significantly affecting medical treatment and have been used to save many lives, many
of them have been relatively narrow in focus and incremental in nature [2]. With rising
pressure to bring healthcare costs down while improving patient outcomes and quality of
life, the need for innovation in the healthcare industry is stark. Healthcare organizations
face unprecedented challenges compared to those in other industries, and a changing
landscape is proving that innovation is increasingly necessary. The old method of fee-forservice medical care is changing to one that is increasingly focused on the patient and
patient outcomes. More power is being given to the patients to allow them to take charge
of their health, changes are being made to who has decision-making and purchasing power
in hospitals, and lastly, there are significant changes being made in regulation and
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reimbursement. All of these shifts are leading to new and complex challenges within the
healthcare system, significantly increasing the need for innovation.
Due to the complexity of the healthcare industry, and the large number of
stakeholders involved with a typical medical innovation, a user-centered design approach
has become extremely important. User-centered design helps to guarantee “the
development of high quality and well-designed devices that are in tune with the patient and
user needs” [3]. It ensures that the design process comprehensively considers the setting in
which the product will be used, the work flow of the users, and the specific needs of the
individual users [4]. However, fully implementing a user-centered design approach,
requires formal training in both human factors and engineering methodologies, as well as
an understanding of business strategy and commercialization [5]. Therefore, it must be a
team effort, involving people of cross-functional backgrounds.
The importance and value of focusing on user needs has been recognized by many,
and research has shown that implementing a user-based approach in healthcare innovation
can lead to a number of benefits, including improved patient safety, compliance, and health
outcomes [6–7]. Additional studies have shown that adopting a more user-centered design
approach in healthcare can also lead to higher levels of patient and physician satisfaction
[8]. Lastly, adopting a more human-centered design approach can substantially reduce
device development time by allowing usability issues to be identified and addressed prior
to launch, avoiding costly design changes and product recalls [9-10].
However, simply focusing on user-centered design is not enough. The shift in
demand for patient-centered healthcare, in addition to the other aforementioned changes,
requires a complete change in the way we have been approaching innovation in the
healthcare space. More focus needs to be placed on defining the right need, and
implementing strategies that allow for quick and effective product development, as cost is
becoming a larger factor and patient outcomes are becoming more important. It is
necessary to consider and understand all potential risks associated with bringing a product
to market before entering into the development and commercialization stages. Therefore,
there is a growing need to develop a comprehensive framework that can be implemented
to foster innovation and utilize proven design-thinking methodologies, user-centered
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design, and needs-based innovation frameworks to ensure value and successful creation of
a medical product. The framework needs to teach innovators how to identify and solve the
real and complex problems that are arising in the ever-changing healthcare industry.
Although there has been more focus placed on using product development
processes and user-centered design frameworks and applying them to healthcare in recent
years, there has been relatively low success rates and low adherence due to the somewhat
fragmented nature of the different frameworks. This brings into sharp and immediate focus
the need for a better method for innovating in the healthcare industry, as well as a better
understanding of how to successfully implement a comprehensive product development
process for the healthcare industry.
1.1: Research Aims
1. This thesis aims to develop and launch a comprehensive framework that will teach
and enable collaboration at all stages of the design process between
interdisciplinary teams and end users in order to design a successful product in the
healthcare industry.
2. I also aim to test the model by participating in and completing the proposed
program and identifying the key factors for enabling success within the process.
1.2: Background
1.2.1: The challenge of innovating in the healthcare industry
The healthcare industry is consistently recognized as one of the most difficult
industries to innovate in, primarily because of its complexity, significant regulations, and
number of end-users or stakeholders [11]. In addition to all of the steps required in order
to develop a product that will be accepted by customers, companies in the healthcare
industry have to jump through multiple hoops to even get their product approved and on
the market.
Additionally, medical companies have to develop products for consumers who are
notoriously resistant to change. Specifically, in the healthcare sector, consumers
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(physicians, nurses, healthcare administrators, etc.) are often against trying new products
or ideas and are resistant to anything that disrupts their normal workflow, even if it could
increase efficiency. Oftentimes innovators believe that their product is so good that they
can overcome this issue and convince the customers to change their ways to fit the
company’s vision. However, this thinking is very unrealistic and often leads to failure.
Lastly, the healthcare industry is so large and complex that there are often multiple
stakeholders that have to be considered, each with competing needs and interests. This
significantly increases the challenges associated with developing a product that meets the
customers’ needs and will be accepted once on the market.
Due to the complex issues mentioned above, developing and commercializing a
healthcare solution can be extremely challenging, and large amounts of time and money
are spent each year developing solutions that are unable to succeed in this marketplace.
1.2.2: Reasons for the failure of healthcare products and startups
Each year, large healthcare companies spend significant amounts of time and money on
projects possessing substantial amounts of uncertainty concerning technical feasibility,
market fit and acceptance, and willingness to pay [12]. Similarly, many healthcare startups
fail each year due to significant uncertainty in the same categories, taking millions in
investment capital down with them.
These failures can often be attributed more specifically to a lack of understanding
regarding the following: the need or problem, the product market fit, the competition and
solutions on the market, the key stakeholders and their needs, the payment landscape in the
healthcare industry, and the regulations in the industry. Although startups fail in other
industries due to the same issues, the complexity of the healthcare system makes each of
these issues much more challenging to address. For example, the healthcare industry has
many stakeholders, often with conflicting needs, making innovating in this space much
more challenging compared to other industries. Innovators often become trapped into
thinking that they have to develop a product that meets the needs of all stakeholders rather
than focusing on key stakeholders and tailoring the product to those key stakeholders. By
attempting to please all stakeholders in the healthcare system, the innovator ends up
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creating a generalized product that fails to address the needs of any of the stakeholders well
enough to create value, and the company eventually fails due to lack of product market fit
and a lack of willingness to pay.
Issues also commonly arise when developing business models for healthcare
products. Reimbursement plays a large role in determining the pricing strategy for many
healthcare products. Understanding the reimbursement landscape and how a product could
be reimbursed can be very challenging, and oftentimes, healthcare startups overlook this
during early stages of development and push it off until commercialization. This leads to
issues when trying to commercialize the product, as the majority of hospitals and healthcare
systems will not purchase products that increase their cost or are not highly reimbursed.
Due to these immense challenges faced by healthcare startups, developing and
commercializing a solution can seem daunting and overwhelming without the help of a
structured plan or framework to guide one through the design and development process.
1.2.3: Innovation frameworks in the healthcare industry
A number of frameworks and methodologies have been developed and applied to the
healthcare sector over the past few years. However, success rates are low and
implementation requires significant time, work, and capital. Additionally, different
disciplines have focused significant attention on different stages of the product
development cycle rather than the entire cycle. For example, engineering researchers
typically focus on developing frameworks involved in engineering design decisions, while
management researchers concentrate on the organizational issues and implementation
strategies associated with product development. This approach, however, leads to
segmented knowledge and the inability to evaluate a product’s potential success from all
angles (customer needs, technical feasibility, and commercial viability). For example,
oftentimes, engineers are taught only how to evaluate a concept based on design inputs,
and they possess limited knowledge as to what it would take to commercialize a solution;
therefore, they cannot evaluate the concept based on its commercial viability. They are also
often taught how to develop solutions based on given design inputs rather than being
required to determine their own design inputs through first-hand observation of the
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problem. This leads to a disconnect between the end users and the engineers, resulting in
the development of solutions that fail to address the actual need, but instead address a
subset of the need.
One of the earliest movements for applying an innovation framework to healthcare
startups was the Lean LaunchPad. This was created by Steve Blank, and it took the
methodologies of Eric Ries and applied them to healthcare. Ries created the idea of a “Lean
Startup” and defined it as “an organization dedicated to creating something new under
conditions of extreme uncertainty” [13]. This methodology focused on creating high value
while keeping costs low and maintaining efficiency. He developed this methodology for
managing technology and software companies, but it has since been applied to companies
outside of the technology sector, including the healthcare industry. Steve Blank was the
first to apply this methodology to the healthcare industry when he created a framework for
his Lean LaunchPad class. This class aimed at teaching students from cross-functional
backgrounds how to take their technology out of the research lab and into the real world.
It emphasized the importance of testing a business idea before spending time and resources
on launching it into a business, especially in the healthcare field [14]. Although the Lean
LaunchPad is a great framework offering incredible insight into how to evaluate a business
idea for commercial viability, it is still slightly segmented. The Lean LaunchPad focuses
on what to do once an idea or concept has already begun to be developed, which is a stage
too late. The first step of an innovation framework should be teaching people how to
properly observe and identify needs in order to obtain a better understanding of customer
requirements and develop a better solution. This way, pivoting (the act of changing a
solution to fit a new or different market) can be avoided. The Lean LaunchPad teaches
innovators how to pivot their idea after realizing there is not a strong product-market fit,
but at that point, significant time, money, and resources could have already been used in
developing the solution. By beginning the process with identifying a need, validating the
need and potential market, and then developing a solution, significant risk and uncertainty
can be eliminated early in the process and with minimal resources, thus eliminating the
need for pivoting.
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1.3 The Proposed Framework

Figure 1: TMC Biodesign process overview.

As previously discussed, most frameworks focus only on teaching part of the innovation
process. Although the insights gained from implementing those frameworks are beneficial
and extremely important in starting a successful business, they are only small pieces of the
overall process. When starting a venture, there is a great deal of risk associated with each
step of the process, and those risks need to be evaluated and mitigated before moving on
to the next step of the innovation process. Therefore, there is a need for a framework that
encompasses all stages of product development to teach innovators how to efficiently
evaluate a business idea and successfully create products that meet large healthcare needs.
This thesis proposes such a framework.
As part of an initiative at the Texas Medical Center to bring healthcare
entrepreneurship to Houston and utilize the abundant healthcare resources at the largest
medical center in the world, I, in partnership with members of the TMC Innovation
Institute, created the TMC Biodesign Fellowship. We created the framework used in this
fellowship by combining the research initiatives of many other innovation processes (i.e.,
Lean Startup, Lean LaunchPad, user-centered design approaches, etc.), and we structured
it very similarly to the fellowship created at Stanford University by Paul Yock and Josh
Mackower.
The proposed framework adopts a broader perspective, focusing on the entire cycle
of product development from identifying a need to developing a strategy for
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commercialization. A much larger focus is placed on the initial stages of a project, aiming
at making explicit the importance of considering not only design processes, but also the
other processes that need to occur in the preliminary phases of innovation. Focusing on
preliminary stages of the innovation process, such as observation and needs validation, has
been proven crucial to the success of a healthcare product, since it is at this point during
the cycle that significant risk and uncertainty can be eliminated relating to customer and
market needs.
After significant research has been conducted to validate a need, the framework
moves the fellows through a series of exercises to help them develop a viable solution that
meets the identified user needs. Following that, the framework outlines a method for
creating a commercialization strategy that encompasses everything from intellectual
property and regulatory strategies to pricing and go-to-market strategies. Each stage of the
process requires the fellows to look at a variety of aspects of the market and the solution,
and with each stage, the research becomes more and more in-depth. This way, the fellows
take into account the factors that lead to a successful business (market size, regulatory,
competitive landscape, reimbursement pathways, etc.) from the early stages of the process
rather than focusing on this only once a solution has been created, thus significantly
mitigating risk.
This thesis outlines the structure of the framework and describes both the methods
used throughout the inaugural year by the first medical device fellows and their results. It
also summarizes some of the lessons I learned by participating in the program and details
what key factors enable this program, or similar programs, to be successful.
The TMC fellowship is a 12-month training program that brings together four
individuals from diverse backgrounds and emphasizes a needs-based approach to design.
Its mission is to bring together the necessary people to solve healthcare problems and train
innovators in how to innovate properly in the complex healthcare industry. The fellowship
begins in September and finishes in the following September. After an initial week of
onboarding, the fellows begin the first stage of the process: needs identification.

Summary of the framework
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Stage 1: Identify
1. Needs identification: During the needs identification stage, the fellows participate
in a number of activities to help them identify needs in the healthcare system. They
are partnered with clinical mentors in their clinical focus areas who will help them
set up rotations for clinical observations. The fellows also conduct research and
clinical interviews to help identify potential needs, in addition to attending industry
conferences in order to better understand the current problems being highlighted in
the different healthcare settings. They begin to turn their observations and research
into simple need statements that capture the problem, the stakeholders affected, and
the desired outcomes.
2. Needs screening: After identifying a large number of needs, the fellows focus on
gaining a deeper understanding of the needs and define criteria to determine the
importance of a need. They work to determine whether the need actually exists and
its scope. The fellows conduct multiple rounds of needs screening, and with each
stage of screening, they dive deeper into their research surrounding the need. They
present their top 12–15 needs to a panel of clinical experts for feedback before
settling on a list of top 3 needs to move forward with into Stage 2: Create.

Stage 2: Create
1. Concept generation: After screening and selecting their top three needs, the
fellows begin the concept generation stage where brainstorming occurs. The
fellows are provided access to a prototyping space that contains multiple materials
intended to spark creativity and enable brainstorming, such as whiteboards, sticky
notes, markers, and so on, as well as a variety of low-fidelity prototyping material
(i.e., clay, paper, pipe cleaners, glue, etc.).
2. Concept screening: Once the fellows have participated in a variety of
brainstorming sessions for each need and have developed a list of potential
solutions, they begin the filtration process once again, this time with a focus on
intellectual property, regulatory and reimbursement hurdles, timeline to launch,
technical feasibility, team interest, and other criteria that they define. They conduct
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multiple rounds of concept screening before determining a concept to move forward
with into Stage 3: Commercialize.
Stage 3: Commercialize
1. Commercialization strategy & pitch deck: During this stage, the fellows spend a
great deal of time developing strategies for intellectual property, regulatory and
reimbursement, R&D, and business development, in addition to crafting the
elements of their pitch. They enlist the help of experts during this stage to aid them
in finalizing their business strategies and reaching a point where they can pitch to
angel investors and apply for business plan competitions.
2. Investors, accelerators, and competitions: The fellows are required to apply to at
least two startup accelerators and to apply to pitch to at least one angel group as
part of the completion of the fellowship. They are also encouraged to apply to as
many business plan competitions as they can. So, during the final stage of the
fellowship, the fellows create a pitch deck summarizing their need, solution, and
commercialization plans.

After the fellowship ends, the fellows are not required to continue working on the product.
However, if there is a great deal of interest and potential for commercial success, the
fellows are encouraged to continue.
To our knowledge, this is the first fellowship program that is not associated with a
specific university and that aims to train multidisciplinary teams on how to innovate in the
healthcare industry.
The most distinctive features of this program are the intensive focus on the needs
identification and user research aspect of the design cycle, the access to a variety of clinical
institutions (clinical immersion in multiple different hospitals and healthcare systems
rather than ones only associated with a specific university) and clinical mentors, and the
length of the program.
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CHAPTER 2: METHODS

2.1: Stage 1: Identify

Figure 2: Overview of the first stage of the fellowship.
Identifying a compelling clinical need is arguably the most important step in the innovation
process. There are many unsolved clinical problems just waiting to be identified; however,
doing so is not as easy as it sounds. It takes hours of observation, research, and clinical
interviews to identify a real unmet clinical need. Many innovators have found that the best
way to identify real unmet clinical needs is to witness them first hand by observing both
the people who encounter them every day as well as the situations in which these needs
take place. Often times, people become so used to performing tasks in the manner in which
they were originally taught that they forget to stop and ask why such a method is used, or
they fail to see the inefficiencies in their processes. This is why simply adding a pair of
fresh eyes can lead to uncovering significant opportunities for innovation.
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By blending in as part of the team and observing the day-to-day operations, one can
really understand how the procedures are currently performed, as well as the difficulties
that arise with the current techniques. Only with a deep understanding of the difficulties
and hurdles that need to be overcome can an innovator design something that truly solves
the problem. This section outlines a method for identifying compelling clinical needs and
provides pointers for determining the best need with which to move forward.
2.1.1 Needs Identification

Figure 3: Overview of the needs identification process.

The fellows are encouraged to use a variety of methods for identifying potential needs
during the initial stage of the fellowship. The majority of needs identification should be
spent in clinical observations and shadowing healthcare providers in a variety of clinical
settings. Outside of clinical rotations, fellows are encouraged to study disease state
fundamentals and market trends, as well as to attend conferences intended to provide the
opportunity to learn more about emerging technology and the problems that are important
to thought leaders in the industry. All of the observations and problems identified through
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clinical rotations and research should be documented and eventually turned into need
statements. The development of a need statement will be an iterative process that should
end with a well-defined need specification. This will be the guiding document throughout
the innovation process and will be extremely important in designing a device that truly
addresses a need. A process for identifying compelling clinical needs and translating them
into need statements is described in detail below.
2.1.1.1: Observations
Observation is the most important and efficient method of identify needs. The goal of
observation is to become a part of the team and observe problems through the eyes of the
different stakeholders, and to see them from different perspectives. Fellows should begin
by setting up their clinical rotations with the mentors they have been introduced to through
the fellowship. As they shadow and meet new clinicians, they should continue to set up
rotations to ensure that they observe in a variety of settings with a variety of clinicians of
varying skill levels. For each clinical rotation, the fellows should document the date and
time of the rotation, the procedures observed, the physicians and clinical staff shadowed,
and the amount of time they shadowed, in addition to any observations they make during
their rotation. Below are some tips for how to prepare for and what to look for while
rotating.
1. Preparing for observation:
Once the fellows have set up clinical rotations, they need to perform initial research
into the procedure they are observing. This will help them understand what is being
done in the procedure, what the outcomes should be, and what type of providers
they will be observing. This allows them to ask educated questions and focus on
the problems associated with the procedures rather than spending time trying to
understand what is happening during the procedures. Fellows should purchase
small bound notebooks that can fit in the pockets of their scrubs to bring into the
OR or clinic in order to document their observations during their shift. They should
always ask the physicians with whom they are rotating if it is okay for them to bring
the notebook in and take notes.
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2. Observation techniques:
During clinical rotations, the fellows should split up to cover more ground and
observe a variety of procedures. If possible, for observations in the OR, one fellow
should be on the floor with the surgical team while another observes from upstairs
in an observation room. This allows more of the procedure to be documented and
different vantage points to be recorded.
During each procedure, the fellows should time-stamp every step that is
performed and take as detailed of notes as possible regarding the steps of the
procedure and who did what during the procedure. This will make it easier to
determine the inefficiencies in the procedures, which steps take the longest, and
how many times specific tasks are done or repeated. Fellows are encouraged to look
for steps that require multiple hands or seem cumbersome, require extreme
precision or skill, require a great deal of time, or actions that, when asked why they
are performed in a certain way, elicit such responses as, “That is the way we were
taught,” or, “That is just how it is done,” and so on. Often times, these are signs that
there is opportunity for innovation. It is important for the fellows to observe
everyone involved in the procedure or process and understand the needs of each
stakeholder, including the patient, provider (physician, nurse, tech, assistant, etc.),
and the system. Figure 4 provides examples of what to look for and what questions
to ask during observation in order to identify potential needs based on the different
types of stakeholders.
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PATIENT

Pain: Is the patient in pain? What is
causing the pain?
Stress: Is the patient stressed? What
steps or problems are causing them
stress?
Complications: Did the procedure
result in a complication or death?
What events lead to poor outcomes?
Inefficiency/time: How much of the
patient’s time is taken up by the entire
process? Where can time be
decreased?

PROVIDER

SYSTEM

Uncertainty: Is the provider unsure or
indecisive about what to do? What is causing
the uncertainty?
Stress: Is the provider stressed? What steps or
problems are causing them stress?
Malfunction/failure: Did any equipment
malfunction? Did any step of the process fail?
What caused the failure or malfunction?
Dogma: Are certain steps being performed
because of established methods, principles, or
beliefs? (“This is how it has always been
done”).

Cost: Does any part of the
procedure or process
significantly increase costs to
the system? What is causing the
increased costs?
Inefficiency/time: Is any part
of the procedure or process
inefficient? What steps of the
procedure/process take the
longest? Where can
inefficiencies be eliminated or
decreased?

Figure 4: Examples of what to look for during observation for each stakeholder
involved in the procedure or process.
It is important for the fellows to document every observation, even ones they do
not think are relevant. A great deal goes on during a procedure, which makes it
difficult to remember everything that happened and know what information might
be useful later; if the fellows have detailed notes from their observations, they can
go back to them later for reference.
When observing surgeries specifically, the fellows should always try to set
up a time to debrief with the surgeon or surgical team after the procedure if possible,
as they will most likely be unable to ask questions during the procedure. Many
surgeons like their OR quiet, or would prefer not to be distracted during the
procedure, so if the fellows have a question regarding a certain step or why
something was performed a certain way, they should make a detailed note regarding
when in the procedure it happened and the circumstances surrounding the step or
event, and then ask the clinician about it in a post-surgery interview or debrief.
After every rotation, the fellows should review the notes they made during
the shift and document all of the problems or needs identified during that shift. They
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should create a shared spreadsheet that includes the problem, the procedure in
which it was identified, the date it was identified, the stakeholder(s) affected, and
any notes or observations surrounding it. This will be helpful when it comes time
for them to translate their observations into need statements.
2.1.1.2: Industry Conferences
Another great way to identify potential needs is to attend conferences related to the focus
area. This will help fellows to understand the issues that the key opinion leaders (KOLs)
in their clinical focus area see as important. Attending conferences is also a great way for
the fellows to network with potential stakeholders and KOLs who might be interested in
becoming clinical mentors or advisors. Additionally, conferences serve as a great place to
develop an understanding of the emerging technologies that address some of the needs in
the industry, as well as new techniques that are being implemented in practice. The fellows
should document the problems they identified through conference panels and
presentations, as well as the emerging technologies or techniques that are related to the
problems, if any, and prepare a presentation to share with their team upon their return.
2.1.1.3: Clinician Interviews and Market Research
Another great way to identify potential needs is to talk with clinicians and determine their
pain-points or frustrations. It is important to understand that stakeholders sometimes do not
see the entire need, and are instead aware of only a small part of the problem, so it is
important to listen to them while also being able to take a step back and understand what
is truly driving their frustration. In addition to interviewing clinicians and other
stakeholders, market research is another great way to identify some of the major issues
associated with a clinical focus area. Fellows should look into diseases that cost the
healthcare system a great deal of money or result in serious complications or death, and
then dive deeper into the diseases or procedures in order to understand the problems
associated with them.
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2.1.1.4: Need Statements
It is often easy to understand the broad nature of the clinical problems observed or
identified, but it can be extremely difficult to define the actual clinical need. Often, needs
are either too broad or too specific, solution dependent, or simply inaccurate due to lack of
information, research, or understanding of the problem. After compelling clinical problems
have been identified through observation, research, industry conferences, interviews, and
so on, the next step is to translate the identified needs into clear need statements. A need
statement is a one-sentence description of the clinical need that includes the problem or
opportunity, the stakeholder or population affected, and the desired outcome (Figure 5).

Figure 5: Components of a good need statement.

Determining the perfect need statement will require a significant amount of work and trial
and error, but this activity is extremely important, because it will help to scope the problem
definition and the specifications associated with the need, and eventually, the parameters
that the solution will have to satisfy [15]. The need statements will start out as very broad,
rough versions of a need statement and, through iteration, scoping, and validation, will be
shaped and refined into a more descriptive need statement.
It is important for the fellows to note that often times, there are multiple desirable
outcomes associated with a need. However, it is important to include only the most
important outcome in the need statement. This will ensure that the fellows are focused on
the most important results, and will keep them from thinking that a solution only addresses
the need if it addresses all of the desired outcomes, which is usually impossible. Three
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examples of potential need statements can be seen in Figure 6. Once the fellows have
created need statements for each of the problems identified through observation, it is time
for them to perform an initial needs screening.

Figure 6: Need statement examples highlighting the problem/observation,
stakeholder/population affected, and the desired outcome.

2.1.1.5: Initial Needs Screening
The fellows should have identified over 250 needs during their time in the needsidentification stage. The needs will be of varying clinical importance, and depending on
the fellows’ goals for their type of solution (i.e. blue sky vs. incremental), their team
enthusiasm, and potential impact/market size, they should consider performing a
preliminary needs screen. It is unrealistic to do in-depth research for all 250+ needs, so a
preliminary screen could be very beneficial in helping the fellows choose which needs to
dive deeper into. Through the exercises performed to develop the need statements and the
preliminary research and validation performed during needs identification, fellows should
already have a basic understanding of the need and be able to determine whether or not a
need is worth looking into with more detail.
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2.1.2: Needs Screening

Figure 7: Overview of needs screening activities.

Once the fellows have turned all of their observations into need statements, scoped and
validated them with preliminary stakeholder interviews, and performed an initial round of
filtering, it is time for them to begin researching the needs in more detail.
The types of research that fellows should be performing for their needs are
described in detail in this section. It is important to note that in the beginning, this research
will be broad because of the large number of needs being researched. However, as needs
continue to pass through the different screening stages, this research will become more indepth.
2.1.2.1: Disease State Fundamentals
Like many other steps in this process, disease state research is iterative and becomes more
refined as it is used throughout different steps of this stage. It starts out as background
research performed prior to observation, and it becomes slightly more in-depth when
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creating a need statement, but it becomes more important after the need statement has been
crafted and refined. This research will help the fellows to compare multiple needs against
each other during the screening processes, and is therefore a critical step. It is important
that the fellows do not skip this step, even though it may seem tedious. This research does
a great deal to help the fellows understand every aspect of the need, which can help them
scope the problem and focus on the most important aspects of the need. After needs are
defined, fellows should begin research into the diseases associated with the needs. This
research is intended to provide the fellows with a deep understanding of the diseases and
aspects of the conditions that are relevant to the clinical needs they have identified. As
specific need statements are developed and refined, this research becomes more focused
on the disease surrounding the specific aspect of the need identified. The fellows should
understand the mechanism of action for the condition in question. They should focus on
the anatomy and physiology associated with the need, pathophysiology, clinical
presentation, clinical outcomes, epidemiology, and economic impact. In the beginning, this
research is very high level. However, as the fellows continue through the different rounds
of screening, this research becomes more in-depth.
2.1.2.2: Existing Solutions
As part of the initial needs identification research, as well as participating in observations
and interviewing clinicians, the fellows should have gained insight into some of the
treatment options that are currently on the market, as well as some opportunities for
improvement. Now it is time to dive deeper into the current solutions that relate to the
specific problem and desired outcome included in the need statement. The point of this is
for the fellows to understand not only what solutions are currently on the market, but also
the solutions that are emerging. This information will be crucial in ranking needs and
determining whether or not a need should move on through the screening process.
Therefore, it is important to not rush through this research. It is important to understand
that there are multiple types of solutions, not just devices, that could be addressing a
problem, and fellows are encouraged to research all types of solutions. Types of solutions
include, but are not limited to, diagnostics, percutaneous treatments, minimally invasive
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treatments, open surgery/invasive treatments, pharmacologic treatments, lifestyle
treatments, services, and disease management [16]. During this research, it is important to
also note what type of stakeholder is involved in providing the treatment. For example,
there are a variety of different treatments available for damaged heart valves. Two types of
the many solutions include open-heart valve replacement and trans-catheter valve
replacement. Although the desired outcome is the same for both of these procedures, the
stakeholders involved and the facilities required are different. For the open-heart
procedure, a cardiothoracic surgeon would most likely be performing the procedure in an
OR, whereas in the trans-catheter procedure, an interventional cardiologist would most
likely be performing the procedure in a catheterization lab. Understanding the different
stakeholders involved with each available treatment will help during the next step:
Stakeholder Analysis.
2.1.2.3: Stakeholder Analysis
Stakeholder analyses are extremely important, especially in the medtech field due to the
complex nature of the healthcare system. Unlike many other industries, healthcare has
multiple stakeholders that drive adoption and possess decision-making power, and often
times, their needs conflict. By collecting and analyzing data on all stakeholders involved
with a need, one can develop an understanding of how they make decisions and what they
require in a solution. It is important to note that it is common for stakeholders to have
conflicting perspectives—solving the need may benefit some stakeholders while
negatively affecting others. For example, a new device or technology that improves the
accuracy of a procedure, but also significantly increases the cost, might be very desirable
to the surgeon who cares most about outcomes, but not be as appealing to the hospital due
to the increased costs. Another example could be a new device that allows procedures to
be performed in a cardiac catheter lab rather than a cardiac OR; this might be appealing to
the interventional cardiologists, but unappealing to the cardiothoracic surgeons because it
could result in less procedures coming their way. Understanding how the need affects each
different stakeholder is vital to creating a value proposition that resonates with all of the
stakeholders.
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A stakeholder analysis aims to identify the stakeholders involved with the need and
understand their individual perspective and how they are affected by the need. It also stands
to help the innovator determine the relevance of each stakeholder, as well as their potential
to drive adoption.
The first step of the stakeholder analysis is to identify the important stakeholders
associated with the need. This can be done through research and clinical interviews with
known key stakeholders focused on identifying other important stakeholders. Due to the
large number of stakeholders often involved in the healthcare industry, it is impractical, if
not impossible at times, to please every stakeholder, so it is important to focus on the most
critical stakeholders. Hospital—or medical—stakeholders can be defined as “individuals,
groups, and organizations who have a stake in the decisions and actions of the hospitals
and who may attempt [or have the power to] influence those decisions and actions” [17].
They can be characterized as primary stakeholders, who are essential to the adoption and
survival of the product, and secondary stakeholders, who the company might interact with
or who might be directly affected by the need, but do not possess decision-making power,
or are not essential to the adoption and survival of the product and company [18]. There
can also be external stakeholders, such as other companies, who might contribute to,
compete with, or have something to gain from a product. These stakeholders are frequently
categorized as potential collaborators or threats [19].
In order to understand and properly categorize each stakeholder, user profiles
should be created for each identified stakeholder. A user profile should include general
information about the person (age, gender, education level, job title, etc.), as well as their
needs, interests, expectations, and behaviors. Much of this information will already have
been gathered during clinical observations, but the fellows will most likely need to go back
and observe and interview the stakeholders again, this time focusing specifically on aspects
that will help them create a user profile rather than identifying needs.
Once the fellows have a strong understanding of each of the stakeholders, how they
are affected by the need, and their influencing power, they can begin to categorize each
stakeholder. One way to do this is to create a plot of the stakeholders, taking into account
their level of interest and their level of power (Figure 8). The stakeholder’s location on the
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plot will help the fellows to understand if they are primary or secondary stakeholders and
the best way to engage them.

Figure 8: Stakeholder analysis plot. Reprinted from Understanding stakeholder analysis:
the key steps, by State Services Commission (2009). Retrieved from:
http://www.ssc.govt.nz/node/6253.

As the fellows continue throughout this process and learn more about their need and,
eventually, design a solution, the user profiles and stakeholder analyses will become more
detailed, and this will be extremely valuable during the concept generation and
commercialization phases.
2.1.2.4: Market Analysis
One of the most frustrating aspects of this process is identifying a real need that, if
addressed, could save lives and make an impact, but realizing that the market is not large
enough for it to be commercially viable. This will likely occur during the screening process,
and it is important for fellows to determine this early on in the process, rather than moving
forward and wasting time and money pursuing a need that is not commercially viable. This
is not to say that fellows cannot address a need that has a small initial market, but if the
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target market is small, then there must be other markets that are associated with the need
to make it a worthwhile need to pursue. The fellows will need to define what makes a
market viable based on feedback from stakeholders and potential investors. Performing a
market analysis is extremely important and will provide valuable information for refining
the need statement and eventually developing a need specification. The insight gained from
performing a market analysis will also help the fellows better understand the different
requirements associated with each market associated with the overall need. Performing a
good market analysis includes multiple steps, which are explained in more detail below.
1. Market mapping and segmentation: As discussed earlier, it is not realistic to
perform a detailed market research on every need. Therefore, fellows are
encouraged to initially perform a high-level overview of the broad markets
associated with each need and then continue to dive deeper into the market
landscape as they move through the screening process. The fellows should begin
by identifying the overall market for the diseases associated with their needs and
then narrow the market size down to the specific conditions, patients, symptoms,
and so on that their need targets. Often times, fellows will have already developed
a broad understanding of the market size through the course of the disease state
fundamentals research.
Fellows should also use the information gathered from the existing solutions
research they conducted to map out how well the needs are being met in the overall
market. This should help the fellows identify where there are opportunities in the
market for new solutions. Fellows should also look into growth opportunities for
the overall market and market trends. They should be aware of whether a market
seems to be shrinking or growing and understand what factors are affecting this
growth or shrinkage. All of this information should be documented and used during
needs screening to evaluate the viability of the need.
After a broad understanding of the overall market is established, it is
important for the fellows to break the market up into segments. Market
segmentation refers to the aggregation of stakeholders into groups that possess
common needs and respond similarly to the identified need [20]. It is unlikely that
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a solution will address the needs of all stakeholders associated with a broad market,
so it is important to understand the requirements of stakeholders in different market
segments and to determine which segments have needs that are not being met by
current solutions. There are multiple ways to segment a market in the medical field.
Four of the most common types of market segmentation can be seen in Table 1.

Table 1: Types of market segmentation
Segmentation Type

Description

Geographic

Geographic segmentation divides markets based on
geographic criteria such as Country, Region,
Population Density, Climatic Zone, City or Town size,
etc. This type of segmentation would be helpful for
deciding which country a solution might bring the
most value to.
Demographic segmentation divides markets based on
variables such as age, income, family size,
professional experience, etc. In the medical device
industry, demographic segmentation might be based
on patient age or physician skill-level/training, or by
the type of payer, such as Medicare or out-of-pocket
payer.
Psychographic segmentation divides markets based on
the activities, interests, and opinions of potential
customers. It focuses on which external influences
they respond to, and how they make decisions for
which products they use or buy.
Behavioral segmentation divides markets based on
observed behaviors. This could include benefits
sought (quality, low-cost, convenience, etc), brand
loyalty (loyal, switcher, non-loyal, etc), buyer
readiness, or adopter status. In the medical field,
adopter status is a popular way to segment markets.
For example certain specialties are known for being
innovative, or having clinicians that are considered
early adopters of new technology.

Demographic

Psychographic

Behavioral

Specifically for segmenting healthcare markets, it can be beneficial to start with
basic patient-based analysis and then build from that by adding in more complex
factors to eventually account for the different stakeholders [15]. A more detailed
approach to market segmentation will be taken once a final need has been selected,
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a concept has been chosen, and the fellows are entering the commercialization
stage.
2. Target market identification: After the fellows have spent some time segmenting
the markets associated with each of their needs, they can begin identifying potential
target markets. The fellows will spend more time looking into potential target
markets during the commercialization stage. To choose a potential target market
for each need, the fellows should use all of the information found during the initial
market analysis process to determine the segment for which a solution could bring
the most value. Fellows need to take into account market size, market dynamics,
the needs of the market segment, willingness to pay, and market enthusiasm. The
target market, and the analysis surrounding the target market, should be used to
help filter needs during the needs screening process

The market analysis process can seem very daunting and time-consuming. However, it is
important to realize that this information is necessary to evaluate the different needs. More
detailed research will be performed as the final needs are determined and a final concept is
selected. The research performed during this stage of the process is preliminary, and it is
unrealistic for the fellows to have detailed market analyses for all of their needs. The extent
of the research performed during this stage should only be as in-depth as necessary to
evaluate the viability of the needs in question.
2.1.2.5: Needs Screening and Selection
Once the fellows have a preliminary understanding of the disease state fundamentals,
existing solutions or treatment options, the stakeholders, and the market landscape, it is
time for them to perform needs screening. Multiple rounds of needs screening will be
required to select the top three needs that will move forward into Stage 2: Create. Each
stage of needs screening will require more information and research than the last. Figure 9
depicts a general approach for the different stages of needs screening.
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Figure 9: The different needs screening and the number of needs in each round.

At the end of this phase, fellows will draft a need specification document—a document
that summarizes all of the important information gathered throughout the identification
stage and the filtering stage, which is explained in more detail in later sections of this thesis.
This document will serve as a starting point for initial concept generation.
Needs filtering is an inherently subjective process, so it is important to develop a
framework for assessing and comparing needs that ensures that all of the data and
information gathered throughout this process is taken into account. An approach for
filtering and selecting needs can be seen in Figure 10.

Figure 10: Process for needs screening and selection.
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As seen from the figure above, this process is iterative and will most likely be performed
multiple times before the fellows arrive at their final needs.
2.1.2.6: Need Specification Document
Once the fellows have identified their top 10–15 needs, they should begin developing a
need specification document, also known as an opportunity specification document, for
each of their top needs. This document will be essential for guiding concept generation and
selection, and will be constantly revised throughout this innovation process. The need
specification document is a detailed document that summarizes the market need and the
information gathered surrounding the market opportunity. It should include the need
statement, a summary of the information and data gathered throughout the needs
identification and needs screening processes, and the need criteria. The need criteria are
the stakeholders’ key requirements for any solution relating to the need. These are often
grouped by “must-have” and “nice-to-have” criteria. Must-have criteria are essential to the
solution and are required in order to fully address the need. They are often related to
function and safety, and are the key requirements for creating value for the stakeholders.
Nice-to-have criteria are not essential to solving the problem, but they increase the
solution’s value and desirability. These criteria should be defined based on the research
with key stakeholders performed throughout this process, and they should be validated with
stakeholders before moving forward into Stage 2: Create.
Breaking the criteria into must-haves and nice-to-haves will help the fellows to
remain focused during concept generation and selection, and prevent them from spending
extra time or energy developing nice-to-have features that don’t add much value. It is
important for them to focus their time and effort on developing the most imperative features
of a solution first (must-have criteria).
It is important to realize that, although need specification documents have to be
created in order to move forward with the innovation process, those are living documents,
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and will most likely evolve over time as the fellows learn more about the need they are
addressing and begin generating concepts and gathering feedback concerning them.
2.1.2.7: Final Selection
After the need specification documents have been created, fellows should arrange for a
feedback session with a group of key opinion leaders associated with each of their top
needs, in addition to their mentors and advisors. They should present the need
specifications to the group and gather feedback on the top needs. The input from the
stakeholders and business advisors should serve as the last screening round before choosing
the top three needs with which to move forward. Fellows should ask the clinicians and
advisors to rank their needs and provide feedback on the need statements and specification
documents. This information, along with all of the information gathered throughout the
needs screening process, should be used to choose three top needs that will continue on to
Stage 2: Create.
2.2: Stage 2: Create

Figure 11: Overview of the second stage of the fellowship.

Inventing a medical device is a much more complex process than inventing products in
many other industries due to the number of stakeholders involved and regulations required.
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Just as there are a number of steps to complete during the initial stage of this process related
to the need, stakeholder interest, and market opportunity, there are multiple activities the
fellows need to partake in during this second stage of product development. During this
stage, it is extremely important for fellows to understand not only how to translate user
needs into product functions, but also the very complex pathways to reimbursement and
regulatory approval. The hurdles associated with regulations and payments in the
healthcare system can be very complicated, making innovating within this industry
extremely challenging. This means that great attention must be placed on understanding
the regulatory and reimbursement pathways associated with the concepts that are being
generated, in addition to the requirements necessary to create an innovative product in other
industries, such as the IP landscape, business model, and feasibility. This section will
describe techniques the fellows should use throughout concept generation and concept
screening.
2.2.1: Concept Generation

Figure 12: Activities included in concept generation.

Once the top three needs are chosen, fellows can begin the brainstorming and concept
generation process. It is important to understand that concept generation requires a very
different mindset than any other stage in the product development cycle—one that is
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neither critical nor judgmental. As there are many different, and often conflicting, theories
around the best way to brainstorm, fellows should implement a variety of techniques to see
which ones work best for the individuals on the team. A process for brainstorming is
described in detail below.
1. Establish rules before beginning brainstorming: The fellows should establish
general rules for the brainstorming sessions so that everybody feels safe sharing
their ideas during the sessions, and so that the sessions can be as productive as
possible.
2. Break needs down into smaller problems, causes, or functions: Hosting
brainstorming sessions on general needs can often be overwhelming and
intimidating, and can lead to unproductive and frustrating sessions. It is often
advantageous for fellows to break down their overall needs into smaller needs or
causes for the problem, and then have brainstorming sessions on each sub-need or
sub-problem.
3. Implement different brainstorming techniques: The fellows should implement
multiple brainstorming techniques throughout this stage to spark creativity and
determine which brainstorming styles work best for the different individuals on
their team. There is an abundance of brainstorming techniques utilized today, and
the fellows are encouraged to determine which ones work best for them. It is
important to host multiple brainstorming sessions, implementing a variety of
brainstorming techniques for each sub-problem or sub-function identified as part of
the overall need. This is important in order to make sure that all aspects of the
problem have been addressed, and looking at smaller pieces of the overall problem
can help the fellows generate ideas when they previously though they had
exhausted all possibilities.
4. Capture and organize the results: It is very important to capture all ideas that
come out of a brainstorming session. During a session, ideas should be documented
on paper, post-its, white boards, or even explained using low-fidelity prototypes.
The ideas generated should be documented immediately after the session has ended.
This allows any confusion to be addressed while the idea is still fresh in the
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inventor’s mind. A process for capturing and organizing the results from a session
is detailed below:
a. Name each idea/concept: After a brainstorming session, review each
generated concept and give it a label and short description in order to
make it easily remembered. The person associated with the concept must
also be documented so that, if clarification is desired, it can be acquired
through follow-up with the person who came up with the idea.
b. Photograph all sketches/lo-fidelity prototypes: If the concept is
complicated or has a sketch or lo-fidelity prototype associated with it, it
should be photographed, and its image should accompany its name and
description.
c. Group and cluster ideas: As mentioned throughout this section, concept
generation is about quantity. As such, it is important that multiple ideas
are generated before settling on a specific solution. However, it is
unrealistic for the fellows to prototype and research every concept that is
generated. In order to move from an overwhelming number of concepts to
a more manageable number of realistic concepts, it is important for
fellows to organize and group their solutions into categories or types of
concepts (Figure 13). This is an effective method for seeing how the
solutions are related to each other and the overall need, as well as seeing if
there are any gaps in the solutions identified. This also helps the fellows
organize their concepts in preparation for concept screening.
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Figure 13: Visual representation of grouping concepts based on organizing principles.

After each brainstorming session, the concepts should be labeled and
photographed (if necessary), and the concepts should be grouped according
to some organizing principle, such as function, technical feasibility,
resources required, and so on. Once clustered or grouped, the concepts
should be visually organized into something like a mind-map. A mind-map,
or concept map, visually represents how ideas relate to one another and the
overall need. They are used to help the fellows cluster their ideas and
recognize patterns, as well as to identify gaps in the solutions they have
generated. An example of a mind map can be seen in Figure 14. This mindmap breaks down a need relating to empyema and pleural effusions. The
organizing principles identified in this example are (1) removing fluid and
(2) removing the peel/rind. These principles are further broken down into
sub-principles when the mind-map is generated. For example, “Removing
the peel/rind” is broken down into mechanical, biomimetic, and
mechatronic ways to remove the peel, and then the solutions or ideas are
placed where they best fit within these organizing principles and subprinciples. By looking at the number of ideas in each sub-group, it is easy
to see that some concepts or ideas are well defined and thought out, while
other solutions are more generalized ideas or approaches. Creating a mindmap helps fellows to identify what their next steps need to be and to
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determine if they are ready to move on to concept screening and selection,
or if they need to spend more time generating new ideas.

Figure 14: An excerpt from a simple mind-map for the need: A way to efficiently address
complicated effusions and empyema that reduces the need for surgical decortication.
Courtesy of inagural TMC Biodesign team: Jessica Traver, Nicole Moskowitz, Yashar
Ganjeh, and Xavier Garia-Rojas.
5. Initial concept screening: Similarly to when the fellows had to perform an initial
needs screening to eliminate a large number of needs so that they could focus on a
smaller number of needs that they could research in detail, the fellows now need
to perform an initial screening of their concepts so that, moving forward, they can
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reduce the number of concepts to research to a more manageable number. At this
stage, it might be helpful to engage with experts in the field in order to stay
objective and ensure that the solutions are addressing the actual need statement.
Speaking with individuals who have diverse backgrounds and experiences can be
helpful in evaluating the solutions on the different criteria assigned for screening.
Two methods that should be used during the initial concept screen are explained
below:
a. Compare concepts to needs specification: Once all of the concepts are
grouped and the fellows have a strong understanding of the concepts
generated, the proposed solutions should be compared against the need
and the requirements set forth in the needs specification document created
during the identification stage. Concepts should be evaluated relative to
the need criteria, as well as the defined “must haves” and “nice-to-haves.”
Concepts that do not meet the “must haves” and the need criteria should
be set aside or removed, while the ones that do should then be compared
against the nice-to-have criteria.
b. Perform initial “gut check” and feasibility screen: After comparing the
concepts to the needs specification documents, the fellows should perform
a simple concept screen based on criteria of their choice (similarly to what
was done for initial needs screening). This could either be a “gut check”
based on feasibility or it could be based on criteria surrounding team
skillsets, team enthusiasm, clinical enthusiasm, timeline to proof-ofconcept, and so on. After the initial concept screening, fellows should
have between 10–20 concepts with which to move forward.
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2.2.2: Concept Screening and Selection

Figure 15: Summary of activities in concept screening.

After brainstorming hundreds of potential concepts and performing an initial concept
screen, it is time to begin narrowing down the list of potential solutions to just one or two.
It is common to see fellows hesitate during this stage and not want to make a decision due
to lack of information or uncertainty concerning whether a solution could work or not. It
is important to realize that it is impossible to seriously consider multiple concepts at the
same time. The phrase “fail fast” is important to keep in mind during this stage. By
choosing one or two concepts and moving forward with them quickly, fellows can gain
valuable insights into the concept and can move on to other potential solutions quickly if
they find that a solution was not feasible. The goal during this stage is to prove/disprove
the top solutions as quickly as possible. However, there is a balance between thorough
research and failing fast that the fellows must find.
It is important to understand the pathway of medical device innovation and how
reimbursement, regulations, intellection property, business models, and feasibility of a
solution are all vital to creating a successful device. Understanding the potential strategies
and pathways for the solutions in review is necessary and should be a large part of the
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concept selection process. The type of research that should be performed for each of the
concepts at this stage is described below. The fellows should use the findings from this
research to rank concepts and determine their top one or two in order to move forward into
the commercialization stage.
2.2.2.1: Intellectual Property (IP) Basics and FTO
It is important to research similar technologies and review existing patents that are related
to the concepts that have been generated. A patent gives the inventor the right to exclude
others from commercial use of the invention, so understanding existing patents related to
a concept under review is extremely important. Biodesign: The Process of Innovating
Medical Technologies [15-16] describes the importance of understanding the patent
landscape well when they say that “the presence of patents with similar technology to the
concept in question can complicate or even derail the fellows’ ability to launch a new
company or product. However, on the other hand, having a strong patent landscape can add
tremendous value to an invention” [16]. Therefore, understanding the IP landscape early
in the concept screening stage is important to determining the commercialization potential
for a solution.
Another thing to be aware of is that a patent gives one the right to exclude others,
but it does not give one the right to practice, which is why it is important to understand
freedom to operate. Freedom to operate (FTO) is only established if the features of the new
invention are “free and clear of valid claims from patents that are still in force in the country
of question” [16] There should not be any claims in a prior patent that describe the features
of the new invention and nothing else, meaning if there is a patent that has claims on
features that are not part of the new invention, or if the new invention has some features
that are not covered by the prior claims, then FTO is preserved [16].
Fellows should begin understanding the IP landscape by performing prior art
searches and documenting any patents that seem similar to the concepts being assessed or
have claims that cover features of the concept being assessed. It is important to determine
if prior art exists for a concept being pursued as soon as possible, because if prior art is
identified, it can either save the fellows a significant amount of time and money by allowing
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them to move forward with a different concept, or it can give them the opportunity to
redesign the concept into something that is patentable and has FTO.
Prior art searches will require a lot of time and will be an ongoing process, as new
patents and patent applications are released every Tuesday and Thursday in the US. In
order to begin a prior art search, the fellows need to have a clear understanding of the
concept they are researching and its potential claims. This will help them to determine key
search terms for identifying potential prior art. While reviewing similar patents, it is
important to understand what claims are important and how they relate to the concept in
question. In order to do that, it is important to understand what makes an invention
patentable. There are three things an invention is judged on to determine if its patentability:
utility, novelty, and obviousness [21]. “Utility” means that the invention has to do
something that is useful, which is easiest to prove in the medical device field. “Novelty”
means that the invention must be in some way different than other patents or products
known to the public anywhere in the world. This is relatively easy to prove, because any
difference between a new invention and a prior invention will suffice. Fellows can
determine if their concept will meet the requirements for novelty by performing a prior art
search. However, it is important to remember that just because an invention is considered
novel and a patent is issued, it does not mean that there is FTO. The last, and hardest,
criterion upon which an invention is judged is “obviousness.” The patent reviewer has to
believe that the new invention is non-obvious, meaning that any skilled person working in
the given field with the technology in question would not think the invention to be obvious
in light of prior patents [21].
Fellows should use this understanding of what a concept requires to be patentable
to help them determine which existing patents could exclude them from receiving a patent
on their concept. All relevant patents and claims should be documented and ranked
according to perceived risk, and they should be used as selection criteria for the final
concept.
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2.2.2.2: Regulatory
Regulatory issues play a critical role in the success of a new medical device. As such,
understanding the regulatory landscape or necessary regulatory pathway for a solution is
extremely important and should be taken into consideration during concept screening.
Often, fellows will seek help from a regulatory consultant at some point during
development, but at this early stage, it is important to understand the basics of the
regulatory pathway that a concept would require, and the costs, timeline, and clinical data
associated with the different pathways. In the US, there are three different classes of
devices, each requiring different requirements to receive FDA clearance. Table 2 explains
the different FDA classifications. Fellows are encouraged to research the different classes
in more detail and understand what class each of their solutions would be considered a part
of.

Table 2: Medical device classification and requirements.
Class
Class I

Class II

Class III

Description

FDA Pathway/Requirements

Examples

Class I devices are
considered low risk, and
therefore present minimal
potential harm to the
patient.

Class I devices are only subject to general
controls, including registering the
medical device, proper branding and
labeling, and proper manufacturing
techniques. The company must notify the
FDA prior to marketing the device.
Class II devices are subject to general and
special controls, including special
labeling requirements, mandatory
performance standards, design controls,
and post-market surveillance.

Elastic bandages,
tongue depressors,
exam gloves,
handheld dental
instruments, dental
floss.
Ultrasound
devices, infusion
pumps, powered
wheelchairs,
surgical needles,
suture materials.

Class II devices are
considered moderate risk
devices. They are more
complex than Class I
devices, and therefore,
companies must prove
that the device does not
cause harm to the user or
the patient. The majority
of medical devices are
considered Class II.
Class III devices are high
risk devices, and have the
highest chance of causing
potential harm to the
patient. These devices are
usually implantable,
therapeutic, or lifesustaining.

These devices generally require a 510(k)
pathway. However, certain Class II
devices without clear predicate devices
may be required to take a De Novo
510(k) pathway.
Class III devices must meet all
requirements for Class I and II devices, in
addition to strict requirements relating to
gathering evidence proving the safety and
efficacy of the device before being able to
be used in humans.
Typically, Class II devices must take the
PMA pathway for regulatory approval.

Implantable
pacemakers, heart
valves, breast
implants, bone
cement.
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A great way to determine the class under which a concept might be categorized, as well as
to understand they type of testing that would be required to receive FDA clearance, is to
research predicate devices. Predicate devices are devices that are substantially equivalent
to the product in question. According to the FDA, “Substantial equivalence is established
with respect to: intended use, design, energy used or delivered, materials, performance,
safety, effectiveness, labeling, biocompatibility, standards and other applicable
characteristics” [22]. Fellows should use this information to help determine whether or not
a device they are researching can be used as a predicate for the concept they are assessing.
2.2.2.3: Reimbursement
In industries outside of healthcare, a product will usually be successful if there is high
enough demand from the customer or end user. However, in healthcare, things are not that
simple. In the healthcare industry, payers (private or public insurance companies) are
responsible for making the decisions surrounding whether or not a device will be paid for
or reimbursed. This is taken into serious consideration by hospitals and healthcare facilities
before introducing a new medical device into their practice, because it can significantly
affect the cost burden to the facility and its physicians, as well as their profit margins.
Securing reimbursement can be one of the most challenging hurdles for a new medical
device to overcome, so it is important for the fellows to understand the basics of how their
solution might be reimbursed.
Many factors are taken into account in order to determine the amount that is
reimbursed for each procedure, including the location of the procedure, the costs associated
with the procedure, and the codes associated with the procedure. Physicians and facilities
submit bills to insurers using standardized codes to document what procedures were
performed. Depending on the setting (inpatient or outpatient), different types of codes are
used to determine what needs to be billed. The different type of codes, when they are used,
and who gets reimbursed (facility or physician) are described in Table 3.
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Table 3: Types of reimbursement billing codes.
Type of code

Description/Use

Setting

ICD-9

Used to document both
diagnoses and procedures for
facility bills in the inpatient
setting.
Used to document procedures
and services provided by
physicians and medical staff.
Used to document products,
supplies, and services that are
not included in the CPT codes
that were used outside of the
physician’s office.

Inpatient setting

Facility or Physician
Reimbursement
Facility bill

Outpatient
setting

Facility & Physician
bill

Outpatient
setting

Facility bill

HCPCS
Level 1 (aka
CPT)
HCPCS
Level II

Simply submitting a properly coded bill to an insurance company does not guarantee that
the facility or physician will be reimbursed for their work. Procedures are only covered
under specific conditions, and the policies surrounding when a procedure is covered is not
uniform across all payers, so fellows are encouraged to reach out to payers, as well as to
speak with reimbursement specialists in order to better understand the type of
reimbursement they can expect for their solutions. A flow diagram of how billing and
reimbursement typically works depending on setting and codes used can be seen in Figure
16. Fellows are encouraged to map out the reimbursement process for the procedures their
solutions are associated with, or to document the setting, applicable codes, reimbursement
rates, and other pertinent information into a table for analysis.

42

Inpatient
procedure?

Yes

Use ICD-9

Code

No

Supplies/products
used outside of
physician office?

Yes

Use HCPCS

Facility

Level II Code

submits claim

Insurance processes
claim and
reimburses facility
only

No

Use HCPCS
Level I (CPT)
Code

Physician

Insurance processes
claim and
reimburses facility
and physician

submits claim

Figure 16: A diagram of how billing and reimbursement works based on the setting and
type of code used.

2.2.2.4: Business Models
In general, a business model is how an organization, product, or service will generate
revenue and create and deliver value to customers. It is just as important to consider the
business model that will be employed as it is to consider the IP, reimbursement, and
regulatory strategies that will be required for a device.
In the medical device industry, a variety of business models are commonly used,
including, but not limited to, reusable products, disposable products, implantable products,
and capital equipment. Each of these business models are briefly discussed below. Fellows
are encouraged to research other business models in addition to the ones listed below.
1. Disposable Products: Disposable products are low-cost, single-use products. They
can be coupled with capital equipment or reusables, or they can be stand-alone
products. They are usually sold through distribution channels, require little to no
training, and require high sales volumes in order to make up for the low margins.
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Disposables generate constant revenue, but they are also very commoditized goods,
and therefore, competition is usually very high. Examples include needles,
collection tubes, ultrasound covers, sterile draping, and surgical sponges.
2. Reusable Products: Reusable products are products that can be used multiple
times but have a relatively short life-span (when compared to capital equipment).
These products have higher costs than disposable products, but are much cheaper
than capital equipment. These products tend to have no recurring revenue, except
for when a device breaks and needs to be replaced. Consequently, they cannot
support a sales force. Sales margins can be high for these products, but due to lack
of recurring revenue, businesses opportunities around only reusable products tend
to be smaller. Examples include clamps, forceps, endoscopes, stethoscopes,
surgical trays, and surgical shavers.
3. Implantable Products: Implantable products tend to be high-cost products,
ranging anywhere from $1,000–$5,000+, and they require the most clinical
validation. They also carry the most liability to the company that manufactures and
markets them. Due to the high risk of the device, implantable products require a
large sales force. However, a benefit of implantable devices is that they provide an
ongoing revenue stream due to the direct link between the number of products sold
and the number of procedures performed each year. Examples include pacemakers,
artificial joints, stents, breast implants, and nerve stimulators.
4. Capital Equipment: Capital equipment are reusable products that have much
longer shelf lives and must be sold at much higher costs than reusable products in
order to offset the lack of recurring revenue. The decision to purchase a capital
equipment product is usually made by a team of people at the facility, and therefore,
sales cycles can be much longer than other products. A benefit of capital equipment
is that there is usually strong brand loyalty once purchased—it is extremely costly
for a facility to switch to another provider after they have already purchased a
capital equipment product from another. Examples include ultrasound devices,
MRIs, X-Ray machines, and CT Scanners.
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A great tool for developing a business model is the business model canvas developed by
Alexander Osterwalder. The fellows are encouraged to fill out the canvas in order to
identify a business model that works best for their product or service. The business model
canvas (Figure 17) is broken up into nine building blocks that can help break down how a
company plans to make money, focusing on the four main areas of a business: customers,
offer, infrastructure, and financial viability [23].

Figure 17: Business model canvas. Reprinted from The Business Model
Canvas. Osterwalder, Pigneur & al. (2010). Retrieved from
https://strategyzer.com/canvas/business-model-canvas.

The nine building blocks, as seen in the canvas above, are customer segments, value
propositions, channels, customer relationships, revenue streams, key resources, key
activities, key partnerships, and cost structure. Each block has a set of questions the fellows
should be asking, which are described in more detail below. For more detailed information
on how to fill out the business model canvas, fellows should refer to the book Business
Model Generation by Alex Osterwalder and Yves Pigneur. It is important to note that
fellows should continue to revisit the business model canvas and make changes as they

45
learn more about their business opportunity. They should also fill out multiple versions for
each concept in order to see how different business models could affect their business.
1. Customer Segments: Fellows should start with this section, because without
customers, a company cannot survive, which makes understanding them crucial
to developing a successful business model. This section defines the different
groups of people that a product aims to reach or serve. It is important to
categorize and group customer segments and then determine which segments
will be focused on and which will be ignored. At this stage, fellows should
already possess a very strong understanding of the customers they are focusing
on and their specific needs. Important questions to ask for this section are as
follows: For whom are we creating value? Who are our most important
customers?[23]
2. Value Propositions: After defining the customer segments, fellows should move
on to the value proposition box. The value proposition is the reason that a
customer chooses one product over another; it solves the customers’ problem or
satisfies their need. At this stage, fellows should also possess a very strong
understanding of their value proposition, which should make filling out this
section easy for them. Important questions to ask for this section are as follows:
What value do we deliver to the customer? Which one of our customers’
problems are we helping to solve? Which customer needs are we satisfying?
What bundles of products and services are we offering to each customer
segment? [23]
3. Channels: Channels constitute the company’s interaction with customers and the
way in which the customer will purchase the product. Questions to ask for this
section are as follows: Through which channels do our customer segments want
to be reached? How are our channels integrated? Which ones work best? Which
ones are most cost-efficient? How are we integrating them with customer
routines? [23]
4. Customer Relationships: This block helps to determine the type of relationship
a company will establish with each customer segment and how they will go
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about establishing that relationship. The questions to ask for this section are as
follows: What type of relationship does each of our customer segments expect us
to establish and maintain with them? Which ones have we established? How
costly are they? How are they integrated with the rest of our business model?
[23]
5. Revenue Streams: This is where the fellows should define how their product
will generate revenue from each customer segment. The questions to ask for this
section are as follows: For what value are our customers really willing to pay?
For what do they currently pay? How are they currently paying? How would
they prefer to pay? How much does each revenue stream contribute to overall
revenues? [23]
6. Key Resources: Key resources are the resources needed to make the business
model work. Key resources can be financial, physical, human, or intellectual, and
they can be owned by the company or acquired by key partners [23]. Questions
to ask for this section are as follows: What key resources do our value
propositions require? Our distribution channels? Customer relationships?
Revenue streams? [23]
7. Key Activities: Key activities are the most important actions a company needs to
take in order to make the business model work. Questions to ask for this section
are as follows: What key activities do our value propositions require? Our
distribution channels? Customer relationships? Revenue streams? [23]
8. Key Partnerships: Key partnerships describe the network of partners that are
required in order to successfully introduce the product to the market. Questions
to ask for this section are as follows: Who are our key partners? Who are our key
suppliers? Which key resources are we acquiring from partners? Which key
activities do partners perform? [23]
9. Cost Structure: This section should include all of the costs required to operate
the business model. All of the costs associated with creating and delivering
value, maintaining customer relationships, and generating revenue can easily be
determined after defining the key resources, activities, and partnerships.
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Questions to ask for this section are as follows: What are the most important
costs inherent in our business model? Which key resources are most expensive?
Which key activities are most expensive? [23]

Fellows should create multiple versions of the business model canvas for each concept
and iterate on them in order to determine the best business models possible for each
solution. The top business model canvas for each solution should be documented and be
taken into consideration during final concept selection.
2.2.2.5: Prototyping and Feasibility Testing
A prototype allows a concept to be transformed into a form so that insights can be gained,
feedback can be given, and adjustments can be made. Prototyping is extremely important
in the design stage and is vital to the concept screening process. Fellows should be
encouraged to fail fast and fail early during this process, meaning low-fidelity prototypes
should be created often during this stage. Having a methodology or process for creating
prototypes efficiently can be very beneficial during this stage. Figure 18 demonstrates a
process fellows should use to efficiently assess concepts and mitigate risk by developing
different types of prototypes.
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Define important
questions for
prototypes to answer

Can question be
answered with a
simple prototype?

No

Break concept
down into
smaller parts

Yes
Determine type of
prototype to build; build
and test prototype

Refine design
requirements based on
feedback, and build
more detailed prototype

Figure 18: Process for developing prototypes to mitigate risk quickly.

1. Define the core questions that need to be answered for each concept to
mitigate risk: To prototype effectively, it is important to understand the most
important questions that need to be answered about a potential solution. The
issues the fellows should be focusing on are ones that, if addressed by a
prototype, will significantly mitigate risk moving forward. The goal of this
stage is to mitigate risk as quickly as possible and with the simplest test
possible. Fellows should focus on designing the least complex model possible
that can still adequately address the key issue or question, also known as a
minimum viable product (MVP). An MVP is a product that has the smallest
number of features that will work as a standalone product while still solving at
least one of the user’s core needs and demonstrating value [24]. This is a great
tool for maximizing customer feedback and learning in a short period of time,
in addition to being a great way to create a product that one can get into early-
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adopters’ hands as soon as possible. Having a clear understanding of what the
MVP should contain (refer to the need specification documents) is extremely
beneficial, because it keeps the fellows on track and does not allow them to
waste time focusing on building and testing “nice-to-have” features rather than
the critical features that bring value to the user.
2. Break concepts down into smaller, essential sub-concepts to test: Similarly
to the concept generation and brainstorming stage, where it can be
overwhelming to brainstorm on an entire need, trying to prototype an entire
concept can also be overwhelming and might take up more time than necessary
to answer the basic questions surrounding the solution. Fellows are encouraged
to break a concept down into smaller parts, or sub-concepts, that represent
different functions of the solution, and to prototype those parts. By doing this,
fellows can quickly prototype the smaller, essential components of the concepts
in order to test their feasibility and mitigate risk quickly. Once the smaller parts
have been prototyped and their feasibility proven, the fellows can begin to mix
and match prototypes to create a more cohesive solution.
3. Determine the best type of prototype to answer the questions surrounding
the concept: There are a variety of different types of prototypes that can be
built in order to test different theories or answer different types of questions. It
would be inefficient to design a prototype with human factors in mind just to
prove technical feasibility in a lab, just as it would be to receive feedback on
the look and feel of a design using a prototype that also functions technically.
It is important to gain answers to the questions surrounding the top concepts as
quickly as possible, and in order to do so, it is necessary to determine what types
of prototypes should be built to best attain those answers. As explained in
Biodesign: The Process of Innovating Medical Technologies, picking the right
prototype is extremely important [16]:
Just as developing a prototype that is unnecessarily
complex can be distracting to the innovators, it can
also be distracting to users when asked to give their
feedback… if an early works-like prototype looks
too much like a finished product, users may
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concentrate on how the device looks and feels
instead of focusing on critical issues related to its
fundamental functionality. The level of the
prototype must match the question or issue being
considered an only incorporate as much complexity
as is needed to find this answer.

Generally, there are three types of prototypes that are commonly used to address
different questions surrounding a concept: a “works-like” prototype, a “feelslike” prototype, and a “looks-like” prototype. During later stages of
prototyping, these models can also be combined to answer more specific
questions surrounding the concept. The types of prototype and the types of
questions they should be used to answer are explained in Table 4.

Table 4: Types of prototypes and their purpose.
Type of Prototype
Works-like
prototype

Description
•
•
•

Feels-like prototype

•
•
•

Looks-like
prototype

•
•
•
•

Demonstrate technical feasibility
May not look or feel like the end
product
Gather feedback about what
stakeholders like/dislike about the
functional aspects of the concept
Demonstrate ergonomics, weight,
size, etc.
Created from final material or
material similar to final material
Gather feedback about what
stakeholders like/dislike about the
usability of the concept
Demonstrate shape, color, size,
packaging, etc.
Used to demonstrate a “finished
looking” prototype to show to
investors or potential customers
Often created during later stages of
development
Gather feedback about what
stakeholders like/dislike about the
form factors of the concept

Purpose
Should be used to
answer questions related
to technical feasibility

Should be used to
answer questions related
to user experience and
usability

Should be used to gather
feedback surrounding
marketing, as well as to
communicate the design
to investors and
customers
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After feedback has been received and questions have been answered using the
types of prototypes described in Table 4, fellows should begin combining the
types of prototypes to answer more specific questions and move closer to a final
prototype. For example, a works-like/looks-like prototype might start to
incorporate some of the feedback surrounding form factors into a working
prototype, allowing fellows to use the device in more detailed testing in order
to better understand how stakeholders interact with the device as a whole and
gather feedback on how the form of the device might change the effectiveness
of the technology.
4. Refine design requirements and design more detailed prototypes: Once a
prototype has been developed and can demonstrate a concept in working form,
it becomes easier to gather specific feedback from stakeholders that can guide
improvements for the solution. Once the original need specifications have been
built into a prototype and tested, additional criteria can be defined based on
what has been learned from the prototyping and testing that was completed, as
well as the feedback gathered using those prototypes. Future prototypes should
incorporate the feedback gathered from earlier stages of testing and the new
design requirements. Through the process of developing more and more
detailed prototypes, fellows will start to understand the technical specifications
necessary for each design, in addition to the trade-offs necessary between
technical specifications and design requirements.
2.2.2.6: Define Ranking Criteria and Perform Final Concept Screen
After creating, testing, and gathering feedback on multiple prototypes, diving deeper into
IP, regulatory, and reimbursement strategies and looking into different types of business
models, it becomes time to decide which solution to move forward with into the
implementation stage. During research into the IP landscape, the regulatory pathway
required, reimbursement options, and potential business models for each concept, fellows
will automatically eliminate some of the concepts based on killer risks or problems that are
so important that it is clear to the fellows that the concept cannot move forward. Then,
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during the prototyping and testing stage, fellows should be able to eliminate the majority
of the leftover concepts based on feasibility. That way by the time they reach the final
selection stage, there should only be a small number of concepts left to evaluate, if they
were not already able to select a top concept through the activities performed during this
stage. At this point, it is time to define criteria to rank each concept against and evaluate
the risks associated with each leading concept. Fellows are encouraged to speak with their
advisors and mentors during this stage to help them evaluate the concepts without bias.

2.3: Stage 3: Commercialize

Figure 19: Summary of activities in the commercialization stage.

Now that the fellows have identified a viable need and proven their concept, it is time to
begin the commercialization process. Although this is the final stage of the fellowship, it
is really just the beginning of the company’s journey. After the fellowship is over, if the
fellows decide to move forward with their idea, they will continuously be iterating on what
comes out of this stage.
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During this stage, the fellows will build off of everything they have learned over
the last two stages relating to their need and concept. They will focus on refining strategies
related to every aspect of their company, including IP, regulatory, reimbursement, product
development, business models, and finances. The fellows will rely heavily on their advisors
and will begin to engage with consultants during this stage. It is imperative for them to
work with people who have a deep understanding of the areas they are researching. Any
money that is left in their budget after prototyping should be used to hire consultants or
bring on part-time advisors. If all of the allotted budget was used during prototyping, they
can discuss other forms of payment with potential collaborators. Commonly, law firms will
defer payments until a funding round, or advisors will help in exchange for equity rather
than money. Often, founders will even use their own funds to help move a project forward.
The payment methods are up to the fellows to negotiate and determine on a case-to-case
basis; what is important is that they find a way to work with experts during this stage to
develop the best strategies they can for moving forward.
2.3.1: Strategy and Pitch Deck Development
At the end of the fellowship, the fellows should possess enough information surrounding
their business and their path forward to pitch to angel investors for seed funding, compete
in business plan competitions, and apply to startup accelerators. The deliverable for this
stage, and therefore the fellowship, should be a complete pitch deck that can be used for
such applications and pitches. A pitch deck is a presentation that consists of 15–20 slides
used to showcase a product or technology and describe the business plan for the company.
It is typically used in place of a formal business plan document, which startups rarely
prepare at this early stage.
I suggest the approach of building the pitch deck as a way to prepare for
implementation, as this helps to identify any gaps in the knowledge and helps the fellows
focus on getting the help they need to fill in those gaps. Once the fellows have a pitch deck,
I would suggest that they pitch to advisors and any investors that they know, not for money,
but to see what questions they ask, where they lose focus, and what they don’t understand.
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This will help the fellows identify where they need more information and help them to
understand what does and does not resonate with their audience.
Throughout this section, I will break down the aspects of the pitch and all that needs
to be included. In doing so, I will explain in more detail the strategies that need to be
developed further during this stage in order to prepare the team to begin the fundraising
process. The steps below are listed in the suggested order for presenting in a pitch deck.
However, gathering the information for these sections will most likely be done in parallel,
as much of the information gathered for one section will also help in another.
2.3.1.1: The Problem
The key questions that need to be answered in this section are as follows: What is the
procedure associated with the problem; what are the problems with the current
method/procedure; why are they important; how important are they; and who are they
important to? At this point, the team should possess a very strong understanding of the
problem(s) associated with current methods of a procedure, but now it is the fellows’ job
to determine which problems are important to which stakeholders, and to tailor their
message to each of them. For this section, the fellows have to go through all of the issues
associated with the current procedure and determine which are the most important to
highlight to their audience.
This section should align very closely with what is presented in later in this section:
The Value. In both sections, there will be a large focus on the stakeholders and what they
value most, so it will be advantageous for the fellows to revisit the user profiles and
stakeholder analyses created previously and dive even deeper into them. They should
conduct even more stakeholder interviews, this time with the prototype and the knowledge
they possess regarding the functionality/potential functionality of their device. They should
gather feedback concerning what problems associated with the overall need are the most
important to the different stakeholders. Again, the fellows should already have a strong
understanding of this due to the extensive research they have performed throughout the
fellowship; now, they should be gathering additional data to substantiate their claims and
summarizing the data they have gathered.
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2.3.1.2: The Market Size
The key questions that need to be answered in this section are as follows: How big is the
market for the problem being addressed; how many procedures are performed each year,
or how many patients are affected; what is the cost of the current procedures; and what is
the total addressable market? Fellows should possess a basic understanding of the market
size based on the initial research performed during in the previous stages. However, now
it is time to for them to evaluate the market based on their solution and develop a better
understanding of the cost associated with the current procedures. Fellows should already
know how many procedures are being performed or how many patients are affected by the
need they are addressing. At this point, they need to focus on the market segments the
device could actually be applied to, in addition to the different sub-populations or
procedures the solution addresses. Segmenting the market in this way will aid the fellows
when it comes time to evaluate what their launch market will be. Once the fellows have
gained a better understanding of the number of procedures or patients that their solution
could potentially address, they can begin calculating their total addressable market. The
total addressable market is the amount of revenue that a business would earn if they
captured 100% of their market. This number needs to be large enough that, if they are able
to capture a small amount of it, their business would still be profitable and attractive to
investors. There are two main methods of calculating the total addressable market: a topdown approach and a bottom-up approach.
1. Top-down approach: A top-down analysis is usually conducted by first
determining the overall market and then applying filters related to the specific
solution in order to narrow the market down to what the solution can address in
order to estimate the share of the market that the company could capture. For
example, assume a company is developing a device for patients with late-stage
COPD (stage 4–5) who are not candidates for lung-volume reduction (LVR)
surgery. The number of patients with COPD in the country—or world, depending
on what market is being evaluated (national or global)—would need to be
determined. It is estimated that currently there are over 11M people with COPD in
the in the US [25]. Next, a filter would be added for the stage of the disease.
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Assuming 5% of patients have late stage COPD (Stage 4–5), the market would be
narrowed to 550,000 patients. Lastly, a filter would be applied for patients that are
not candidates for LVR surgeries. Assuming that only 25% of late-stage COPD
patients are candidates for LVR procedures, then the market would be 412,000
patients. This example is represented in Figure 20.

11M
55,000
412,000

Figure 20: Example of the top-down approach for a device
that targets patients with late-stage COPD who are not
candidates for LVR surgeries (Filters are based on
assumptions; therefore, end market value is not accurate and
should not be taken as such).

The cost of similar procedures or devices would then be determined and multiplied
by the market size in order to determine the total addressable market. For example,
assuming the average LVR alternative procedure costs approximately $35,000 per
patient, the total addressable market would be 412,000 x 35,000 = $14.42B.
2. Bottom-up approach: A bottom-up approach sizes a market based on estimates
related to small, defined segments of the market. One would start by identifying the
customer segments the device is intended to reach, the settings or places in which
the product could be sold, and how the customer segments are expected to grow
based on comparable products on the market and expected adoption rates. For
example, assume a technology company is entering a new market to provide health
and fitness data through a wearable device. Through research, the company
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determines that there are two customer segments that are likely to adopt the product:
Women ages 22–45 in urban centers, and married men ages 35–50 in urban centers.
In this case, the company would look at other devices on the market addressing
similar market segments to determine acceptable estimates for growth and adoption
rates. They would take into consideration where tech accessories such as wearables
are typically sold, how many locations sell wearable technologies, and how many
of these places would be willing to sell their wearable. This would require a mix of
stakeholder interviews and research into similar devices and the places they were
able to sell their products. They could then look at how many places sell devices
similar to their wearable each year in order to estimate the market size for their
product. This method is usually more time consuming and requires more research
than the top-down approach, but it is typically more accurate.

It is important to understand that market sizing in general requires a fair amount of
guesswork and estimations, and it will never be perfectly accurate. The goal is to make
educated assumptions based on a mix of research into the potential markets, comparable
devices, and stakeholder adoption rates so that one can better estimate how much money a
business could make when on the market.
2.3.1.3: The Competition
The key questions that need to be addressed in this section are as follows: How is this
product better than the competition; how will this invention be protected; and how can
competitors be kept from copying this product?
2.3.1.3.1: Understanding the Pros and Cons of Existing Products or Emerging Products
It is extremely important for the fellows to possess a strong understanding of how their
product differs from others on the market, and to be able to explain the benefits of their
product. This will be important not only for investors, but also for marketing strategies in
the future. There are typically three categories companies use to differentiate their product
on the market: Functional positioning, i.e., “Our device disinfects the tool 5x better than
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the leading brands;” symbolic positioning, i.e., “Our device reduces disposable waste
generated in the OR,” which appeals to a symbolic position that the consumer may value;
and experiential positioning, i.e., “Our bone saw is quieter than the competition,” therefore
making some steps of the procedure less annoying, loud, uncomfortable, etc. for the
physician.
The fellows should break down each of their competitor’s products and look at how
their product differs, focusing on the three different categories of positioning explained
above. They should determine a set of criteria to compare their product against based on
feedback from stakeholders regarding what aspects of the product the stakeholders value.
There are two main methods for visually demonstrating the competitive landscape
and how the solution being presented stacks up against competition: a graph or a table. If
displaying competition in the form of a graph, the fellows should choose two important
factors for comparison, which would become the axis of the plot. Then, they should plot
their competition, and themselves, on the graph, ideally showing that their product is a
better choice than that of their competition. An example of a competition graph for the
popular technology startup, Airbnb, can be seen in Figure 21. This option is beneficial if
there are few important factors that stakeholders consider when purchasing a product. If
there are multiple pieces of criteria to rank products with, the fellows should display their
product and competition as a table.

Figure 21: Competition graph for Airbnb. Reprinted from Slideshare. PitchDeckCoach (2015).
Retrieved from https://www.slideshare.net/PitchDeckCoach/airbnb-first-pitch-deck-editable.
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If the fellows choose to display their competition as a table, they should pick the most
important criteria that stakeholders are interested in when purchasing a product and list
them in the rows of the table. They should then develop a visual ranking system (i.e., red,
yellow, and green dots, or simply ‘x’s and check marks) to demonstrate how well each
product meets each criterion. An example of a competition table for a company called
Vidinterest, who claims to be “the Pinterest for video,” can be seen in Figure 22.

Figure 22: Competition chart for Vidinterest. Reprinted from Pitch Club: The Competition Slide
in Your Startup Pitch Deck. StartupsHK (2013). Retrieved from
http://www.startupshk.com/pitch-club-the-competion-slide-in-your-startup-pitch-deck/.

Both methods for displaying the competitive landscape are acceptable and widely used, so
the fellows should choose whichever method works best with their product.
2.3.1.3.2 : Protecting Against Competition
Understanding how a product compares to its competitors, and proving that the product
being developed is superior to them, is only half of the competition strategy. Another
extremely important factor is related to the company’s intellectual property (IP). Having a
strong IP strategy is particularly important in the medical device field. A strong IP strategy

60
can cause significant barriers to entry for potential competitors, as well as help to avoid
any costly lawsuits down the line. In order to have a strong IP strategy, the fellows need to
be consistently reviewing the patent landscape related to their solution and working with
patent experts to help create a patent portfolio that makes sense for them.
During this stage, fellows should consult with legal counsel to determine what IP
they should be filing at this stage and what they should think about filing in the near future.
Usually, this will result in the fellows filing one, or many, provisional patents on their
solution.
Fellows should also discuss with their attorneys whether or not it is a good time for
them to have an FTO search completed. It is commonly assumed that receiving a patent
means individuals are allowed to commercialize their product, but this is incorrect. There
are frequently situations where a device may have a patentable feature, but other features
of the device infringe on other patents. Therefore, it is very important to evaluate FTO.
The FTO searches performed by big law firms can cost anywhere between $10–
20k, so if the fellows cannot afford that, or their firm will not agree to defer the costs, they
should begin attempting a search themselves. This will most likely be sufficient for a
friends and family or seed round of funding, but once they raise money, they need to have
an official FTO search performed.
Often, startups will not include their IP landscape as an entire slide, but it is useful
to have this information on hand, or as a backup slide in case someone asks. Some investors
will want to see the FTO, as well as any patent applications as part of their due diligence
process, so it is wise to have these available.
2.3.1.4: The Solution
The key questions that need to be answered for this section are as follows: How does your
solution work; what are the features of your product; and how do you plan to test and
develop your product? This should be one of the easier sections to complete at this point.
After the concept generation and selection stage, the fellows should possess a strong
understanding of the different functions of their device and the features that their
stakeholders care most about. This section should be a general overview of the technology
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and the features of the proposed solution. It is very important that if a provisional patent is
not yet in place for any aspects of the design, drawings of those parts should not be included
in a pitch deck for public display. It is common for investors to decline signing a nondisclosure agreement, so it is sometimes acceptable to share details with investors before a
provisional is in place. However, the fellows should always consult their legal counsel
before disclosing any confidential information.
Below are two examples of acceptable solution slides for a deck (Figure 23 and
Figure 24). Figure 23 is for a technology company called Intercom, which developed a
platform that brings more of an engaging and personal experience to customer
communication and support.
Figure 24 is an example taken from the pitch deck for a company called LastBite,
which developed a mobile app to sell perishable food to last-minute consumers. Although
both examples are outside of the medical device industry, the same template can be applied
for a medical device.

Figure 23: Example of a solution slide for a company called Intercom.
Reprinted from Pitch Deck Examples: Intercom Pitch Deck. (2016). Retrieved
from https://pitchdeckexamples.com/startups/2016/11/4/intercom-pitch-deck.
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Figure 24: LastBite's solution slide from their pitch deck. Reprinted from Pitch Deck
Examples: LastBite Pitch Deck. (2016). Retrieved from
https://pitchdeckexamples.com/startups/last-bite-pitch-deck.

The purpose of this section is to tell the audience about the features of the proposed device.
It should focus on the features that are the most important to the stakeholders and that best
address the need. This will allow for an easy transition into the value section, in which how
the product creates value is explained.
In addition to focusing on the features of the solution during this stage, the fellows
should think about developing their strategy for moving the product forward through R&D.
They should create a development timeline and a testing timeline, as well as strategies to
accompany them. They need to think about the types of activities they need to complete
before moving onto the next stage of development. Working with engineering mentors will
be extremely beneficial for this. Having a strong path forward is extremely important, and
it will allow the fellows to understand what it will take from an R&D standpoint to get the
product market ready. They should focus on what their product will need to prove and the
most efficient way to acquire the necessary data. This includes, but is not limited to, benchtop testing, usability testing, animal studies, cadaver studies, human studies, sterility
testing, and biocompatibility testing.
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2.3.1.5: The Value
The key questions that should be answered for this section are as follows: How is your
product creating value for each stakeholder and why should stakeholders care about your
solution? It is extremely important to test assumptions surrounding value with stakeholders
before presenting to investors. Preparing this section will require a great deal of research
and numerous interviews, and this section will constantly change throughout
commercialization as the fellows continue to learn more and more about their stakeholders
and markets. Determining the of value a solution is a very complex process and utilizes a
mix of understanding what each stakeholder wants, how their needs differ, and how a
solution could affect them. Value can be emotional, physical, or monetary, and the fellows
have to determine which type of value their solution brings to each stakeholder and how to
quantify that value.
It is important that the points in this slide mimic the points presented in the need
statement slide. However, simply saying that a product addresses each of the major issues
defined in the need slide will not suffice. The fellows need to include numbers and data
with their value propositions in order to make them convincing and interest stakeholders.
The fellows should begin by determining the metrics that are most important to each key
stakeholder. For example, an ER physician might care most about efficiency and
throughput because the more patients he can see during his shift, the better. A hospital
administrator might be more focused on reducing complications and readmission rates. A
patient might care most about wait time, pain, and recovery time. Each stakeholder has
different priorities, so it is important to understand what they are and to develop a value
proposition for each of them. Some factors that fellows should research include, but are
definitely not limited to, average procedure times; costs of time in the OR/ER/Fluoroscopy
suites, etc.; readmission and complication rates and the costs associated with those; and the
number of physicians/staff required to perform a procedure and the hourly costs for each
staff member. This could be a very time-consuming activity depending on the product, and
it should be a huge priority for all fellows. It may be beneficial to enlist the help of a
healthcare economics specialist if public data is not readily available for the procedure in
question.
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It is important to understand that emotional values can be quantified as well. They
usually just take a little bit more time and creativity to determine how to quantify them.
For example, simply stating that a device improves patient satisfaction may not gain the
attention of hospital procurement staff. However, many hospitals are moving towards a
value-based healthcare system, and having poor patient satisfaction scores can result in a
hospital losing up to 2% of Medicare reimbursement payments. So, when pitching to a
hospital administrator or procurement director, rephrasing the value as “the unnecessary
suffering of the patient caused by the current procedure can lead to negative patient
satisfaction scores, undermining your hospitals’ ability to capture up to 2% of at-risk
Medicare payment,” for example, might make them more interested in that value
proposition.
For another example, assume a company is developing a device that improves the
emergency C-section procedure, reducing stress on the mother and recovery time. Both of
those are emotional values for the mother, and at first look could be hard to quantify and
generate interest from stakeholders other than the patient. However, women tend to be
decision makers when it comes to their family’s healthcare and where they are treated, so
their experiences can directly affect the number of customers a hospital has. A new tool
that promises to reduce recovery time and stress for a soon-to-be mother requiring a Csection might be a great marketing tool for a hospital to attract the decision makers of the
household, and thus grow their customer base.
This process will be very iterative, and similarly to market sizing and pricing, will
require a great deal of guesswork and assumptions. It is important to meet regularly with
advisors and stakeholders to evaluate the different value propositions and the assumptions
made in order to ensure that they make sense and resonate with the targeted stakeholders.
It is not required to present the numbers associated with each value proposition
during a pitch or presentation. However, the fellows must have this information available
in the event that it is brought up in a meeting or during due diligence with investors. Fellows
should create back-up slides, memos, or, at the very least, basic calculations for how they
have quantified each value proposition.
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2.3.1.6: The Business Model
The key questions that should be answered in this section are as follows: How can the
product make money; how will the product be delivered to the customers; and how much
will the product cost? The fellows should possess a strong understanding of potential
business models for their device from the work they performed with the business model
canvas. At this point, they need to dive deeper into their proposed business models and
focus on how they plan to get their product to the customer. The fellows should have a
strong understanding of the business models of devices currently on the market, as well as
those of their competition, and they should determine what makes sense for their product.
Often, a business model can help set a product apart from the rest and make it more
attractive than its competition.
More details surrounding the cost of goods, the price of the product, and the sales
and distribution plan should be determined during this step. The fellows should work with
local manufacturers to attain quotes for the cost to produce their product so that they can
build that into their pricing strategy. They should also speak with sales and pricing experts
to help them determine a suitable price range for their product, taking into account valuebased pricing. Lastly, the fellows should work with hospital procurement specialists and
value analysis committee members to determine whether or not their price reflects the value
of their product.
Unless the team has a medical device sales experts as a member, the pricing and
sales strategy will most likely be very preliminary at this point. These strategies are
expected to change once the fellowship is over and the fellows continue to commercialize
their device. As the design moves closer and closer to a design freeze, the cost of goods
sold (COGS) will become more finalized, and as they move closer to launch-stage
fundraising rounds, they will begin to bring on experts to help with building out a sales
team or identifying and managing the relationship with a suitable distributor. As the
product moves closer to launch, the business model will become more solidified.
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2.3.1.7: The Go-To-Market Strategy
The key questions that should be answered in this section are as follows: What is the
product’s path to market; what is its regulatory pathway; how will the product be
reimbursed; what is the initial target market; and what hurdles stand in the way of launch?
The go-to-market (GTM) strategy should consist of everything necessary to bring the
product to market, including information regarding regulatory classification and pathway,
reimbursement strategies, and launch activities. It can also include information regarding
sales and distribution of the product, but often times that is discussed during the business
model section.
2.3.1.7.1: Regulatory
The fellows should already possess a strong understanding of their regulatory pathway and
a comprehensive list of potential predicate devices from the research performed during
concept selection. During this stage, fellows should engage with a regulatory consultant to
review the research they have conducted and predicate devices they have identified in order
to see if the consultant agrees with the fellows’ assessment of their regulatory pathway.
The fellows should also discuss a plan for meeting with the FDA and whether or not a presubmission meeting would be beneficial for them. A pre-submission meeting is a meeting
with the FDA wherein the company requests feedback on questions surrounding specific
actions necessary to guide product development or preparation for their FDA submission.
Pre-submission meetings are generally beneficial if the company is unsure about their
classification, use of predicates, or testing strategy. It is usually advised that a company
have a pre-submission with the FDA once they are close to a design freeze, so that the FDA
can evaluate the design the company plans to submit for clearance, rather than early-stage
versions that will most likely see many changes before submission.
It is often advantageous for a company to have a memo written and signed by a
regulatory consultant detailing the company’s classification, pathway, and strategy to show
to investors during due diligence.
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2.3.1.7.2: Reimbursement
The fellows should already have a very strong understanding of their reimbursement
strategy due to earlier research. At this early stage, it is not expected for a company to have
already begun the process of talking with payers to begin the process of acquiring a new
code or being added to an existing code. What is important is that investors feel that the
company possesses a strong understanding of the reimbursement landscape; a sound
strategy for gaining reimbursement, if necessary for the business plan; and that there is a
willingness to pay for the solution. The fellows might consider working with a
reimbursement specialist to draft a memo similar to that of one drafted by a regulatory
consultant to either help determine a reimbursement strategy or approve the strategy the
team has already developed. It is also advantageous for the fellows to research similar
devices and see what their reimbursement pathway looked like and how much those
devices are reimbursed for. Having all of this included in a memo for future investors will
be extremely beneficial during due diligence, and it will make the company look very
prepared for investment.
2.3.1.7.3: Launch Market
The last part of the GTM strategy is choosing a market segment in which to launch the
product. When launching a new product on the market, the narrower the target market is,
the better. When a startup has a product that could be used in a variety of ways, it is often
tempting to try to design and market the product for all potential users. However, this can
be detrimental for a number of reasons. First, startups usually have a limited product
development and promotional budget, so concentrating that money on a very clearly
defined target group of users will produce much better results than attempting to spread it
across multiple different groups. Second, it is nearly impossible to design one thing that
satisfies the direct needs of all stakeholders. Companies that try to do this typically end up
with a very general and mediocre solution that contains a lot of features, but fails to
comprehensively solve any stakeholders’ problems. The fellows should focus on
developing and promoting a product that addresses one or two of their market segments.
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They should also realize that once they are on the market and gaining traction in the initial
market(s), they can expand into other markets.
The fellows should begin by looking at the different market segments they
identified during their market research and evaluate how likely they are to adopt the product
early on. The fellows should already possess a good understanding of what user types are
more engaged with the product and which are more hesitant from the market research,
stakeholder analysis, and value-proposition activities. However, users are not the only
thing that needs to be considered when choosing a target launch market. The fellows should
also consider which settings possess the lowest barrier to entry for testing, piloting, or
getting it into the hands of their users.
It is important to remember that the largest market segment may not be the best
segment to launch in. Although the fellows might encounter some push back from future
investors if they choose to launch in one of their smaller market segments, as long as they
have sound reasoning to back up their decision, it is okay.
2.3.1.8: The Financial Model
The important questions that need to be answered in this section are as follows: How much
money is required to get to the next significant milestone, or the next three significant
milestones; what partnerships need to be established to get to those milestones (product
development firms, manufacturing firms, etc.); and how many products will be sold in three
or five years? Creating a financial model is the last activity that needs to be performed
before pitching in front of investors or applying to accelerators or business plan
competitions. This can be an extremely challenging step, because it is hard to estimate how
much money an early-stage company will need in order to meet important milestones. This
section requires significant planning for all aspects of the business (R&D, testing,
regulatory, legal, business, marketing, etc.). The fellows should start off by evaluating their
timeline and the key milestones they will need to hit before launching their product. They
should then determine which milestones they think they can meet within a reasonable
amount of time that would significantly de-risk their product and raise their valuation. For
example, for an early-stage medical device company, a common milestone that falls under
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an initial seed round is completing proof-of-concept testing on animal models. There are a
number of other milestones the company would hit along the way, but that might be the
milestone they think will de-risk their product and increase their valuation enough to raise
another round. So, the company would then look at their timeline and determine what
exactly it would take for them to reach that milestone, as well as the other milestones along
the way. They would determine how many more employees they would need to hire or if
they would need to partner with a product development firm to help them get there. They
would also look at what type of consultants they might need and how much prototyping
and bench testing the product might cost. They would talk with advisors, mentors, and
other startup companies to create estimates for each of the activities that would need to be
done in order to meet those milestones. This is how the fellows should begin to approach
creating a financial model.
After the fellows have worked with their mentors to plan out the activities and
personnel required to reach certain milestones, they should begin working on creating
financial projections for their product. Investors commonly want to know what the
company’s revenue will look like at least three and five years out. Adoption rates and
growth rates can be very challenging to estimate, so it is advised that the fellows identify
similar products, or products that have similar business models and are sold in similar
settings. By researching similar products, the fellows should be able to acquire more
realistic estimates for adoption rates, which will allow them to more accurately project
early-stage revenues.
It is important to remember that adoption is much harder than it seems. A company
could have significant physician enthusiasm surrounding their product, but when it comes
time to sell it to the hospitals, the process all of a sudden becomes much more complex and
can take more time than estimated. It is always better to be conservative rather than overconfident in estimates related to adoption rates. The fellows should continuously run their
financial predictions by mentors and advisors, and may consider hiring an expert to help
them develop their financial model and financial predictions at this early stage.
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2.3.2: Investors, Accelerators, and Competitions
Creating a pitch deck is very different from an academic presentation. There should be very
few words on each slide, and it should be very visually appealing. At this point, the fellows
will have an abundance of information and will want to present it all to investors in order
to demonstrate their knowledge. However, it is important to keep the pitch concise. The
point of a pitch deck is to portray the most important information about a product and
business opportunity to the audience, not all of the details associated with a business. It is
important to craft a deck that resonates with the audience, so it is typical for startups to
have multiple decks to present to different types of audiences (clinicians, investors,
competition judges, etc.). They should work to pull the most important information
gathered in each of the sections in Stage 3: Commercialize and determine the best way to
visually represent the information. They should show the pitch deck to a variety of advisors
to gain feedback before presenting to investors or submitting to competitions and
accelerators.
The fellows should submit their deck to at least one local angel group, two startup
accelerators, and any business plan competitions in the near future that they can find. They
should research different types of startup accelerators and determine how their company
might benefit from them in order to choose ones that could truly accelerate their company.
Identifying and applying to accelerators and business plan competitions can be extremely
time consuming. However, most applications ask the same type of questions, so it is
suggested that the fellows create a master list of questions and formalize answers for each
question. This way, each time they apply to an accelerator or business plan competition,
they will already have the majority of questions answered, and simply need to modify them
for that specific application.
The fellows will learn a great deal by presenting to investors and applying to
competitions and accelerators. They should document all questions asked during any
presentation and craft answers for them. It is common for the same questions to be asked
after each presentation. If the same questions are being asked after each presentation, they
might consider creating backup slides that have more information relating to the questions
being asked. For example, if questions surrounding the current reimbursement landscape
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often come up during presentations, they might want to consider creating a slide that
contains the current codes used today and how they think their device would fit in under
those codes, or how they plan to acquire a new code and what reimbursement would look
like for their device.
The more pitches the fellows perform, the better they will become with them and
the more they will understand about their product and what their audience cares about
learning. It is a great experience and they should be encouraged to participate in any
opportunities to present their business in front of an audience of stakeholders or investors.
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CHAPTER 3: RESULTS

3.1: Stage 1: Identify
3.1.1: Needs Identification
Before beginning the fellowship, we were notified that our two clinical focus areas would
be emergency medicine and cardiac surgery. Upon arrival to Houston, rotations were set
up with one emergency medicine physician and one cardiothoracic surgeon. After initial
rotations with them, it was our responsibility to set up follow-up rotations with them and
any colleagues they were willing to introduce us to. We spent the majority of our time
during the needs identification stage in clinical rotations shadowing a variety of healthcare
providers in a range of settings. We spent a combined total of 245.5 hours in clinical
rotations, approximately 120 hours conducting research on disease state fundamentals and
market trends, and approximately 75 hours attending industry conferences. Throughout the
needs identification process, we identified a total of 373 unmet clinical needs, 104 of which
I identified. The percentage of needs identified for each need-finding activity can be seen
in Figure 25.

Research/interviews
4%
Conferences
22%

Rotations
74%

Figure 25: Percentage of needs identified from each need-finding activity.
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3.1.1.1: Observation
As Figure 25 demonstrates, the majority of our needs were identified during clinical
rotations (75%). This is most likely because the majority of our time was spent in clinical
rotations during the need-finding stage. Additionally, I believe that observation is the most
efficient method for identifying clinical needs. During the observation stage, we
participated in both cardiac and emergency medicine rotations (Figure 26). The cardiac
rotations were performed at the Texas Heart Institute (THI), and the emergency medicine
rotations were performed in a local community hospital (part of Harris Health System) and
with Harris County EMTs.

THI

surgery

HARRIS HEALTH

other

CABG

Cardiac Bypass Surgery

AATA

Ascending Aortic Thoracic Aneurysm Repair

AVR

Aortic Valve Replacement

LVAD

Left Ventricular Assist Device Implantation

PM

Pacemaker Implantation

EP

Electrophysiology Studies & Ablation

ICU

Intensive Care Unit Rounds

Animal
EMT
ER

New Device/Technique Studies in Animal Lab
Ambulance with EMTs
Emergency Room

Figure 26: Types of rotations completed and procedures observed.

For each rotation, we documented the date of the procedure, the type of the procedure, the
physician(s) we were rotating with, which fellows were observing (and where), and the
number of hours spent in observation. The complete breakdown of our observations and
the hours spent in each observation can be found in Appendix A. I performed 97.5 hours
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of clinical rotations and observations, including the cardiac operating room (CVOR), where
I observed multiple cardiac bypass procedures, a pacemaker implantation, ascending aortic
thoracic aneurysm repairs, left ventricular assist device implantations, and an aortic valve
replacement.

In addition to my rotations in the CVOR, I rotated in the cardiac

catheterization lab, the cardiac ICU, the community ER, and with EMTs. I was able to
identify 98 needs from the 97.5 hours of clinical rotations I performed.
As a team, we spent over 245 hours in the various clinical rotations, the breakdown
of which can be seen in Figure 27.
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Figure 27: Hours spent in each observation setting.

The 245 hours of clinical rotations performed as a team resulted in the identification of 277
needs. The breakdown of the number of needs identified for each clinical observation
setting can be seen in Figure 28.
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Figure 28: Number of needs identified in each clinical observation.
By comparing Figure 27 to Figure 28, it is not evident that there is a clear correlation
between the amount of time spent in a rotation and the number of needs identified, but that
is simply due to the nature of some rotations. For example, we spent 66 hours in EMT
rotations but only identified 31 needs. This was because we shadowed EMTs for
approximately half of their shift (roughly 10 hours), but there was a lot of downtime during
those shifts, as EMTs are not constantly being called out to an emergency. The animal
lab(s) was also not the best place to identify needs, as these involved devices in
development that were already addressing a need. However, it was very beneficial to
observe an animal lab in order to better understand what goes into designing and
conducting an animal study.
For rotations in the emergency department, the number of good needs identified
depended heavily on luck and the type of procedures that were occurring the day of
observation. Due to the inconsistent nature of ER shifts, a lot of the needs identified in that
setting were related to administration, communication, or patient throughput.
I found that, for surgical rotations, the more rotations I completed in one setting,
the better I understood the procedures being performed or the processes implemented, and
therefore, the more easily I could identify needs. I also felt that surgical rotations tended to
result in more needs being identified because of the highly technical nature of the
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procedures, in addition to the fact that there are a lot of people involved and a lot of things
going on at one time.
Sometimes we had access to video streams of live surgeries, either from a
conference or from online, so we would watch those whenever we had the chance. A total
of 10 hours were spent watching live surgeries, which, while not resulting in any new
needs, helped us to better understand some of the needs that had already been identified.
1. Preparing for observation: Before each procedure, we researched the procedure
and strove to understand what happens before, during, and after the surgery. If
multiple members of the team would be rotating at once, we would tradeoff which
member would perform the initial research and present a quick overview of the
procedure to the rest of the fellows. For rotations in the ER or with EMTs, it was
much more difficult to prepare, as we did not know what to expect. Often, we would
do research into the procedures we saw after our rotations and then go back to the
ER and ask the physicians any questions we had about anything that happened
during the previous shift.
2. Observation techniques: Each of us purchased a small notebook that could fit into
the pocket of our scrubs that we took into every observation (with the exception of
one animal lab where we were asked not to take notes due to the proprietary nature
of the study). We tried to observe surgeries in pairs, because we found that it was
difficult for one person to focus on the entire procedure, and we achieved more
clarity and needs from having two fellows observing at once. If two of us were
observing the same procedure, we either had one on the OR floor and one in the
observation dome, or, if there was no dome, we divided up what we would be
focusing on. For example, sometimes I would be standing by the anesthesiologist
watching the surgeon perform the steps of the procedure while one of the other
fellows would specifically be watching the surgical team and techs and how they
interacted with each other. In this way, we were able to observe the procedure from
multiple viewpoints and fully focus on different aspects of the procedure without
worrying about having to document the entire procedure.
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We timed each step of the procedure and looked for any inefficiencies or
repetitive steps. Any step of the process that did not make sense to us or seemed
unnecessary, we highlighted or starred in our notebooks so that we could ask about
them after the surgery. After each surgery, we spoke with the attending, residents,
and/or surgical team for approximately 15–20 mins to go over any observations we
made and ask any questions we had during the procedure. If the doctors were
performing something that was too complicated to explain with words, I quickly
sketched out what was happening. Figures 29 and 30 are excerpts from my
observation notebook, and they show my time-stamped notes, as well as a sketch I
made to demonstrate how a physician tied off a chest tube.

Figure 29: Example of timestamping a procedure.

Figure 30: Example of a quick sketch
that was used to explain what was
happening in a procedure.

We created a shared Excel spreadsheet to document our needs and observations.
After every rotation, we individually reviewed the notes and documented the needs
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identified during the rotation, along with any questions or observations we made
related to each need. At the end of every week, we debriefed as a team, discussed
the observations we made, and went over the needs we identified during our
rotations.
3.1.1.2: Industry Conferences
We attended three different conferences during the year, but only two of them occurred
during the needs identification stage. Two of the fellows attended the Transcatheter
Cardiovascular Therapeutics (TCT) conference where 80 needs were identified, and one
attended the American Heart Association conference, where no new needs were identified,
but a number of physicians that could help with needs validation were identified and
connected with. The conference I attended was called The BIOMEDevice Conference, and
this occurred during the concept generation stage. We decided that I would go to this
conference during the concept generation stage because it was about design thinking,
product development, and manufacturing. We believed that during the concept generation
stage, it would be beneficial to attend a conference such as BIOMEDevice in order to gain
a better understanding of the design and manufacturing process and identify potential
product development partners or manufacturing partners.
3.1.1.3: Clinician Interviews and Market Research
In addition to clinical rotations, we interviewed physicians about problems they see often
or needs that they would like to be addressed. For example, one of our needs, “A way to
restore elasticity to lung tissue affected by bullous emphysema or COPD that improves
treatment,” came out of an interview I conducted with a thoracic surgeon concerning
common issues he sees in his patients. He explained that when a patient has late stage
COPD, their lung tissue beings to lose its elasticity, and the equilibrium between the chest
wall and the lung is affected. This leads to air being trapped in the lungs, causing patients
to have short and fast breathing. He said there was some research being conducted
concerning new techniques and devices that could help restore elasticity. However, the
standard treatment was either a lung volume reduction surgery or a lung transplant, both of

79
which are extremely risky procedures and have very mixed results. By conducting
interviews with clinicians, such as the one I conducted with the thoracic surgeon, we were
able to identify eight new needs.
In addition to clinical interviews, we performed market research to identify some
of the costliest and most common diseases and complications in our clinical focus areas.
We each researched different segments of our focus areas and began performing research
surrounding the needs that industry and clinicians were concerned with. I chose to research
cardiac catheterization and minimally invasive cardiac procedures. Through market
research, I realized that aortic valve replacements were common yet dangerous procedures,
and they were often performed as an open-heart procedure. However, a minimally invasive
procedure, called a transcatheter aortic valve replacement (TAVR), had been invented, and
there was a big push for physicians to perform the replacements using the minimally
invasive TAVR technique. With further research into TAVR procedures, I realized that
there are still a lot of fatal issues with the TAVR, one main issue being that it is common
for the valve to leak once inserted, a problem that is unique to the transcatheter approach.
This research led me to identify the need for “an improved method for interventional
cardiologists to implant the aortic valve during a TAVR to reduce the incidence of
paravalvular leaks (PVL).” In total, eight new needs were identified during market
research.
3.1.1.4: Need Statements
After we had completed the majority of our needs identification activities and had
documented the observations and needs identified, we began translating the observations
into official need statements. In our shared observation spreadsheet, we deconstructed each
observation into the problem we identified, the stakeholder affected, and the desired
outcome. This helped us to prepare for translating the observation into a need statement.
Figure 31 is an excerpt from our Excel spreadsheet once we had taken the observations and
broken them down into the problem, stakeholder, and desired outcome.
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Figure 31:Excerpt from observation spreadsheet with observations broken down into the
problem, the stakeholder, and the desired outcome in order to prepare for turning them
into need statements.

We then went through and crafted initial need statements for each observation using the
format described in stage one of the Methods section (Need Statements). After crafting
need statements for each observation, we separated the needs by the procedure or
observation activity in which they were identified, and then we further grouped the needs
by type. For example, the needs identified during clinical observations were organized by
the procedure they were associated with and further grouped by whether the problem
related to a tool, communication, controls, the environment, or the procedure. The needs
identified at a conference or through research were grouped based on the disease, setting,
or procedure (heart failure, neuro-intervention, global health, TAVR, LVAD, etc.). If needs
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were identified at a conference that were also identified through observation, we kept both
needs in their respective groups rather than combining them so that we could track where
each need was identified and who we should speak with to validate the need. Eventually,
during the scoping process, we combined the needs that related to each other.
After grouping the needs, we gave each need a unique identifier to help us know
where it was identified and the type of need it was. For example, a need identified during
an aortic valve replacement surgery that related to a tool or device would be given the
identifier AVRt1 (AVRt1 if it was the first need in that category, AVRt2 if it was the second
one in the category, and so on).
After giving each need a unique identifier, we created a mind-map for each
procedure, setting, and conference, as well as a miscellaneous map for the needs identified
through other activities, such as clinical interviews or market research. We added each need
statement, along with the problem and the desired outcome, to the mind-map. Figure 32 is
an excerpt from our ER mind-map and demonstrates our naming system.

Figure 32: Excerpt from ER mind-map demonstrating how the needs were organized.
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As evident in Figure 32, some of our needs were not properly scoped and did not
include all of the necessary information (problem, stakeholder, and desired outcome) upon
initial creation. Once all of the needs had been captured in a mind-map, we began scoping
and refining the need statements. First, we looked for needs that were similar to each other
in order to determine if we could combine them into one succinct need statement. For
example, in an LVAD procedure, I noticed that closing the sternum was a time-consuming
process and that it caused a great deal of trauma to the tissue, resulting in a long recovery.
In a CABG procedure (and a follow-up interview with the physician after the procedure),
I learned that closing the sternum with sternal wires was not only inefficient, but it also
often caused infection at the site. These were three different needs, with three different
outcomes, and two different stakeholders, so I combined them into one need with the most
important outcomes: “A less traumatic way to close the sternum after open-heart surgery
that reduces the risk for separation and infection and allows for accelerated patient
recovery.” Table 5 demonstrates how I combined each of the related needs into one
comprehensive need focusing on the most important outcomes.
Table 5: Example of need statement scoping.
Need ID

Need

Desired Outcome

CABGt19

A less traumatic way for cardiothoracic
surgeons to close the sternum after openheart surgery that reduces the risk for
separation and infection.

Reduce separation
and infection

LVADt22

A way for cardiothoracic surgeons to
close the sternum that causes less trauma
to the tissue, reducing patient recovery.
A way for cardiothoracic surgeons to
quickly close the sternum after openheart surgery that minimizes time in the
OR.
A less traumatic way to close the
sternum after open-heart surgery that
reduces the risk for separation and
infection and allows for accelerated
patient recovery.

Reduce patient
recovery time

LVADt29

CABGt19 +
LVADt22 +
LVADt29

Minimize time in
OR

Minimize time in
OR
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As evident in the combined need, I focused more on the outcomes associated with patient
safety. I was able to make that choice based on conversations I had with cardiothoracic
surgeons who validated the more important outcomes, in addition to looking into costs
associated with the complications and recovery time versus costs associated with OR time.
We found need statement scoping to be an ongoing process, and one that continued
throughout need screening, as we learned more information about each of the needs and
better understood the problem. However, once we had created need statements for all of
our observations and had taken a few passes at scoping each of them, we moved into initial
needs screening so that we could begin diving into the necessary research to better
understand and scope each need.
3.1.1.5: Initial Needs Screening
With over 370 unmet clinical needs identified, defined by need statements, and categorized,
we performed an initial round of screening so that we could eliminate less important or
incremental needs and begin diving deeper into researching the needs that could have
significant impact. For an initial screen, each of us went through each mind-map and
ranked each need with either a 1, 3, or 5, individually. This was essentially a gut check, but
we used the information gathered from our clinical interviews and the observations we
made to rank them based on perceived clinical impact and our personal enthusiasm. A
ranking of 1 meant that we felt it had minimal clinical impact and/or there was minimal
personal interest, a 3 meant it had medium clinical impact and/or there was medium
personal interest, and a 5 meant it had high clinical impact and/or there was high personal
interest. After each of us had a chance to rank the needs, we went through the mind-maps
as a team and discussed our ranking for each need. There was a consensus on the ranking
for the majority of the needs, but any needs that were not ranked the same by each fellow
were discussed as a team and assigned a final ranking. Any need that we ranked as a 1 was
immediately eliminated. Through this initial need screening, we eliminated 181 needs,
leaving us with 192.
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3.1.2: Needs Screening
With just under 200 needs remaining after the initial screen, we began researching the
remaining needs and developing a more structured way to filter them. At this point, there
was still a large number of needs, so research was very broad. In preparation for the first
official screening, we each chose approximately 50 needs to research. After the first round
of screening, we were able to narrow the list down to 50 needs, so each of us continued
research into 11–14 needs to prepare for the second round of screening. After the second
round of screening, we had narrowed the list of needs down to 16. At this point, we each
performed deeper research into approximately four needs for the purpose of creating a need
specification document, which we would present to stakeholders in order to receive
feedback. We then used the information gathered during the clinical feedback panel to aid
us in choosing our top three needs. The research we conducted throughout the need
screening process, as well as the different rounds of needs screening, are described in more
detail in the following sections.
3.1.2.1: Disease State Fundamentals
For each need, we researched the disease state fundamentals in order to try and understand
the cause of the problem and the anatomy associated with it. When conducting my disease
state fundamentals research, I specifically looked at the patients affected by the problem,
what causes the problem, and how the problem is addressed or diagnosed. For example,
for the need of “an efficient way to restore elasticity to lung tissue affected by bullous
emphysema or COPD that improves treatment,” I broke my research down into what
causes inelasticity (hyperinflation of the lung), the types of hyperinflation of the lung, at
what stage hyperinflation occurs, the type of patients who get hyperinflation, and the
current method of diagnosing the problem. I then looked further into the physics and
biology of the problem. For example, I found that two types of hyperinflation occur with
later stage COPD: static hyperinflation and dynamic hyperinflation.
As this need continued to make it through each screening round, I continued to
perform deeper analyses into the disease state fundamentals. A more detailed analysis of
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the disease state fundamentals for this need can be found in the need specification
document created for this need in Appendix C.
3.1.2.2: Existing Solutions
In order to assess how well a need is already being met, or the potential competitive
landscape for a solution, we had to look into the existing treatment options. For the needs
I was researching, I created a table to document and organize the current treatment options.
Table 6 is an example of an analysis I performed for the existing and emerging solutions
for the need “a way for physicians to perform lumbar punctures (LPs) that saves time and
reduces the incidence of complications.”

Table 6: An example of a treatment analysis performed for a need relating to the
inefficiency of LPs.
EXISTING TREATMENTS
Treatment Option

Benefits

Blind technique
(physician uses
palpation to identify
landmarks and
estimates where to place
needle; uses
commoditized kit)

•

Ultrasound-guided LPs

•

•
•

•
•
Fluoroscopy-guided LPs

•
•
•

Risks

Cheap/cost effective
solution
No additional
setup/prep (compared
to US/Fluoro)
Can be performed in
the ER/clinic (no
additional resources
necessary)

•

Provides visualization
of midline
Provides some
visualization of
vertebrae and gap
Reduces first attempt
failure rate
High precision for
needle placement
Increases efficiency of
needle placement
process
Less pain to patient

•
•

•
•
•

•
•
•
•

Not placing needle properly on first
try (causing harm to patient)
Causing post-LP headache
Causing “bloody-tap” (they cannot
use the sample and will have to
repeat the LP)
Having to send patient to radiology
because they cannot properly place
the needle
Increases cost of procedure
Image output difficult to interpret,
resulting in inaccurate needle
placement
Potential to increase time of
procedure
Significantly increases cost of
procedure
Exposes patient to radiation
Could cause delays or throughput
issues when patient has to wait for
radiology suite to open up

EMERGING TECHNOLOGY
Technology

Benefits

Risks
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TABLE 6 CONTINUED:
Specialty ultrasound
devices for vertebral gap
identification

Non-invasive
intracranial pressure
monitoring systems

•
•

•
•

Improved visualization
of gap and vertebrae
Designed specifically
for spinal needle
placement

•
•

Non-invasive
Accurately measures
intracranial pressure
without harming patient

•

•

•

Increases cost of procedure
Used prior to prepping patient, so
still room for error when inserting
needle
Potential to increase prep/setup
time
No collection of CSF, so cannot
diagnose meningitis
Limited to measuring intracranial
pressure and diagnosing issues
related to that

Similarly to the other research performed during this stage, the treatment options and
existing solutions analysis continued to become more and more detailed as the needs
progressed through each screening round. A more detailed example of a current treatment
options analysis can be seen in the need specification document for the need “a way to
restore pulmonary function in lungs affected by COPD that improves clinical outcomes
and patients’ quality of life” in Appendix C.
3.1.2.3: Stakeholder Analysis
We began the stakeholder analysis by first identifying all of the potential stakeholders
involved with each need. We then reached out to those stakeholders and inquired about
other potential stakeholders we might have overlooked. Once we felt that we had a
comprehensive list of stakeholders, we began plotting each stakeholder on a chart
according to their decision-making power and their level of interest. An example of an
initial stakeholder analysis chart can be seen in Figure 33. This helped us to determine
which stakeholders were primary stakeholders and which were secondary. It also helped
us identify which stakeholders we needed to learn more information about to see if a
potential solution could help us move them from one box to another. For example, it would
be beneficial for us to be able to move stakeholders that are currently in the top left box
(high power and influence, but low interest and commitment) to the right, into the high
interest, high influence power box, and in order to know if that was possible, we needed to
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find out more information about them and understand how a potential solution could affect
them.

Low interest, high influencing

d

Power and Influence

power

Low interest, low influencing
power

Interest and Commitment

Figure 33: Example of initial stakeholder analysis created for the
need: A way to restore pulmonary function to lungs affected by
COPD that improves clinical outcomes and patients' quality of
life.

After creating a stakeholder analysis chart, we began creating user profiles for each of the
stakeholders with a significant focus on primary stakeholders and stakeholders that we
believed could become primary stakeholders. At first, we categorized them by general type
(i.e., physician, payer, patient, hospital administrator, etc.). However, as we learned more
and more about the different stakeholders, we further categorized them into sub-users (i.e.,
ER resident, ER attending, physician’s assistant, nurse, private insurer, public insurer, etc.)
and created more detailed profiles on each new sub-user. We validated each assumption
we made with a number of stakeholders in order to ensure that we were as accurate as
possible in our characterization of each user.
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These profiles were living documents and continuously changed as we learned
more about each stakeholder and moved further along in this process. An example of a user
profile that I created for a teaching hospital ER resident can be found in Appendix B.
3.1.2.4: Market Analysis
One of the criteria we used during each screening round was market size, and so we had to
develop an understanding of the market(s) associated with each of our needs. We began by
researching the number of procedures performed each year in the US or the number of
people affected by the disease associated with the need, and we began narrowing our
research from there. For example, with the need relating to COPD, I began by researching
the number of people affected by COPD, after which I researched the different stages of
COPD and the approximate number of people affected in each stage.
I also researched the cost associated with each need. Continuing with the COPD
example, I looked at the cost of the different treatment options and the cost of the
complications associated with each option. I also looked at factors such as the number of
days of work missed each year due to COPD and the costs associated with those missed
days. All of this information helped me develop an understanding of the size of the market,
with respect to both the size of the population and the cost associated with the need.
1. Market mapping and segmentation: For many of the needs, it was beneficial to
create a basic map of the market. An example of a basic market map I created for
a need relating to COPD, segmented largely by stage of COPD, can be seen in
Figure 34.
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COPD (14M+
patients)

Mild (40%)

2% hospitalized
each year

moderate costs
associated with
hospitalization

High number of
treatment options
(non-surgical)

Moderate (55%)

7% hospitalized
each year

Moderate costs
associated with
hospitalization

High number of
treatment options
(non-surgical)

Severe (4%)

18% hospitalized
each year

Few treatment
options avaliable
(Surgical +
pharmaceutical)

Significant costs
associated with
hospitalization

Very Severe (1%)

33% hospitalizaed
each year

Very few-no
treatment options
avaliable

Significant costs
associated with
hospitalization

Figure 34: Example of a simple market map for a need relating to COPD.
Although this map is very simple and is segmented in a very basic manner, I was
able to understand how the stage of the disease affected the market based on both
population and cost. From the map, it is clear that even though the majority of
COPD patients are categorized as mild/moderate, the hospitalizations for severe
and very severe patients are much costlier. This helped me to better understand how
different solutions would work in different market segments. For example, a
solution focused on helping the severe/very severe COPD population might not
have a large market size in terms of the number of patients affected, but it could
have significant value if it was able to keep those patients out of the hospital.
Conversely, a solution that addressed mild/moderate stage COPD would be able to
affect a large number of people, but it might not be as valuable in terms of lowering
costs to the healthcare system due to hospitalizations. Creating maps like this not
only helped me in understanding the different segments of the market, but also what
a solution would have to address in order to be valuable.
I also segmented markets based on factors other than stage of disease, such
as the type of physician performing the procedure, the reason for the procedure,
procedure setting, population demographics (low-income vs high-income), and so
on. Different types of segmentation made sense for different needs, and thus I
created different market maps. An example of a market map I created for a need
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relating to LPs, which I segmented by the reason for performing the procedure and
the setting in which it is performed, can be seen in Figure 35.

Spinal punctures
(12.7M)

Therapeutic
(Epdiruals/
Epidural Steroid
Injections) (11.9M)

Diagnostic (800k)

Emergency
Department

ER Physician

Neurology

Physician's
Assistant

Neurologist

Obstetric
Anesthesiology

Anesthesiologist

Nurse Anesthetist

Radiology

Radiologist

Orthopedic
Anesthesiology

Anesthesiologist

Nurse Anesthetist

Figure 35: Example of a market map segmented by the procedure and the setting the
procedure is performed in.

Originally, the need associated with the market map in Figure 35 was specific to
only LPs, a diagnostic procedure. However, when we began market research and
segmentation, we were able to uncover a number of other markets that a solution
addressing the inefficiency of LPs could also address. Epidurals and epidural
steroid injections are very similar to LPs in terms of anatomy, the methods used,
and the materials used, so we were able to include those procedures as part of our
market as well. If the only potential opportunity had been with LPs, we would not
have been able to move forward with that need because the market size would have
been too small to make a solution commercially viable.
2. Target market: After we understood more about the market and the different
ways to segment it, we picked the market we thought would be the most
advantageous for us to focus on (our target market). This initial choice was based
on information gathered during this stage of the process. However, in Stage 3:
Commercialize, we conducted a much deeper market analysis on the top need and
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solution, and thus were able to make a much better informed decision as to what
market we should target first.
Choosing a target market was necessary in order to scope the need and
evaluate it against others during the need screening process. We chose the target
market based on multiple factors, including market size (population and financial
size), market dynamics, existing solutions/solution gaps in certain market
segments, and stakeholder enthusiasm.
3.1.2.5: Needs Screening & Selection
We performed two official rounds of needs screening to reach the 16 top needs that we
presented to a panel of clinical experts for the final screening round. For each round of
screening, we determined the criteria that we would use to rank the needs against. Each
fellow individually ranked the needs based on the determined criteria, after which we
compiled all of the rankings and determined which needs made it into the next round.
Before eliminating any needs, we went through the list as a team and highlighted any needs
that any of us felt should not be eliminated and discussed them as a group. A detailed
explanation for each round of needs screening is described below.
3.1.2.5.1: Round 1
During this round, we conducted broad research focused on the clinical impact and market
size. We each chose approximately 50 needs to research. After we conducted broad
research into each of our needs, we summarized the initial findings and presented them to
the team before screening. The needs were ranked by each individual on a scale of 1–4 so
as to avoid any neutrality (i.e., the rank of 3 if it was on a 1–5 scale). We assessed each
need using the four weighted criteria, which can be seen in Figure 36. Explanations for the
criteria and their weight are described in more detail below.
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Figure 36: Criteria for the first round of need screening.
1. Clinical impact (weight: 0.4): This was deemed the most important criteria
because we did not want to create an incremental solution. We wanted to solve a
need that could have significant impact.
2. Personal enthusiasm/interest (weight: 0.25): This was the second highestweighted criteria because we agreed that it was important for all of us to be
interested and passionate about the problem so that we would be dedicated and see
it through development.
3. Market size (weight: 0.2): This was the next criteria because we felt that without
a large market, it would be very difficult to raise capital and create a sustainable
business model.
4. Feasibility (weight: 0.15): This was defined by the team’s experience, the basic
understanding required to create a solution to address this problem, and the
expected timeline for a solution. This was weighted the lowest because at this point,
it was difficult to know what types of solutions could address the problem.
However, we still wanted to include this in order to eliminate any needs that seemed
more like research projects, or needs that would lead to solutions requiring
significant experts in a certain field just to reach a proof-of-concept prototype.
After defining the criteria and assigning them a weight, each of us took one day to
individually rank each need based on the four criteria. We then inserted all of our rankings
into a shared spreadsheet and calculated the average ranking for each need for each person,
as well as the overall average ranking for each need based on all of our rankings. Needs
were then organized by ranking and color-coded to determine which needs should be
eliminated and which should move on to the second round. Any need with an average score
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of 2.85 or lower was colored red. We chose 2.85 as a cutoff value because that allowed us
to cut the list down to approximately 50 needs Any need ranked higher than 2.85 was left
white. We spent the following two days going through all of the needs and flagging any
we thought were unfairly ranked (i.e., should be eliminated but were not, or were
eliminated but should not have been). These needs were highlighted yellow. We also
flagged any needs that we thought were similar to others and could either be eliminated or
combined and scoped to be turned into one need statement. These needs were highlighted
purple. We then discussed every need that was highlighted and decided whether or not to
eliminate it. After discussing each flagged need, we finalized a list of our top 49 needs for
further research. An excerpt from our need ranking spreadsheet can be seen below in Figure
37.

Figure 37: Excerpt from the needs screening ranking spreadsheet for the first round of
screening.
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3.1.2.5.2: Round 2
With only 49 needs left, we began extensively researching each need. We split up the needs
amongst the fellows, so each of us chose between 11 and 14 needs. We tried to split up the
needs by who observed them and had been doing research on them, but this wasn’t possible
for every need, because some fellows had many of their needs make it through to the next
round, while other fellows only had a few of their needs make it. In the event that we were
assigned a need that we had not been researching, the person who had any preliminary
research on the matter shared the research with whomever was assigned the need. I was
given 13 needs to research, the majority of which I had already been researching.
We created a shared document on our Google drive with sections for the need, a
summary of the disease state fundamentals, the competitive landscape, the important
stakeholders and their requirements for a solution, the market size, and other key facts
about the need. As we performed research into these needs, we summarized the information
we found and added it to the document on the shared drive. After approximately three
weeks of in-depth research into each of our needs, we each presented our findings to the
group and discussed each of the needs in great detail.
After each of us had presented our findings for the needs, we performed another
round of screening. We identified and weighted seven different criteria for ranking the
needs for this round. The criteria and weights can be seen in Figure 38. In this round, we
determined the weight by having everyone individually weight each criterion and then
averaging the weights from each individual. The sum of the weights for each criterion
added up to one. We included market size, team enthusiasm, and feasibility from round
one, and then we expanded on “clinical impact” to include patient impact, provider impact,
and facility impact. We did this because at this point, we had much more detail surrounding
the type of impact a solution could have, and we wanted to weight different impacts
differently. We felt that patient impact was the most important, followed by provider
impact and then facility impact. We also added a criterion that was not included in round
one, namely, competitive landscape, because after our in-depth research into treatment
landscapes during this round, we had enough information to rank needs based on how
adequately current solutions were meeting them.
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Figure 38: Criteria for the second round of needs screening.

We each took a few days to review all of the research conducted on each need and
individually rank the needs, similarly to what we did for the first round of screening. I then
aggregated everyone’s rankings and calculated the average ranking for each need, sorted
the needs by average ranking, and determined the top 15 needs based on average rankings.
I also went through everyone’s individual rankings and flagged any needs that were in
someone’s top 5 that did not end up making the overall top 15, or that were in at least two
team members’ top 15 that did not make the list. For example, the need “an efficient method
of simultaneously sealing tissue and skin layers after an open-heart procedure that reduces
time in the OR” was ranked 18th once everyone’s rankings were averaged, but it was
included in the top 15 needs for both myself and Nicole, so it was flagged for discussion.
Once all necessary needs were flagged, we discussed them as a team and determined that
we had 16 strong needs that we wanted to move forward with and develop need
specification documents for. Figure 39 shows the top needs taken from the ranking
spreadsheet for this round of screening. As evident in Figure 39, we decided to keep need
19 after discussing it as a team, and it became our 16th need. It is also evident that we added
another color to the spreadsheet for flagging, namely, blue. This color was used to mark
needs that we had specific questions about that came up during the needs screening process
and that needed to be answered during the next stage of research.
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Figure 39: Excerpt from needs screening spreadsheet for round two.

3.1.2.6: Need Specification Document
With only 16 needs remaining, we conducted more in-depth research so that we could
create a need specification document. During this stage, we looked for any gaps in our
research and sought to fill them. We elaborated on the research already compiled for the
disease state fundamentals, competitive landscape, stakeholder analysis, and market
analysis. We summarized all of the research we conducted for each need into a need
specification document. We chose to format them into PowerPoint presentation so that they
could easily be presented to stakeholders for validation and our clinical panel for final
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needs selection. An example of a need specification document I created can be seen in
Appendix C.
3.1.2.7: Final Selection
Once we created a need specification document for all of our top needs, we presented them
to a group of mentors of varying clinical and entrepreneurial backgrounds for feedback and
validation. We presented each need to the panel, opened the floor for questions, and had
detailed discussions about each need. After the feedback session was over, the mentors
summarized their thoughts on each need, and ranked the needs based on their opinion and
the topics discussed in the session. By the end of the session the top 5 needs were very
clear, so we had to decide on two to eliminate. We reviewed the top 5 needs as a team, took
into account the mentors feedback and all of the research we had conducted, and decided
on our top 3 needs. The top 3 needs we decided to move forward with into Stage 2: Create
can be seen in Figure 40.

Figure 40: Our top three needs.
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3.2: Stage 2: Create
3.2.1: Concept Generation
Once we finalized our top three needs, we began the brainstorming and concept generation
phase. We used a variety of the brainstorming techniques listed in the Methods section
(Methods, Stage 2: Create, Concept Generation) to account for every team member’s
individual style, and we closely followed the methods recommended for concept
generation.
1. Establish Rules: We created a list of rules similar to those used at IDEO, but we
added and changed some to suit our specific needs (Table 7). We posted the rules
during every brainstorming session to ensure we remembered them and held
ourselves and others accountable.

Table 7: Team rules for brainstorming sessions.
Rule

Description

Rule 1: Capture every
idea

Use the space around you to document your ideas, either
on post-its, white boards, notepads, etc. Capture all of the
ideas at the end of the session.
Think outside the box—wild ideas get people thinking
and they lighten the mood to allow the mind to flow.
Do not dismiss any ideas during the session.

Rule 2: Encourage wild
ideas
Rule 3: No devil’s
advocates
Rule 4: One
conversation at a time
Rule 5: Stay focused on
the problem at hand
Rule 6: Build on the
ideas of others
Rule 7: Quantity over
quality

Allow everyone to get their entire thought out before you
begin another. Do not interrupt anyone.
Try to stay on the topic of the brainstorming and don’t
allow for tangents.
Collaborate as much as possible during these sessions
and allow others’ ideas to spark your own.
At this stage, the goal is to come up with as many ideas
as possible in the allotted time. No idea is stupid or
unrealistic during this stage.

2. Break needs down into smaller problems, causes, or functions: We completed
2–3 general brainstorming sessions for each need before deciding to break the needs
down into sub-problems for brainstorming. We found that brainstorming on an
entire need or problem was good for initial brainstorming sessions and for preparing
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us for the concept generation stage. However, it also quickly became overwhelming
and resulted in scattered, partially thought-out concepts. Additionally, we noticed
that during brainstorming sessions on broad needs, there was not much building off
of others’ concepts. To help ourselves focus and be more collaborative in the
sessions, we broke down the overall problems or functions required for a solution
into sub-problems or sub-functions. Figures 41 and 42 below are examples of how
we broke down two of the problems associated with a need into sub-problems.

Need: A way to restore pulmonary function to lungs affected by COPD that improves clinical
outcomes and patients’ quality of life.

Pulmonary function
decreased due to
COPD

Enlarged air sacs

Impaired gas
diffusion

Air trapped due to
collapse

Poor equilibrium
between lung and
chest wall

Narrowed small
airways due to
fibrosis/smooth
muscle contraction

Figure 41: Example of problem/sub-problem breakdown for our COPD need.
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Need: A way for physicians to perform LPs that improves efficiency and reduces the
incidence of complications

Lumbar punctures
are inefficient and
inaccurate

Difficult to identify
landmarks

Difficult to insert
needle consistently

Fluid collection is
unsafe and
inefficient

Pressure reading is
inaccurate and
cumbersome

Figure 42: Example of problem/sub-problem breakdown for our LP need.

3. Implement different brainstorming techniques: We implemented a variety of
brainstorming techniques throughout the concept generation process and found that
it was beneficial to use a combination of different techniques for each need and
sub-need so that every person on the team could be productive in a session. The
techniques we used most are described below
a. Timed brainstorming: The goal was to come up with as many ideas as
possible as a team in a specified amount of time (usually 30–60 mins).
This was great for the extroverts in the team and helped to prepare our
minds for concept generation. It was easy for certain people to dominate
in this type of brainstorming session, though, so it was important to have
a moderator to keep everyone on track and following the rules.
b. Individual brainstorming: We set aside a few hours over a couple of
days (we did a couple of hours over three days on average) to focus on
the problem individually and to brainstorm ideas, after which we came
back together as a team and presented our ideas. This was productive
because it allowed each team member to think about concepts generally
throughout the day and document them as they came into their minds.
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Usually, these concepts/ideas were more thought out and detailed
compared to the ideas generated in the timed brainstorming sessions. An
example of a concept that was generated during an individual
brainstorming session on fluid collection for the need relating to LPs
can be seen below in Figure 43.

Figure 43: Example of a concept that was generated during individual brainstorming on
fluid collection.

c. Silent team brainstorming: We spent between 3–5 minutes coming up
with as many ideas as possible individually for the specific need being
addressed, and then we presented and discussed our ideas as a team once
the time ran out. This worked well for the introverts in the group because
they were able to gather their thoughts without the constant talking that
occurred during the group timed brainstorming sessions. After everyone
presented their ideas, we brainstormed on the ideas that were presented
and tried to build off of the ideas of others.
d. Cross-pollination sessions and research: We conducted research on
technologies and devices in other practices that were solving similar
problems to help in our brainstorming. For example, when researching
ways to solve the need “a way for physicians to perform LPs that
improves efficiency and reduces the incidence of complications,” we
looked at other devices that were eliminating blind insertion techniques,
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as well as devices or technology that helped visualize underlying
structures in the body. Not only did we look across different areas in
medicine, but we also looked at solutions in completely different
industries. One of our sub-problems was “identifying landmarks for LP
placement.” During cross-pollination sessions and research, we looked
at many different industries, including medicine, oil and gas,
defense/military, and home improvement. Some examples of the
technologies that we identified in various industries can be seen in Table
8.

Table 8: Findings from cross-pollination research session.
Medicine
(How do you image
for other
procedures?)
• Ultrasound
• XRay/Fluoroscopy
• Tactile
• IR
• UWB
• MRI
• Echo

Oil & Gas
(How do you
know where to
drill?)
• Thermography

Defense/Military
(How do you find
landmines and
objects hidden
underground?)
• Radar
• SONAR

Home Improvement
(How do you find
objects hidden in
walls?)
• Radar
• Capacitive sensing

After the cross-pollination sessions, we added all of the technologies we
identified into a mind-map and organized them by type of technology used
(i.e., acoustic, electrical, EM waves, etc.). An excerpt from the mind-map
created for “identifying landmarks for LP placement,” with a focus on
identifying the gap between vertebrae, can be seen in Figure 44 (next page).
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Figure 44: Excerpt of mind-map for “identifying landmarks for LP placement: Identify gap between
vertebrae,” with findings from a cross-pollination and research sessions.

e. Brainstorming sessions with external people/experts: After multiple
brainstorming sessions, it was common for us to feel stuck and have the
opinion that we had exhausted our ability to come up with new
solutions. When this happened, we often brought outside people into our
brainstorming sessions, and we found that this helped generate new
ideas. These people were either mentors or physicians who were
familiar with the problem or people who knew nothing about the
problem at all. We found that bringing in someone who had not been a
part of past sessions could help spark new ideas and generate types of
solutions that nobody in our group had ever thought of. However, we
realized that this can also be tricky and cause some issues surrounding
IP, so we always discussed this potential issue before a session and had
an agreement in place before starting regarding any Intellectual Property
(IP) that was generated during the session.
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4. Capture and organize the results: During sessions, we documented ideas on
paper, post-its, and white boards, and we sometimes explained concepts using lowfidelity prototypes. After each session, we named each idea, photographed sketches
or prototypes if necessary, and then documented them in mind-maps. We created a
mind-map for each of our top three needs and found that it was easiest to group
ideas based on function and sub-function. These functions/sub-functions were
defined by the problems/sub-problems that were previously defined for
brainstorming. For example, for the need “a way for physicians to perform LPs that
improves efficiency and reduces the incidence of complications,” the concepts were
organized by their sub-functions: localize underlying landmarks, consistently insert
needle, measure spinal pressure, and collect CSF.
5. Initial concept screening: In order to perform the initial concept screen, we reengaged with the physicians that led the rotations where the need that the solution
addressed was identified. We gathered their feedback to determine whether the
solution was meeting the needs defined in the need specification document. In
addition to talking to physicians and other important stakeholders, we developed
some general criteria to use to help us screen some of the concepts and perform
“gut checks” on the solutions. Our team focused primarily on perceived feasibility,
time required to develop a proof-of-concept, team enthusiasm, and whether or not
the skillsets necessary to develop an early-stage prototype were represented on the
team. For example, we knew that some concepts would require more technical
expertise than the team possessed in order to develop a proof-of-concept prototype,
so we had to eliminate those concepts; other concepts relied on technology that did
not exist yet and would require significant R&D to develop, and were therefore also
eliminated. During this initial screening process, we were able to eliminate the wild
ideas or concepts that were generated during brainstorming sessions that were really
intended to help spur creativity and lighten the mood of the session. This made
moving into concept screening more manageable because we had a smaller number
of concepts that needed to be evaluated.
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3.2.2: Concept Screening and Selection
After eliminating a number of concepts in the initial concept screening stage, and
understanding which concepts needed a great deal more information in order to assess, we
began the concept screening stage.
3.2.2.1: IP Basics and FTO
In order to determine the IP landscape, and whether or not we would have FTO with the
concepts we were assessing, we began searching existing patents using the websites of
USPTO (http://patft.uspto.gov), Google Patents (https://patents.google.com), Lens
(www.lens.org), and Free Patents Online (www.freepatentsonline.com). We began by
identifying key search terms for each of our top needs and the concepts that addressed
them. An example of some of the search terms used for the concepts associated with the
need “a way for physicians to perform LPs that improves efficiency and reduces incidence
of complications” is listed in Table 9.

106
Table 9: Examples of search words used for concepts for our LP need.
Concept

Function

Search words (also searched combination of these
words)
Epidural, epidurals, spinal tap, spinal taps, spinal
anesthesia, combined spinal anesthesia, combined
spinal epidural, combined spinal epidurals, spinous
process, spinous processes, lumbar spine, meningitis,
meningitis diagnosis, dural puncture, dural punctures.
Tactile sensing, tactile imaging, FSR, FSRs, force
sensing resistor, force sensing resistors. (*in
combination with search terms defined in “General”).
Spinal fluid collection, fluid collection, CSF
collection. (*in combination with search terms defined
in “General”).

General

Help physicians
place needle for
epidural and
spinal taps

Tactile sensing

Identify
landmarks

Fluid collection
system (multiple
concepts
surrounding this)

Fluid collection

Needle guide
(multiple
concepts
surrounding this)

Needle
guidance

Needle guide, needle guidance, needle stand, needle
injection, automatic needle injection, needle insertion,
automatic needle insertion (*in combination with
search terms defined in “General”).

Radar

Identify
landmarks

Uwb, uwb radar, ultra wideband radar, ultra-wideband
radar, ultrawide-band radar, radar *in combination
with search terms defined in “General”

Some of the websites we used to search the patents had “Similar Documents” or “Related
Patents” listed at the bottom of the patent, so when we found patents that were similar or
related to a concept we were researching, we often researched and documented those as
well. We documented every relevant patent in an Excel spreadsheet, along with the patent
number, the website used to find it (with a link to the patent), the title, the function of the
concept to which it was related, the publication date, the filing date, the expiration date,
the abstract, and the key claims. After we felt we had gathered a comprehensive list of
existing patents related to the concepts, we ranked each patent on its claims and their
relevance to our concepts. A rank of 1 meant the claims were very relevant to our concept
and had to be researched further to understand if we could still have FTO, a rank of 2 meant
there was some relevant claims, but there was room to work around them, or we could still
have FTO with the current design of our concept, and a rank of 3 meant the claims had no
relevance to our concept at all.
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During this processes, we were forced to eliminate some concepts that we knew
would not have FTO. The majority of our concepts relating to the need “a way to restore
pulmonary function to lungs affected by COPD that improves clinical outcomes and
patients’ quality of life” were eliminated during this stage because the IP landscape was
very competitive and a lot of our concepts would not have FTO. At this point, we decided
to move forward with concepts from our other two top needs.
3.2.2.2: Regulatory
We found that one of the best ways to determine the FDA pathway for our concepts was to
research proxy devices and then look up their required regulatory pathway and studies for
clearance. We documented any similar devices we came across for each concept we were
researching and determined whether or not we believed they could be used as a predicate
device for an FDA submission. To find proxy/predicate devices, we used a variety of
sources, including the FDA 510(k) website, physician and entrepreneur advisors who knew
of similar devices, and regulatory advisors who worked in acquiring similar devices
through the FDA. We also conducted our own individual research into similar devices and
emerging technologies related to our concepts.
For example, one of our concepts utilized tactile sensing as the means of identifying
underlying landmarks, so we researched devices in the medical industry that utilize tactile
imaging and came across the SureTouch device. According to their website, the SureTouch
device (Figure 45) utilizes tactile sensing for pain-free and radiation-free imaging to
identify breast lesions. They were considered a class II device and went through the FDA
510(k) process for approval.
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Figure 46: SureTouch Breast
Exam device. Retrieved from
www.suretouch.us.

Figure 45: Mirador Compass (now owned by
Centurion). Retrieved from
http://compass.centurionmp.com/?compartm
ent.

Another one of our concepts related to real-time fluid pressure measurement and the
measurement of intracranial pressure. During a search for predicate devices, we discovered
the Mirador Compass (Figure 46). Their indications for use related to measuring and
monitoring intracranial pressure, which was very similar to what we would expect the
indications for use to be for one of our concepts. The FDA classified the Mirador Compass
as a class II device, and it went through the FDA 510(k) process without the need for
clinical testing. They were only required to provide data from pre-clinical tests, including
in vivo studies (bench studies) and in vitro (animal studies) studies to prove efficacy, along
with the necessary biocompatibility, packaging, sterility, software validation, and
electrical/EMC studies. With the help of one of our regulatory advisors, we determined
that this would be a very suitable predicate device if we decided to move forward with a
concept involving intracranial pressure measurement, meaning that the concept could most
likely also be classified as a class II device and be submitted through the 501(k) process
with the Mirador Compass as a reasonable predicate device.
At the beginning of the fellowship, we decided as a team that an important criterion
for our device would be that it would have a relatively quick time to market, and therefore,
we were not interested in pursuing any devices that would require PMA approval from the
FDA. As a result, we eliminated multiple concepts based on their required regulatory
pathway. We also wanted to avoid solutions in consumer health, but we did not eliminate
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concepts based solely on whether they would be a class I device or would not be regulated
by the FDA (like many consumer health devices). However, we made note of the class and
required pathway of each concept and used that information during final concept selection
as a way to eliminated some of the concepts.
3.2.2.3: Reimbursement
We looked into reimbursement strategies in parallel to potential business models because
we felt that, for our concepts, these subjects were closely related. At this time, we did not
yet have access to any reimbursement specialists, so we performed all of the research
surrounding reimbursement as a team. We began by researching reimbursement codes that
related to the procedures our concepts would be used in. We documented all of the relevant
codes, broke down what parts of the procedures were actually reimbursed and for how
much, and gathered information to determine whether we thought our concept would be
able to fit under an existing reimbursement code or if we would need to apply for a new
code. We researched devices that had similar value propositions and business models to
the ones we were considering to see how they were able to gain reimbursement (i.e., fall
under an existing code or require a new code). If they required a new code, we looked into
the steps that would need to be taken in order to prove their value and be granted the code.
We mapped out the procedure and reimbursement process for our concepts in order to
better understand how the codes were used and how the facility and physicians were
reimbursed based on different aspects of the procedure. An example of a map of the
reimbursement process I created for a concept addressing the need “a way for physicians
to perform LPs that improves efficiency and reduces the incidence of complications” can
be seen in Figure 47.
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Insurance processes claim
and reimburses hospital and

Facility submits claim to

physician.

insurance using CPT

- Facility reimbursement:

code 62270

Perform lumbar puncture:

approx. $510.

Outpatient diagnostic

-Physician reimbursement (no

procedure (ER, neurology,

imaging, facility): $90

or radiology)

No
Was imaging used?

-Physician reimbursement (no
imaging, non-facility): $175

Yes

Ultrasound

Fluoroscopy

Physician submits claim

Physician submits claim

to insurance using CPT

to insurance using CPT

modifier code 76942

modifier code 77003

Insurance processes claim and reimburses physician
for using imaging:
- Additional physician reimbursement for imaging

modifier: $90.

Figure 47: Flow chart of reimbursement and coding for performing a diagnostic lumbar
puncture.

We did not eliminate any concepts based solely on reimbursement at this stage. However,
the information gathered from researching potential reimbursement pathways for the
concepts was used during final concept selection.
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3.2.2.4: Business Models
determine the best business model for the concepts we were assessing, we filled out
multiple business model canvases. One of the more detailed business model canvases that
we created for a concept for our LP need can be seen in Figure 48.

Figure 48: Example of a business model canvas created for the LP need.

The concept that was used in this example had an imaging component to aid in identifying
landmarks, a needle guide for improved insertion accuracy, a digital pressure sensor for
measuring intracranial pressure, and a fluid collection component for easy collection of
CSF. The device would follow a razor/razorblade model in which the commoditized
products (fluid collection system, collection tubes, needles, fluid pressure sensor, etc.), as
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well as the tactile imaging sensor array, would be single-use and the handheld component
with the micro-controller and screen would be reusable.
1. Customer segments: In this section, we listed all of our important customers and
stakeholders. The people we were creating value for included ER physicians,
physician’s assistants, anesthesiologists, pain specialists, CRNAs (nurse
anesthetists), patients, hospital procurement staff, and group purchasing
organizations.
2. Value propositions: The concept would offer a variety of value propositions to the
different customer segments we identified, with each customer segment valuing
different propositions more than others. The physicians, physician’s assistants, and
CRNAs would value the improved accuracy provided by the device, improved ease
of use, and reduction in procedure time the most. The hospital procurement and
group purchasing organizations would value the reduced complications, improved
throughput, reduced costs associated with keeping patients out of radiology, and
reduced re-admissions the most. Lastly, the value propositions most important to
the patients would be related to decreased pain, improved accuracy, fewer
complications, reduced time, and reduced patient anxiety.
3. Channels: For the business model created in this canvas, we would partner with
specialty distributors and in-house clinical specialist to sell our device. We would
use a specialty distributor because of the reusable components in this design. A
specialty distributor would be able to help us sell our device to multiple hospitals
very quickly, similarly to a mass distributor. However, unlike a mass distributor,
they can commit more attention to the devices they sell, and they possess more
technical knowledge about their products. Because this concept would require some
technical knowledge, a specialty distributor would work well. We would also hire
in-house clinical specialists to work with the specialty distributors and help drive
adoption sales of the device. They would also help train physicians on how to use
the device. We would also attend industry conferences and reach out to leaders of
specialty societies for ER physicians and anesthesiologists to help get the word out
about our device and educate them on its benefits.
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4. Customer relationships: We identified a variety of ways to create and uphold
relationships with our key customer segments. The in-house clinical specialists that
we would hire for sales and distribution would be the contact person for the
physicians when they had issues, questions, or comments regarding the product.
We would also add a number of physicians to our advisory board who could help
with outreach and act as champions for our product. Additionally, we would hold
frequent feedback sessions or panels with physicians during development, which
would serve two purposes. First, it would be extremely helpful to continually
receive user feedback on the concept during development, and second, it would
engage physicians early in the process and allow us to establish relationships with
key customers before entering the market, so when ready to enter the market, we
would have physicians that were excited and willing to use the device. Lastly, we
would develop customer relationships at industry conferences and specialty society
meetings focused on ER and anesthesiology.
5. Revenue streams: In this example, the majority of our revenue would be generated
from our disposable components, which we would sell as part of a LP or epidural
kit. This is how the tools currently used in one of these procedures are sold. Unlike
the kits currently on the market, however, our kit would contain the technology
necessary to image the vertebrae (tactile sensing array) and read the opening
pressure more accurately (fluid pressure sensor in place of the currently used
manometer). These technological improvements would allow us to price our kit
significantly higher than the kits that are used currently. In addition to the
disposable component, we would sell a reusable component. This would be the
handheld device and would contain the micro-controller, the battery, and the LCD
display.
Another potential revenue stream we see with this device would be licensing
the technology to other companies. If we attained a patent on the tactile imaging
array, we could license the technology out to other companies who might want to
develop similar devices for different uses.
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6. Key resources: Some of the key resources we identified in order to develop the
product included funding, regulatory consultants, patents, engineers, and testing
facilities. We would require funding to hire the necessary employees for sales and
distribution, as well as to cover costs associated with product development,
manufacturing, and testing. A regulatory consultant would help us determine both
the best path through the FDA and the necessary tests to perform for clearance.
Patents would protect our technology and keep others from commercializing a
similar device. Tactile sensing and mechatronics engineers would help us with
development and optimization of the technology, and having access to a testing
facility would allow us to test the device and iterate on our design before submitting
to the FDA.
7. Key activities: The key activities required to launch this product with this business
model would be identifying a contract manufacturer and a specialty distributor to
work with closer to launch, performing proof-of-concept testing and pre-clinical
testing to gather data for submission to the FDA, submitting to the FDA, and raising
funds.
8. Key partnerships: Some of the most important partnerships we would need to
develop for this concept are highlighted in this section. It would be crucial for us to
partner with medical institutions for testing the device, as well as physicians for
both testing the device and championing the product post-launch. It would also be
very beneficial for us to partner with a product development firm and a contract
manufacturer in order to help us design the product for manufacturing and usability,
optimize the technology, and manufacture the device. Lastly, it would be beneficial
to find a distribution partner—either a large one like Becton Dickinson or Cardinal
Health, who already has distribution channels in place for kits similar to the one we
are proposing, or smaller distributors like the specialty distributors discussed in
earlier sections.
9. Cost structure: The costs required to operate this business model include
manufacturing (low volume initially, then high volume), salaries for employees,
consultant costs, and patent protection costs. Additionally, to get the product to
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market, we would need to conduct pre-clinical testing and industrial design and
engineering activities. Pre-launch, the R&D and testing would be the most
expensive activities. After launch, manufacturing and general operating costs
would be the most expensive activities.

After creating multiple business model canvases, we were able to determine what business
models would work best for each of our top concepts. We had to eliminate some concepts
based on the lack of a viable business model. For example, one concept would require us
to charge the customers an extremely high price to justify development of the device and
cover the cost of the sales force necessary to sell the device. The price required to cover
development costs was much higher than industry averages, and the value propositions
were not strong enough to support the increase in price; therefore, the concept had to be
eliminated.
3.2.2.5: Prototyping and Feasibility Testing
Due to the time constraints of the fellowship, it was important to us that we chose a concept
that we could demonstrate proof-of-concept with fairly quickly. The fellowship covered
our expenses for one year, and it would be important for fundraising to have a prototype
and initial data. This constraint forced us to eliminate concepts we were enthusiastic about.
For example, we were very enthusiastic about our need regarding heart failure; however,
after reviewing the concepts that came out of concept generation for this need, it became
clear that we did not have the skillsets or expertise necessary to develop proof-of-concept
prototypes for the top concepts. We could not develop a proof-of-concept prototype
without adding team members with additional skillsets, and we would not be able to do
that without raising money, so we were forced to eliminate many of the concepts for that
need. As a result, the majority of the concepts that we prototyped and tested addressed the
need “a way for physicians to perform LPs that improves efficiency and reduces incidence
of complications.”
1. Define the core questions that need to be answered for each concept to mitigate
risk: Because we brainstormed on sub-functions of a potential concept, a lot of our
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initial concepts were grouped by function (i.e., fluid collection, needle guidance,
identification of landmarks, etc.) and were already broken down into sub-concepts
(concepts focused on addressing a sub-function). This meant that we did not yet
have any comprehensive concepts that could be used to answer core questions.
Rather, during the initial stages of prototyping, the majority of questions we had
concerned the feasibility of the sub-concept. For example, for the sub-function
“identifying underlying landmarks,” the top concepts we were evaluating used
ultrasound, tactile sensing, and radar. The main question we had for each of those
modalities was “can we use this technology to image bone through multiple layers
of soft tissue?” This question would require us to build multiple low/mid-fidelity
prototypes to test functionality. These prototypes will be explained further later in
this section.
During later stages of prototyping, once we had proved functionality of
different sub-concepts and eliminated sub-concepts that didn’t work, we began
mixing and matching sub-concepts to create different comprehensive concepts.
During this stage, there were still multiple questions concerning functionality, but
they were specific to how the sub-functions would interact with each other.
Additionally, there was a larger focus on answering questions about how physicians
would interact with the device. For example, for a concept involving tactile sensing,
an important question we needed to answer was “how will the physician apply force
to the device?” This was both a question concerning technical feasibility (which
force application method results in the highest resolution and most accurate image)
and usability/human factors (which method of applying force was most comfortable
to the physician? Which method allowed them to hold the device comfortably while
also performing other steps of the procedure?). These questions required a number
of different prototypes to be constructed and tested to determine the answers. More
information on the types of prototypes that were built to answer these questions is
provided in later parts of this section.
2. Break concepts down into smaller, essential sub-concepts to test: As discussed
in the previous section, due to the way we brainstormed, our concepts were initially
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sub-concepts. So, we began prototyping and testing the individual sub-concept
components relating to “identifying underlying landmarks, collecting CSF,
consistently inserting the needle, and measuring opening pressure” before putting
them together to create a cohesive solution. This allowed us to quickly eliminate
sub-concepts that would not work without needing to spend time determining how
to build them into a comprehensive concept. We created multiple lo-fidelity
prototypes initially (Figures 49 and 50) using pre-existing medical equipment, clay,
pipe-cleaners, paper, Legos, and so on to help us determine the feasibility of subconcepts.

Figure 49: Low-fidelity
prototype of fluid collection
system using K'NEX tongue
depressor, plastic tubes, and clay.

3.

Figure 50: Low-fidelity prototype of a
concept where the needle slides along a track
and has a variable needle guide angle.

Determine the best type of prototype to answer the questions surrounding the
concept: During the initial stages of prototyping, the majority of our questions
concerned feasibility. Therefore, we built multiple low- and mid-fidelity prototypes
to see if our concepts could be feasible. Continuing with the example from part one
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of this section, in order to answer the question “can this technology be used to
image bone through multiple layers of soft tissue,” we not only had to build a
“works-like” prototype, but we also had to build a suitable testing platform. For
example, in order to evaluate our tactile sensing concepts, we used a lumbar spine
block (Figure 52) that is used to teach medical students how to perform LPs and
epidurals to test our prototype. We began building a tactile imaging platform by
using commercially available, single-point, 5.1mm active-diameter, model-400
FSRs (Figure 51). These are two-wire, robust polymer thick film (PTF) sensors that
decrease in resistance in response to an increase in force.

Figure 52: Image and
mechanical representation of
model 400 FSR.

Figure 51: Lumbar spine block used to perform
bench testing.

Our initial proof-of-concept testing was performed using a single sensor with a
voltage-divider and output to an oscilloscope. By visualizing the outputted voltage
as the sensor was advanced along the spinal model, we were able to verify its
sensitivity to underlying bone versus interspinous ligament and fat. These findings
proved that tactile sensing could be a viable technology for this application, and so
we continued to develop more robust prototypes involving tactile sensing.
In order to answer questions related to usability and gather physician
feedback on the form factors of a concept or sub-concept, we built some low-
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fidelity feels-like prototypes to show to physicians. These prototypes were just form
factors and had no technology integrated into them. They were used to gather
feedback on the way the device would be held, how the physician would have to
apply pressure to the device, and the position of the screen.
During later stages of the fellowship, we developed a looks-like prototype
for investor pitches and startup competitions (Figure 53). This looks-like prototype
was created using a CAD drawing of a concept that was then rendered to resemble
a final product. We expect multiple changes to be made to this prototype as we
continue to test different versions of the device and learn from those tests. As the
design changes, the looks-like prototype will change as well. A final, constructed
looks-like prototype will be developed closer to a design-freeze once more usability
testing has been conducted and when we need to gather feedback on aesthetics,
packaging, and so on.

Figure 53: Example of a looks-like prototype
developed for the LP need.
1. Refine design requirements and design more detailed prototypes: We built
many low-fidelity prototypes, performed initial testing on the sub-concepts, and
eliminated multiple sub-concepts based on feasibility and team skillsets. For
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example, although our initial simulations proved that radar could be used for
identifying bone through soft tissue, we determined that we did not have the
skillsets necessary to develop a solution using that technology, and we would need
to bring on a radar specialist and spend a great deal of time and resources in R&D
before the technology could be ready for commercialization.
For the concepts that passed the initial phases of prototyping and testing,
we continued to iterate on their design. The example that has been used throughout
this section concerning testing tactile sensing will continue to be used to explain
the iterative process we used to develop a more robust prototype. After the initial
proof-of-concept test, we developed signal acquisition, processing, and
visualization schemes in Arduino and Python to allow us to more robustly observe
the sensors’ characteristics. In our initial studies, we recorded the voltage
distribution for a single sensor moved in 1 cm increments along the lumbar spine
model and observed its change with applied force. It was clear that voltage
increases could be seen when the sensors were over bone with an applied force as
low as 20g, so we decided to develop an even more robust prototype. To allow for
more comprehensive visualization of the lumbar spine, we designed and
constructed a 12-sensor array utilizing multiplexer circuitry (Figure 54). The array
consisted of two 6-sensor columns with 1 cm spacing between neighboring sensors
(along both axes). First, we set out to validate sensor uniformity and sensitivity. We
recorded voltages across each sensor for six trials with the column advanced along
the spinal model in 1 cm increments (Figure 55). Again, voltage increases were
reliably observed when sensors were above spinous processes (“bone”). Additional
studies observing sensors’ resolution with changes in force-application method and
BMI were also performed to optimize the design and construction of our
electronics.
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Figure 54: Prototype of tactile sensing
array.

Figure 55: Bench test of tactile sensing
array.

In parallel to continuing development on the tactile sensing platform and other subconcepts, we used a morphological matrix to mix and match promising sub-concepts
to create complete concepts that we would show to stakeholders to determine which
features they found most important. Our morphological matrix can be seen in Table 10.
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Table 10: Morphological matrix for concepts surrounding the LP need.
Localization

UI/Feedback

Tactile sensing
Ultrasound

LEDs
LCD screen

Radar

Lasers (project
entry spot)

Transducer

Blind (status
quo)

Haptics

Concentric
housing

--

Handheld guide +
display
2 part grid

--

--

Overlay with
structural image
Voice over/walk
through
Sound/beep

--

--

None

--

--

--

--

Split
array/vertical
needle adjustment
Sticky
display/multiple
holes
Skin marking
(status quo)

4
compartment
plunger
Rail with
cartridges
Standard drip
(status quo)
--

--

--

--

Needle
Positioning
Grid
Frame

Pressure
Sensing
Digital
Pressure
gauge
(analog)
Manometer
(status
quo)
--

--

Fluid
Collection
Spoke
Iris diagram

Faucet

We wanted to create prototypes that exaggerated the different benefits our sub-concepts
could create if combined so that it would be easy to tell what features were important
to the key stakeholders. Using the morphological matrix above, we mixed and matched
sub-concepts to create a very low-cost/low-tech integrated prototype, a high-cost/hightech integrated prototype, a low-cost/high-tech integrated prototype, a high-cost/lowtech integrated prototype, and a prototype that we thought embodied the perfect
solution. We then developed the five integrated prototypes to show to physicians and
gather their feedback. After speaking with multiple physicians, iterating on the
prototypes, and going back to the physicians for more feedback, we were able to
finalize the five sub-concepts that physicians were most interested in. The concept that
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made the most sense for adding value while keeping costs low included tactile sensing,
an LCD display, a needle guide, a digital pressure sensor, and a rail with cartridges for
fluid collection.
We created CAD models for a variety of form concepts and 3D printed them in
order to receive feedback from physicians concerning their usability and ability to meet
the physicians’ needs (Figures 56 and 57). With each prototype and each physician
feedback session, we gathered valuable insights into the design and usability of our
prototype, and we were able to adjust the need specification documents accordingly.

Figure 57: Example of a form
factor prototype.

Figure 56: Second example of a form
factor prototype.

By prototyping and testing the form-factors and integrated concepts, and by showing them
to physicians and gathering feedback, we were able to decide on a general embodiment
that incorporated all of the essential elements necessary to meet the user needs.
3.2.2.6: Define Ranking Criteria and Perform Final Concept Screen
Following all of the research performed during the different concept selection phases, we
were able to identify our top concept without having to define ranking criteria and go
through a final selection process, as discussed in the previous section (Prototyping and
feasibility testing). We continued to iterate on that design, as well on the design of the

124
tactile sensing array for improved imaging. After multiple design iterations and bench tests,
we were able to build a works-like/feels-like model that we could use to demonstrate the
device’s capabilities at conferences, competitions, and investor pitches. We expect that this
design will change multiple times throughout development after the fellowship, but the
final prototype developed during the fellowship can be seen in Figure 58, with the image
output shown in Figure 59.

Figure 58: Integrated prototype of lumbar
puncture assist device.

Figure 59: Real-time image
generated on computer when
device is pressed against the
patient's back.
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3.3: Stage 3: Commercialize
3.3.1: Strategy and Pitch Deck Development
Once we built and tested the proof-of-concept prototype, we began the final phase:
Commercialization. During this stage, we built upon all of the research we performed in
previous stages concerning the need and the concept for the purpose of developing a sound
strategy for commercializing our device. We summarized all of the research into memos
and a final pitch deck that we would use at the end of the fellowship to apply to accelerators,
pitch in business plan competitions, and present to angel investors for funding. I was in
charge of creating the pitch deck. I designed the slides, wrote the script, and presented to
investors and at business plan competitions.
For some research areas, we split the work up amongst the team members and
worked individually, while for others, we worked on the research together. I lead the
research for the problem, the competition, and many aspects of the GTM strategy. I also
took the lead on developing the financial model and determining how much money we
would need to raise in our seed round.
3.3.1.1: The Problem
I began this section by listing every issue we had identified with the current procedure and
available devices, and I attempted to rank the ones that were the most important based on
research we had performed during needs finding and the stakeholder analyses we had
previously performed. Table 11 categorizes all of the issues I identified with the procedure
based on the stakeholder they affect.
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Table 11: Summary of issues related to the LP need.
Hospital/System
• LP patients
occupy ER beds
for a long time
• Complications=
return for
treatment
(additional cost,
potential loss of
reimbursement)
• ER throughput
suffers due to
multiple
attempts
• Throughput
suffers due to
failed
attempts—sent
to radiology
• Multiple
attempts lead to
low patient
satisfaction
scores—reflects
poorly on
hospital and
affects
reimbursement

Physician

Patient

• Identifying landmarks via palpation is
unreliable and inconsistent
• Difficult procedure, especially for
non-experts
• Technology available is unreliable or
unintuitive (ultrasound)
• Multiple attempts required, which
leads to frustration
• Multiple attempts increase likelihood
of “bloody tap,” which requires a
repeat LP
• Multiple attempts lead to low patient
satisfaction scores—reflects poorly
on physician and can affect
compensation
• Manometers used for determining
opening pressure are cumbersome
• Manometers are outdated and
inaccurate
• Using manometers to determine
opening pressure adds time to
procedure
• Collecting fluid is cumbersome and
time consuming
• Collecting fluid exposes physicians to
potentially harmful CSF
• Procedure requires three hands
(always need assistant)
• Radiologists are unhappy when failed
LPs are sent to them—disrupts their
schedule and causes bottleneck
• (Epidural) not knowing depth can
cause physician to accidently
puncture the dura, potentially causing
CSF leak or improperly administered
anesthetic

• Multiple attempts are
painful
• Increased time in ER due
to multiple attempts,
leads to frustration and
anger
• Increased time in ER due
to failed procedure—
sent to radiology, leads
to frustration and anger
• Unnecessary exposure to
radiology in the event of
failed LP (unsafe)
• Multiple attempts
increase likelihood of
post-LP headache;
affects QOL and
potential need for
additional treatment
• Inaccuracy of procedure
can cause “bloody tap,”
resulting in misdiagnosis
or extended stay
• Inaccuracy of procedure
can cause “bloody tap,”
requiring additional LP
• Inability to accurately
place epidural can result
in patient not receiving
epidural for labor

Originally, I struggled with which problems to include in the deck and which to exclude. I
felt that all of the problems were important and helped to support the argument for a new
device. At first, I tried to include as many of the issues as possible, but after presenting the
slide to some of our advisors, I realized that I was spending too much time explaining the
problem, when in reality people just wanted a short summary of the most important issues
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associated with the current procedure. I then went back through the needs identification
and validation research, as well as the stakeholder analyses we created, to identify which
problems were the most important. It was clear that the main issue was that the current
method for performing LPs and epidurals is inefficient and inaccurate. That became the
main focus of the slide and determined how I needed to structure our value slide.
After I was able to clearly and concisely state the overall problem, it was clear that
every other issue was a result of that problem. After breaking down all of the problems
associated with the need, it was clear that most of them could be covered by highlighting
four categories: physician frustration, patient satisfaction, procedure length, and ER
throughput. These became the four points I highlighted in my pitch deck regarding the
problem.
I then had to conduct more research into the problems I was highlighting on the
slides so that I could present supporting data. I researched failure rates of epidurals and
LPs, the average duration of the procedure, and the costs associated with complications.
There was literature to support the claims I made about first-attempt failure rates, but there
was not much data surrounding the average duration of the procedures, which was
necessary to convince people that the procedure length was in fact a problem. To determine
a range for this, I had to review our notes from observation and see how long the LPs we
observed were, in addition to interviewing physicians to determine an estimate for how
long they believed the procedures took. I also returned to the hospital to observe and time
more LPs. I used this information to create supporting sentences for each of the four issues
I was highlighting on the problem slide. Figure 60 shows an example of the problem slide
I created for our pitch. The slide was animated to display different statistics and information
on the bottom section of the slide based on the different problems. Figure 60 is a screenshot
of the presentation when highlighting the issues associated with patient satisfaction. The
entire pitch deck can be found in Appendix D.
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Figure 60: Example of one of the “problem” slides I created for the pitch deck.

I also created a simple background slide to help the audience understand why the procedure
is performed, the steps of the current procedure, and what cases are considered difficult
(Appendix D, Slide #2).
3.3.2.2: The Market Size
The market research conducted throughout the fellowship helped us to identify a number
of procedures that required a spinal needle to be inserted into the lumbar region. In order
to calculate the total addressable market, I had to determine the number of procedures
performed in each setting and then add those numbers up to calculate the overall market
size based on procedures. There are four main spinal puncture procedures performed:
diagnostic LPs (performed in ER and neurology), epidurals for anesthesia in surgery
(performed in orthopedics), epidurals for anesthesia in labor and delivery (performed in
obstetrics), and epidural steroid injections for back pain (performed in pain management).
I found that approximately 800k diagnostic LPs are performed each year in the US, 500k
epidurals are performed in orthopedic surgeries, 2.4M epidurals are performed in labor and
delivery, and 9M epidural steroid injections are performed annually in the US for pain
management, resulting in a total annual number of 12.7M spinal puncture procedures
performed in the US.
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The next task involved determining the average cost of the procedure. Because
there are no devices on the market that really address the need like our proposed solution,
it was challenging to determine the Total Addressable Market (TAM) the way in which it
is normally calculated. There were no comparable devices on the market that we could use
as a cost estimate to size the market in terms of economics, so we decided to look to
reimbursement data for the different procedures to estimate the cost of the procedure,
which would also help us in pricing our device. I will discuss this in more detail in the
GTM strategy section, but to summarize, we determined the average cost of the procedure
across the different settings based on reimbursement to be approximately $500. This led
me to determine that the total addressable market would be $6.4B. The slide I created on
the market opportunity can be found in Appendix D.
3.3.2.3: The Competition
3.3.2.3.1: Understanding the Pros and Cons of Existing Products or Emerging Products
I took the lead on researching the competition and performing an analysis on the
competitive products on the market. I began by identifying what products could be
considered competition. During our research in the concept selection stage, we came across
our only technologically relevant competitor, the Accuro by Rivanna. It is a handheld
ultrasound unit designed specifically to help physicians identify the epidural space. I also
researched the standard LP and epidural procedure kits/trays, because they currently
capture the majority of the market share and were considered the standard of care, in
addition to standard ultrasound machines, which are often used in the event that a physician
cannot accurately identify the vertebral gap. Additionally, I researched products that
addressed certain aspects of our need, including the Mirador Compass, previously
discussed in the concept selection section, and Loss of Resistance Syringes, which are
commoditized tools used to help anesthesiologists know when they reached the epidural
space based on a pressure drop that occurs when entering that space. I included Loss of
Resistance Syringes because people often asked if any innovations had been made in this
area in the last couple of years and were often interested in adoption rates, business models,
and so on of those products. Loss of Resistance Syringes are really the only product on the
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market that is somewhat related to helping physicians place spinal needles for epidurals,
so I included them in my analysis, even though they only solve a very small part of the
problem.
To start the analysis, I had to determine the most important criteria to evaluate the
competition against. To help with this analysis, as well as our value analysis and adoption
rate predictions, I created a survey to send out to ER physicians and anesthesiologists. The
questions on the survey focused on features and their perceived importance. It also
contained questions concerning the need, such as the number of attempts they think it takes
them to place an LP/epidural on average, the number of LPs/epidurals they perform a week,
and the most difficult steps of the procedure. I sent this out to a number of physician
contacts, who forwarded it on to their colleagues. We received a total of 79 responses,
which were used to help us to better develop our competitive strategy and value analysis
and to predict adoption rates. I will discuss these results and how they related to specific
strategies in the respective sections. Based on feedback from the survey, in addition to the
research conducted during the previous two phases, I was able to identify five criteria on
which to evaluate the competition, namely, their ability to reduce the procedure time,
reduce the number of attempts required, improve the pressure measurement process,
improve the fluid collection process, and whether or not they incorporated needle guidance.
I created a competition table to visually represent how the IntuiTap device compared to its
competition. This table can be seen in Figure 61.

Figure 61: Competition table for IntuiTap device.
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3.3.2.3.2: Protecting Against Competition
The second part of the competition strategy is determining how to defend against new or
existing competition. As part of the fellowship, the law firm Wilson Sonsini Goodrich &
Rosati (WSGR) agreed to write a provisional patent for us pro-bono. Technically, a couple
of drawings and a description would suffice as a provisional patent, however, they drafted
a provisional patent as if they were creating a utility patent application so that it would
reduce the time and costs associated with filing for a utility in a year, so it was very
beneficial. They were extremely helpful in determining what types of claims we should
include and in conducting a more official prior art search than the one we conducted
previously. They also conducted a preliminary FTO search to see if any patents stood out
right away as ones that could pose a problem down the line, but they suggested that we
hold off on having them perform an official FTO search until we had raised money and
were closer to converting to a utility, because they can cost anywhere between $10–$20k.
We worked with them to develop a preliminary patent strategy. Sometimes, it is
advised to only include technology that has already been developed, as well as any obvious
changes or improvements, in a first patent so that patent protection can be extended by
filing separate patents at a later date on other ideas, inventions, or improvements. However,
due to the terms of the fellowship, the program would cover half of the costs associated
with the filing of our first patent, so we decided to include as much information as possible
into our first patent. In this way, we could reduce costs related to patents in our first year
as a company by not having to pay for additional patents relating to different aspects of the
device. Any IP generated during the fellowship was owned by the TMC, but it was
exclusively licensed back to our company, so it made sense to include all of the IP that had
been generated in the fellowship in the first provisional patent. We knew that new IP would
be generated after the fellowship was over, so we could try to grow our patent portfolio
with the new IP that was generated once the fellowship was over.
WSGR worked with us to brainstorm all of the different ways our device could be
described and generated over 100 claims for us to include in our provisional patent. The
provisional included information about all of the top concepts we generated, not only the
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final form factor we selected to move forward with. We submitted the provisional patent
in April 2016 so that we could begin publically presenting our solution.
3.3.2.4: The Solution
Determining a strategy around our solution largely consisted of creating an R&D timeline
and testing strategy, since the desired features were identified and conceptualized during
the concept generation and selection stages. The first slide that I created concerning our
solution was a simple slide that included a rendering of our device and a brief summary of
the features, as shown below in Figure 62.

Figure 62: The solution slide created for IntuiTap pitch deck.

The majority of our time and effort developing a strategy around our solution was spent
creating a plan for R&D. As a team, we went through each feature of our product and
determined what we needed to do to develop and test it. We knew that it would be
extremely important to have data to show to investors when raising seed money, so we
worked with researchers at Baylor College of Medicine and professors at Rice University
to develop a protocol for a low-risk study involving healthy human subjects to prove the
accuracy of our core technology. The goal of this study was to compare our device’s ability
to image the vertebrae and identify an accurate insertion location against the palpation
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technique and an ultrasound. We conducted the study through a Rice University IRB. An
overview of the study and its results can be found in Appendix E.
We learned a great deal from the IRB study and had very promising results.
However, we felt that we had exhausted our team’s knowledge of tactile sensors and that
we would need to either build a team of experts or hire an engineering firm to help us take
our core technology to the next level. We decided that it would be more efficient and costeffective to partner with an engineering firm, and so we began researching firms and startup
accelerators that focused on helping companies with devices with electronics and sensors.
We also realized that we had hit our limit for brainstorming new form factors and decided
we needed an outsider’s opinion on how to improve the device for usability and human
factors. We looked into hiring a human factors expert, but it seemed that working with a
firm, or trying to work on that during an accelerator, would be more cost effective, so we
added human factors and usability as criteria for a firm we wanted to work with. We came
across a couple of engineering firms that seemed suitable, and we reached out to them for
more information regarding costs and timelines. Two of the companies we identified often
worked with startups and had their versions of accelerators where they would work with
the startup companies at cost in exchange for equity in the company. This was extremely
attractive to us, as we did not have any money, and even after a seed raise, money would
be tight. We applied to this company’s accelerators in hopes of working with them to
optimize our imaging platform and re-design our device for usability.
For the fluid pressure sensor that would be used to determine the opening pressure
of the spinal column, we found that there were multiple off-the-shelf options and that it
would be cheaper to purchase those rather than attempt to build our own to incorporate into
our device. Because the pressure sensor was primarily beneficial for the ER case and was
not critical for improving the accuracy and efficiency of the procedure, we decided to delay
testing of the fluid pressure sensor until the spring of the following year so that we could
focus most of our R&D efforts into optimizing the sensor array for improved vertebral gap
detection.
We created a Gantt chart to organize our R&D milestones, and we aligned them
with the fundraising round we expected them to be associated with. The exact numbers
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associated with each range will be explained in more details in Section 3: Financial Model
& Predictions. The high-level Gantt chart can be seen in Figure 63. The green boxes are
for testing milestones, light blue are prototyping milestones, navy are operational
(fundraising, hiring, etc.) milestones, and grey are IP and regulatory milestones.

Figure 63: Gantt chart for development of the IntuiTap device.

I then took the information from the Gantt chart and summarized it to put on a slide for the
pitch deck. The timeline I created for the pitch deck can be seen in slide 15 in Appendix
D.
3.3.2.5: The Value
I began our value analysis by focusing on our three stakeholders’ (hospitals, physicians,
and patients) pain points and how our device could add value to each of them. We knew
from our research concerning the need that the overall issue with the current procedure, for
all stakeholders, is that it is inaccurate and inefficient. As such, our biggest value driver is
that our device makes the process more accurate and more efficient. I created a value tree
(Figure 64) to break down in more detail the different value propositions related to the
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overall goal of improving accuracy and efficiency. Our product primarily addresses the
need by reducing the number of required attempts to place a needle. By reducing the
number of required attempts, our device can reduce complication rates, reduce the need for
patients to be sent to radiology, and decrease procedure times. These were the most
compelling value propositions that addressed each of the stakeholders needs, and we
defined them in such a way that they matched up with needs explained in “the problem.”
However, after testing our value proposition statements with a variety of stakeholders, it
became clear that simply stating that we add value in these three ways was not sufficient.
Instead, we needed to further explain our value adding in terms of the endpoints they care
most about, which is typically cost.

Improved accuracy &
efficiency

Fewer required
attempts

Shorter procedure times

Fewer complications

Reduced costs associated with
throughput, bed occupation, and
procedure time

Reduced costs associated with
readmissions, medication, and
pain.

Reduced need for
radiology
Reduced costs associated with
referral, fluoro suite upkeep, and
consultation time

Figure 64: Value tree for IntuiTap device.

I hypothesized that the three main cost drivers associated with the need were procedure
time, complication rates, and radiology referrals. However, I needed to put numbers to each
assumption in order to determine whether my hypothesis was correct. We began
researching the different value propositions, assumed cost drivers as a team, and attempted
to determine accurate values for cost-savings associated with each value proposition.
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1. Shorter procedure times: It is commonly known that throughput is extremely
important in the ER, in addition to the fact that ER beds are valuable and efficiency
is essential, so this is the value proposition we focused on first. We began by
breaking down LP cases into three categories: easy, difficult, and failed (sent to
radiology). We defined an easy LP as one that required 30 mins or less and had a
maximum of two attempts. A difficult LP was one that required more than two
attempts and help from a colleague, and on average took an hour. A failed LP was
one that required multiple attempts in the ER with no success and was sent to
radiology; we predicted that failed LPs took on average an hour and a half. Based
on the survey we conducted with physicians, and on some studies about failed
epidural and LP rates, we estimated that approximately 45% of cases fell into the
“easy” category, 40% fell into the “difficult” category, and 15% fell into the
“radiology” category.
In order to calculate cost savings associated with simply reducing the
procedure time, we had to determine the hourly cost of an ER bed during a
procedure. One study determined that the hourly cost of an ER bed is $99.50 [26],
so we used that amount to determine costs associated with procedure time for each
procedure. Figure 65 shows the cost comparison of the palpation technique and the
IntuiTap device for case.

$49.25
$49.25

$49.25
$148.75

$49.25
$199

Figure 65: ER bed costs comparison by case types.
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We felt that if we could reduce the number of required attempts, we could not only
reduce the overall procedure time, but also reduce bed time associated with having
to wait for an attending to assist in the procedure, or physicians delaying the
procedure because of inconvenience or reluctance. We attempted to quantify this
using costs associated with ER boarding time. We assumed, based on a number of
cost estimates surrounding boarding time and revenue loss due to diversion, that
the average hourly cost of boarding in the ER is approximately $1,100 [26-30]. This
number is applicable for situations in which a patient is waiting for treatment, or to
be transferred to radiology, in addition to the costs associated with taking up an ER
bed that could be used for other patients. Based on our observations, research, and
survey responses, we estimated that for easy cases, the average boarding time
would be approximately 30 mins, for difficult cases 75 mins, and for failed cases
120 mins. This would result in costs due to boarding to be $543.00, $1,357.50, and
$2,172.00 for each case respectively.
After we calculated the costs associated with procedure time and boarding
time for each type of LP case, we calculated the potential cost savings of using our
device compared to the standard procedure (Figure 66). We estimated that our
device could save approximately $570/patient in boarding time reduction, and
$43/patient in procedure time reduction, resulting in a total cost savings to the
hospital of over $600/patient.

Figure 66: Cost savings of the IntuiTap device by type of case and type of cost.
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We decided to omit this figure from the pitch deck due to amount of space and the
information we wanted to provide. However, we often included it as a backup slide
in case there were questions concerning how we calculated our average cost savings
of $600/patient. The final design of our value slide can be found in Appendix D.
2. Fewer complications: The medical community has hypothesized that the need for
multiple attempts leads to an increased chance of causing a variety of lasting patient
complications; however, no studies have been conducted to prove this. Until we
conduct a study using our device and track the rate of complications that occur
when our device is used compared to when the traditional technique is used, we can
only assume that our device will have some sort of cost savings due to reduction in
complications, but we cannot assign a number to that value. So, we focused on
researching costs associated with current complications and noting that we hope
our device can reduce such costs. The most common complications are post-dural
puncture headaches (PDPHs), which occur in approximately 40% of cases, with
incidences cited between <1% and 88% depending on the setting and needle type
[31-34]. PDPHs account for 15% of anesthesiology malpractice claims (40% of
which result in successful lawsuits), and treatments alone cost the healthcare system
$10.4M per year, with per-patient costs of over $500 in epidural cases where dural
puncture is specifically unintended [35–40]. Other complications are related to
local trauma, including nerve-root irritation and low-back pain in 13% and 35% of
cases, respectively, in addition to bleeding, including traumatic taps and needleinduced blood in the CSF—a diagnostics concern—in 14% and 72% of cases,
respectively [41–43]. However, we do not yet have cost estimates for these types
of complications. Due to the fact that we do not have estimates concerning costsavings, we often do not include numbers referring to complications in our pitch
deck. Usually, we have back-up slides that contain some of the statistics listed
above in case investors ask for more details, or we send them this information in a
follow-up e-mail if they are interested.
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3. Fewer referrals to radiology: We struggled to quantify the costs associated with
sending a patient to radiology, and we are still working with hospitals, pain
physicians, and radiologists to better quantify this cost. In the meantime, we
focused on identifying the potential cost drivers of sending patients to radiology
based on interviews with hospital staff and radiologists. We determined that the
major issues and cost drivers concern having to reschedule already scheduled
procedures due to unforeseen procedures, such as failed LPs; the fact that LPs are
relatively poorly reimbursed procedures compared to many of the other procedures
done in fluoroscopy suites, so doctors do not get reimbursed for their time as well;
and lastly, the costs associated with having to compile a team to perform an LP in
the fluoroscopy suite (not just a doctor and a nurse or two like in the ER). We are
still working with stakeholders to determine a better idea of the actual costs
associated with each of these issues, but we will most likely have to hire a
consultant to help us pull the necessary data.

At this point in the fellowship, this was all we could do to estimate the monetary value our
device could add. In the future, we plan to conduct studies to determine how effective our
device is at reducing complication rates, in addition to working with consultants to
determine potential cost-savings associated with keeping patients out of radiology. After
we acquire a better understanding of the numbers associated with those value propositions,
we will be able to better craft our value propositions and more accurately factor that into
our pricing strategy.
3.3.2.6: The Business Model
We already possessed a strong understanding of the type of business model that would best
suit our product based on the research and business model generation activities we
performed during concept generation and concept screening. For our device, we knew that
a hybrid business model including both reusable and consumable parts would make the
most sense and allow us to generate reasonable profits. However, nobody on our team
possessed any experience with hybrid business models, so I reached out to multiple
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industry contacts to better understand what the sales and distribution process might look
like for a hybrid device and determine how to price our products.
3.3.2.6.1: Sales & Distribution
I met with mentors and advisors to better understand what typical relationships with
distributors look like, how much market penetration can be expected with a hybrid model
such as ours, and the costs associated with working with distributors versus hiring in-house
sales people, as well as how adoption rates could be affected by that choice.
I researched products that possessed similar business models and came across the
EZ-IO device. The EZ-IO is an intraosseous bone drill used in almost every ER and
ambulance in the country to place IVs on difficult patients or patients with collapsed veins.
The device is made up of a reusable handheld component (a drill) and a specialty needle
kit that has to be used with the drill. Because the business model is so similar to ours and
the market it was being used in was also very similar to our initial target market (ER), I felt
that Dr. Larry Miller, the inventor of the device and CEO of the company that
commercialized it, would be an extremely valuable mentor. I reached out to him and asked
if he would be willing to meet with the team and I to discuss our business plan, and he was
more than happy to help. He quickly became one of our best resources for developing our
sales and distribution strategy, and for building out our financial model. He gave us detailed
information about his sales and distribution strategy and how many hospitals he was able
to get his device into in the first one, two, three, and five years of sales. We based our sales
and distribution strategy very closely after his because of the similarities of our business
model and the success he had with his product. From the discussions with Dr. Miller, as
well as our other mentors, we decided that it made the most sense to move forward with
the hybrid business model consisting of a reusable handheld component that included the
LCD screen, microcontroller, battery, and wiring, and a disposable kit that included the
array of sensors, fluid pressure sensor, collection tube and holder, and other commoditized
components that came in the current kits. For our sales plan, we decided on a hybrid model
where we would work with specialty distributors to sell our product, but also include a
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number of in-house clinical specialists (i.e., ex-nurses) that would work with the
distributors to help train physicians on how to use the device and help drive adoption.
3.3.2.6.2:Pricing
The last aspect of the business model we needed a better understanding of for the pitch was
pricing. Again, nobody on the team had any experience with pricing products, so I reached
out to multiple medical device sales and pricing experts to help us determine a plan for
pricing our product. The general response from every person I spoke with was that pricing
is extremely complicated and there is no standard way of determining it, and that further
down the line, closer to a product launch, it would be beneficial to work with a consultant
or bring someone on in house that could help us really refine our pricing strategy. However,
they also said that, for the early stage we are in, it is acceptable to estimate a selling price
based on similar products and value-based pricing.
We decided to take a blended approach and base the cost on both the cost to make
the products, the value created by the product (i.e., value-based pricing), and how much
the product could be reimbursed for. We needed to determine the cost of goods sold
(COGS) for the financial model in order to determine an estimate for revenue, as well as
to determine the type of profit margin we would need to survive. By speaking with many
of our advisors, we determined that most medical device companies using a consumable
business model aim for ~70% profit margins, so we needed to determine how much the
disposable products would take to make in order to determine the minimum price we would
need to sell them for in order to achieve a 70% profit margin. We met with local
manufacturers to get quotes on how much it would cost to develop our device at different
volumes (low-volume, high-volume), and we developed an estimate of the COGS for each
of the different components for our device. We determined that the disposable components
would cost approximately $35 to make at high-volume and that the reusable components
would cost approximately $45 to make at high-volume. We determined in our valueanalysis that our device could save on average approximately $600/patient, making that the
ceiling for value-based pricing, meaning we should sell the product for less than that so we
can still claim they are saving money by using our device. Additionally, based on the goal
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of ~70% profit margins on the disposable, the floor price we could sell our kit for would
be approximately $150. However, it is not advantageous for a company to simply use
COGS-based pricing and not include any value-based pricing in the pricing strategy, so we
determined that our kit should be priced somewhere between $200 and $500.
We then used information gathered from our reimbursement strategy research
(explained in more detail in the GTM strategy section) to further help us narrow the pricing
range. We determined that the average reimbursement rate for an LP or epidural is
approximately $500. From talking with our advisors and mentors, we learned that we
should price the product somewhat lower than the reimbursable rate so as to incentivize
hospitals to buy the product. We decided that we would price our product at $300. This
way, even though the hospitals would be paying approximately $280 more on our kit
(typical epidural/LP kits cost between $10 and $30), hospitals would still receive
approximately $200 in profits from reimbursement (after removing the cost of the kit), and
they could save up to $600/patient due to the improved accuracy and efficiency our product
brings to the procedure, allowing them to save up to $800/case, which is $320 more than
if they were using the standard kit (Table 12).

Table 12: Summary of cost savings with IntuiTap device.

Standard
Kit
IntuiTap
Kit

Kit
cost
$20

Reimbursement
$500

Cost-savings due to
increased efficiency
$0

Total
savings/profit
$480

$300

$500

$600

$800*

*Up to $320 additional savings with IntuiTap

At this early stage, it is challenging to determine a cost based on value, as we have not yet
been able to prove any of the claims made, so these numbers are still very rough
approximations of what we will sell our device for. Once we are closer to a product launch
and have some studies conducted demonstrating our value, we plan to work with hospital
procurement specialists and pricing specialists to better refine our pricing strategy. As
discussed in the value section, we also plan to perform large studies to back up the claims
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we make concerning value, including our device’s ability to reduce the number of
complications and reduce ER bed time.
3.3.2.7: The Go-To-Market Strategy
to finalize the majority of our GTM strategy. She led the research into predicate devices
for regulatory, but I identified a regulatory consultant with whom I then worked to finalize
a memo to send to potential investors outlining our regulatory strategy. For reimbursement
strategies, Nicole and I both researched potential procedure codes that our device could
potentially be categorized under and how much each code is reimbursed. Lastly, I led the
majority of activities concerning determining a suitable launch market and growth
activities after launch.
3.3.2.7.1: Regulatory
Through our own research conducted in earlier stages of the fellowship, we believed we
would be a class II device and would have to go through the standard 510(k) process.
However, after speaking initially with a couple of regulatory experts, some believed there
might be a chance we would have to submit to the DeNovo pathway due to new rules
concerning split predicates. We decided to engage with a regulatory consultant who was a
former FDA reviewer to review our research and perform some initial research of her own
to determine, in her expert opinion, if we were in fact a class II device and which pathway
we should expect to submit through (typical 510k or DeNovo). We had our consultant write
and sign off on a memo of her findings so that we could have an official document to
present to investors as part of due diligence. Her research stated that she was confident that,
with the predicates we had identified, we would be a class II device and would be able to
submit our device to the FDA through the traditional 510(k) pathway. She included the
predicates and reasoning for her opinions in the memo as well.
3.3.2.7.2: Reimbursement
I began this research by identifying potential CPT codes that could be used for our device.
We had already identified some during our initial research stages, but I continued to
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research the reimbursement codes currently used for different spinal puncture procedures
in order to determine if we missed any codes. After gathering a preliminary list of potential
CPT codes that could be applied to our device, Nicole Moskowitz (fellow) then took the
lead on developing this strategy and worked closely with CPT coders to conduct more
detailed research concerning a strategy for reimbursement. There are two different payment
types we looked into for this strategy, namely, facility fees and provider fees, and findings
for both are described below.

1. Facility fees: The CY 2017 hospital outpatient prospective payment system
(OPPS) was used to determine facility reimbursement rates for LP, epidural, and
epidural steroid injection (ESI) procedures. For the facility case, it is important to
distinguish between reimbursement for surgical punctures (i.e., LPs and ESI) and
administration of perioperative anesthesia.
In the case of diagnostic and therapeutic taps or injections, we determined
that facilities are reimbursed at a rate of $507 (this value is slightly higher in the
case of continuous ESIs; however, considering their comparably small share of the
market, these were ignored for simplification). It is important to note that this rate
remains the same for procedures performed with or without imaging—that is to say,
that imaging is bundled at the facility level. The perioperative anesthesia case (e.g.,
for orthopedics and obstetrics) is slightly more complex, since, at the facility level,
these punctures are fully bundled into their respective procedures. We are still
working with reimbursement experts to determine with greater accuracy the
reimbursement landscape for those procedures. Since we are initially targeting the
ER setting, we therefore considered procedure costs as the $507 rate.
2. Physician fees: It is of interest to note that while imaging is bundled into these
codes at the facility level, physicians do get reimbursed for add-on imaging codes.
For the LP and ESI codes, 2017 fee schedules suggest the following average nonfacility and facility payment rates: $175 or $90, respectively, without image
guidance; and $265 or $145, respectively, with image guidance. The imaging
component, specifically, is reimbursed at a rate of ~$90 and varies depending on
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whether it is claimed as an add-on code (i.e., for LPs) or as a specialized imaging
code (i.e., for ESIs).
Similar physician fees are observed in the case of perioperative anesthesia
administration. As an aside, there are is no flat rate for these codes; instead,
reimbursement for anesthesia services is based on the multiple of a pre-assigned
base fee with case-specific factors, including anesthesia time and a provider
identity. Physician’s fees are of interest because, if we can get our device to be
included under the image-guidance code, it will incentivize physicians to use our
device, as they will receive higher reimbursement.

Reimbursement is very complicated, and because there are few devices like ours on the
market, it is unclear exactly what our pathway for reimbursement will look like, or whether
our device will be allowed to be classified under current reimbursement codes. We decided
that, after the fellowship, we would work more closely with the CPT coders to better
understand how bundling affects our product and better understand the epidural
reimbursement landscape. We made this a main goal moving forward with accelerators.
3.3.2.7.3: Launch Market
We had three main markets to choose from as a potential launch market (diagnostic LPs,
epidurals in L&D, and ESIs in pain management). I worked to put together a list of pros
and cons for each of the target markets and present them to our team. In validating our
solution across potential stakeholders, we identified ER physicians as the earliest
technology adopters, primarily due to the fact that their work requires a high degree of
flexibility. Thus, we decided to focus the first iteration of our device on the most emergent
application of spinal-needle placements, LPs, resulting in a beachhead market of ~$350M.
We planned to start out at the Texas Medical Center through our close network of ER
physicians at Ben Taub hospitals’ acute-care and level-I trauma facilities. Once we gain
traction in the ER, we plan to expand to spinal anesthesia and epidural markets, whose
physicians are generally more conservative and require larger amounts of data when it
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comes to adopting new technology. Along the way, we also plan to target other LP settings
(e.g., neurology) with help from our clinical network.
The prospective investors we spoke with, as well as some of our advisors, brought
up the pain management market and why we were not targeting that as a launch market,
simply because of the size of the market. We decided that, because we identified that
market later in the fellowship and had not completed much analysis on the market and the
stakeholders, we did not possess a thorough enough understanding of the market to make
it a launch market. It was also not a great launch market, as the majority of pain procedures
are performed with higher levels of technology than our device (fluoroscopy) compared to
the ER setting, where they use no technology (palpation technique). Through initial
physician interviews, we felt that it would be challenging to convince pain specialists to
switch to our device without a great deal of supporting data proving its accuracy. We
decided that, moving forward, we would conduct market research into the pain
management market and consider a co-launch in that market if, after gathering more
research, we thought it might be beneficial, while still keeping ER as the initial target
market.
3.3.2.8: Financial Model & Predictions
We created a detailed model in Excel to help us determine the amount of money we would
need to raise in our seed round and future rounds in order to reach a point of profitability.
We attended workshops held at the local startup accelerator, TMCx, taught by Silicone
Valley VCs to help us develop our first version of the financial model.
1. Determining necessary personnel and costs associated with developmental
milestones:

We

created

spreadsheets

for

costs

associated

with

the

employees/consultants we would need to hire over the next three years, the
expenses we expect to incur throughout development and preparing for launch, and
lastly, the fixed assets we would have. On each sheet, we broke down the costs by
business department (i.e., engineering, operations, sales, marketing, consultants,
etc.). I then went through our timeline and expected milestones and attempted to
identify how many employees we would need at each stage and when we would
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need to bring them on, or engage with them if they were consultants. I also went
through our expected milestones to determine what type of activities it would take
to meet each milestone so that we could develop a cost estimate associated with
each milestone. Once I came up with a list of types of employees/consultants I
thought we would need and the activities necessary to meet our milestones, I
presented them to the team and we discussed what I had come up with. We then
went through the list as a team to determine when we would need to hire each
person, how much we think the market salary would be for each position, which
activities would be done in house and which we would hire consultants for, and
how much we thought consultants would cost, and we added our estimates in to the
financial model. We then met with advisors, consultants, manufacturers, and so on
to develop a better understanding of what expenses to expect at each stage, and we
continued to refine our estimates as we talked to more and more people and were
able to get more accurate estimates for each type of activity we would complete or
employee we would hire. Figure 67 is an excerpt from the “heads” sheet of our
financial model, which shows estimates of the type of employees we think we need
to hire, when we expect to hire them, and how much we expect to pay them.

Figure 67: Excerpt from “heads” sheet of financial model, estimating the cost of hiring
new employees.
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Figure 68 (below) is an excerpt from our expenses sheet on the financial model
showing some of the estimates we made regarding engineering activities,
consultants, and SG&A expenses.

Figure 68: Excerpt from “expenses” sheet of financial model, showing estimates made
for expenses related to engineering, consultants, and SG&A.

1. Creating revenue predictions: After refining our expected expenses and costs
associated with our hiring plan, we began creating projections for yearly revenue.
I worked closely with Dr. Xavier Garcia-Rojas, another medical device TMC
Biodesign fellow, to gather information on similar device companies that we could
use as economic proxies to help us predict potential revenues for our target launch
market (ER). For example, we worked very closely with our advisor Dr. Larry
Miller, who developed the EZ-IO, to learn more about how his device gained
traction in the marketplace and what his revenue looked like by its third year of
sales. The EZ-IO device reached approximately 1,000 hospitals by its third year of
sales, capturing approximately 20% of the market. We used this data to help
determine potential adoption rates for our device. However, we felt that the EZ-IO
device was more successful than the average medical device in capturing market
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share, so when estimating our potential adoption rates, we were more conservative.
We conservatively estimated that our product could capture half of what the EZ-IO
device captured by year three (10% market share, 500 hospitals) and decided to set
that as our base projection for market penetration. We then created two more
scenarios for market penetration: a high estimate and a low estimate. We estimated
that our highest possible adoption rate by year three of sales would result in 15%
market penetration, which is still more conservative than the actual adoption rate
for the EZ-IO device, and that a lower than expected adoption rate would lead to
5% market penetration by year three.
We also worked with Dr. Miller and some hospital staff to help determine
the number of units each hospital would need or use. We estimated that an ER
would keep an average of two units on the floor, an OR would potentially have one,
and inpatient floors would have an average of four units. This led us to determine
that the average hospital, using the device for both diagnostic and therapeutic
purposes, would purchase an average of seven units. However, we did not know at
what point we would expand into markets outside of ER, so we did not incorporate
information regarding adoption in those markets in our three-year revenue
projection.
We then used information gathered by talking with Dr. Miller and hospital
staff, as well as information gathered about the frequency of spinal puncture
procedures, to estimate the number of kits an average ER would use each year. We
estimated that the average ER would use approximately 220 kits/year. Therefore,
with an assumed market penetration of 10% (base assumption), and only including
our target market, we calculated that our revenue by year three of sales would be
approximately $33M. See Figure 69 for a breakdown of the calculation for year
three of sales revenue.
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Figure 69: Revenue calculations for year three of sales for the IntuiTap
device in ER market.

We also spoke with advisors and experts to determine how to model our revenue
after year three of sales and how to estimate how our costs would grow as the
company grew so that we would not have to build out a plan for 5–10 years of the
company to the detail we did for the first two years of the company. We also built
in costs associated with our business model, such as distribution cuts and costs to
manufacture the product. Examples of the assumptions we made to generate future
predictions for revenue can be seen in the excerpt from our “yearly revenue” sheet
in Figure 70. It should be noted that the revenue in Figure 70 was calculated
assuming a yearly depreciation in selling price (2.5%) of the reusable and
consumable parts and after removing the commission taken by the distributor.
Therefore, the revenue value is smaller than that calculated using the simple method
explained in Figure 69 (above).
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Figure 70: Excerpt from “yearly revenue” sheet of the financial model.
1. Determining how much to raise: Once we had revenue projections and the costs
associated with our hiring plan and potential expenses, we were able to determine
how much money we should expect to raise in order to reach a point of profitability.
We created a cash flow sheet that used the total expenses for each month and the
revenue generated each month to determine how much money we would have left
at the end of each month. We then used that to determine how much money we
would need each year. In the early stages, before we were generating revenue, this
was simply the sum of expenses. We used the cash flow sheet to determine how
much money we would need each year. We decided that the milestones we sought
to reach after our first round of fundraising (seed round) would be optimizing our
imaging array, conducing human factors and usability testing, filing for a utility
patent, and testing the device on cadavers and, potentially, animals. We decided
that those milestones would be sufficient for us to raise our next round on a higher
valuation without losing too much control of the company. Using our financial
model, we determined that we would need to raise $1M in our seed round, that this
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money would last us a little over one year, and that this would allow us to meet the
previously mentioned milestones. We also used the model to estimate that we
would need to raise a $4M Series A round to take us through the FDA and launch
our product.
After creating a financial model and revenue projections, the pitch deck was
ready for submission for business plan competitions and presentations to potential
investors.
3.3.2: Investors, Accelerators, and Competitions
After creating a complete pitch deck and refining it with the help of our advisors and
mentors, we were ready to submit to accelerators and business plan competitions, and to
present it to potential angel investors. We applied to four startup accelerators, five business
plan competitions, and two angel groups. We performed a comprehensive search of angel
investment groups in the medical device space to determine which groups would
potentially be interested in our device. Before the fellowship ended, we applied to the
Houston Angel Network (HAN) and the Central Texas Angel Network (CTAN), and we
were able to pitch to HAN (CTAN’s initial pitch occurred after the fellowship ended). We
applied to four accelerator programs: TMCx medical device startup accelerator, Medtech
Innovator, Insight Accelerator Labs, and Highway1. We were accepted into every
accelerator we applied to. Lastly, we applied to five business plan competitions: the
Innovation Showcase, the SoGal ventures challenge, 43 North, the James Dyson design
competition, and Tech.Co startup of the year. We noticed that having students on a team
significantly increases the number of business plan competitions that a team can apply for,
as many competitions are geared towards students. After the fellowship, we plan to
continue applying for business plan competitions and applying for grants to supplement
our fundraising efforts with non-dilutive funding.
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CHAPTER 4: DISCUSSION

Considering the difficulty of true innovation and the complexity of the healthcare system,
the medical industry could benefit greatly from a structured framework to guide the
development and innovation process, such as the one presented in this thesis. Utilization
of the methodology presented here could significantly reduce the amount of product
failures in the medical industry and increase the ability to launch new and innovative
products more quickly and effectively, and with greater success. It could also reduce costs
associated with the development process and the time required to get a product to market.
The framework presented in this thesis can significantly mitigate the numerous risks
involved in innovation and product development in the medical industry, and it can also
better prepare innovators to develop a successful company, as evidenced by the results
presented.
The fellowship was successfully launched for the first time in September of 2015
with two teams of fellows, one medical device and one digital health. This thesis focuses
on the framework and fellowship as it is applied to the medical device industry, in addition
to the results of the first medical device team, of which I was a part. The fellowship is
currently in its third year and has graduated two classes of fellows (the third class is
currently in the fellowship). From this, two medical device companies have been
successfully started (i.e., the fellowship has enabled a medical device team to successful
create a product and company each year it has been running).
It was extremely beneficial to have been afforded the opportunity to participate in
the fellowship after being a part of the team that developed the fellowship and framework.
It offered a great deal of insight that could only be gained through participation within it.
It was also helpful for the growth and development of the fellowship to have me participate
during the inaugural year. Getting a program off the ground can be difficult, and it allowed
for more open communication between the fellowship directors and the fellows about what
was and was not working.
I learned a great deal about the comprehensiveness of the fellowship and what about
it enabled success by participating in it and implementing the framework we developed.

154
Through this process, I was able to identify a number of key factors for enabling success
in the program. The most important factors were identifying a real need, having access to
a wide variety of mentors and stakeholders, having a truly cross-functional team, and lastly,
having a team member or fellowship director that can ensure the fellows follow the
framework.
4.1: Identifying the need
After participating in the fellowship, it is very clear that the most critical part of the
program is the needs finding and validation stage. As discussed in the introduction, this
step is often overlooked or rushed, and that significantly contributes to the failure of
medical products. A great deal of our success in the fellowship can be attributed to the fact
that we closely followed the guidelines for needs finding and validation and were able to
identify a real need that stakeholders wanted to be solved. By spending a great deal of our
time at the beginning of the fellowship in clinical immersion, we were able to truly
understand the needs we identified, as well as how they affected the procedure or setting
they were related to.
Needs identification and observation is a skill, and like any other skill, it gets easier
the more frequently it is performed. Having three months set aside specifically for rotations
significantly contributed to our success and allowed us to identify concrete needs. Only
spending a week, or even a month, in clinical rotations results in feeling rushed and
pressured to identify needs quickly, which often leads to identifying general or incremental
needs. We experienced this feeling and saw these results in the needs we identified in our
first few weeks of rotations. While there were a few early needs that made it through to
later stages of screening, the majority of our top needs were identified after a significant
amount of time was spent in clinical rotations. It was clear that the more time we spent in
rotations, the better we became at understanding the needs, how they related to the
procedures, the issues they caused, and whether or not they were being addressed or needed
to be addressed.
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4.2: Mentors and stakeholders
Another critical component for enabling success in the fellowship was our unprecedented
access to mentors and a variety of stakeholders. This factor is very closely related to
successfully implementing the needs identification stage. Without access to dedicated
mentors and a number of different stakeholders, we would not have been able to gain the
deep understanding of the problems we identified, which was necessary for developing a
solution that successfully addressed the need. We also would not have been able to
understand, especially with such depth, the complexities of each stakeholder involved with
the need and how a solution affected each stakeholder differently. Having access to a
variety of stakeholders throughout the fellowship was extremely beneficial from
identifying an important need to developing a solution that successfully met the need and
identifying the value that the solution could bring to each of the different stakeholders.
Additionally, without consistent interaction with clinical and business mentors, in
addition to our deep understanding of the need, we would not have been able to efficiently
generate concepts and iterate on our device. Our ability to frequently interact with key
stakeholders during the different stages of the innovation process enabled us to gather
feedback often and iterate quickly to develop a successful product more efficiently.
4.3: Program director
It is very important to have someone involved in the fellowship who is very familiar with
the framework and can ensure that the fellows stick to the process. Because I helped
develop the framework and possessed a clear understanding of the process and why it is
important, I was able to act as this person on the team. However, we also had two
fellowship directors who helped us stay on track. For other programs looking to implement
this framework in their area, it is important to have a fellowship director or lead mentor.
This person needs to understand the framework and be able to enforce the process during
the fellowship. They are responsible for determining the milestones and timeline and
keeping the fellows accountable for their deliverables. While they should engage with the
fellows frequently, they also need to be able to guide the teams without actively working
on the project. This person can be thought of as a high-level project manager.
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This role is very important, because at times, it can be very challenging to follow
the methods outlined in the framework. My team struggled often with the notion of constant
feedback and failing fast. It is normal to be adverse towards failure and rejection or looking
stupid, and therefore to want to think through an idea in more detail, or to develop a prettier
or better prototype before presenting to a group of experts. Even though we all understood
the importance of gathering feedback frequently at all stages of development, and in fact
had seen the benefits of doing so, we were still often hesitant to gather feedback out of fear
that someone would have negative things to say. It is tempting to ignore negative feedback,
but in our experience, that feedback will typically come back over and over again, and it is
better to address it early rather than push it off in the hopes that it will eventually go away
or that other parts of the product will make up for it. Negative feedback or issues with the
device do not simply go away, and by delaying the gathering of feedback or the addressing
of the issue, this only results in the team having to deal with it in a later stage when it is a
bigger deal. Having someone outside of the team, such as a program manager or director,
to push the team to stick to the process, like gathering feedback consistently and often, for
example, is crucial to enabling success in the fellowship.
One of the main reasons this framework works is because of the constant interaction
and feedback being received by key stakeholders. Without that feedback, understanding,
and interaction, this program would not be successful. So, it is important to make sure that
the fellows are asking the tough questions and listening to the feedback, taking it seriously,
and using it in their evaluation of needs and concepts.
4.4: Team composition
I also found that it is very important to have a truly cross-functional team. The goal of this
fellowship, and the framework implemented within it, is to teach all of the stages of
innovation, from idea to commercialization, in such a way that every type of person
involved in the process (engineers, clinicians, business-minded people, etc.) possesses an
understanding of what it takes to successfully innovate.
It may seem inefficient at times during the fellowship to have only one or two
experts for each stage participating in the entire fellowship rather than segmenting each
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stage and building teams of experts for each part of the process, but that is what enables
this program to be so successful at teaching the innovation process and creating innovators
that can successfully evaluate an idea. Having a truly cross-functional team participate in
this fellowship enables the team to grow together, learn together, and gain a deep
understanding of the process extremely quickly.
By having one person that knew enough about the process at each stage, our team
was able to execute and move through the different stages extremely efficiently. The person
familiar with the stage of development would lead the rest of the team through the
activities. They had enough knowledge to develop a plan for the stage and answer general
questions while still requiring the rest of the team to participate in the activities. For
example, during the concept generation stage, I led brainstorming sessions and helped the
non-engineers on the team to learn about different brainstorming activities, low-fidelity
prototyping, and competitive analyses. In most settings, the engineers would do this stage
by themselves and the clinicians and business people would rarely interact. The way the
fellowship was structured required the fellows with non-engineering backgrounds to
participate in this stage, giving them hands-on experience with design and allowing them
to develop an understanding of the design process very efficiently.
By guiding the team through the stage, the experts were also able to gain valuable
insights and a deeper understanding of the process for themselves. For example, although
I had conducted a number of competitive analyses for projects in undergraduate and
graduate school, having to apply those skills to a real-world application, on a product we
were creating, to solve a need we had spent months validating and that we planned to
actually commercialize, required significantly more detail, and a different perspective, than
projects I had performed these analyses for in the past. This furthered my understanding
and knowledge of the process and skills required.
By having different members of the team take on leadership positions and guide
the team through the different stages of the process while also allowing all team members
to participate in every stage of the process, the fellows were enabled to learn incredibly
quickly and gain insights into each stage of the development process. This is what makes
this fellowship and framework so incredible, and this is what allows it to be successful.
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4.5: IntuiTap now
After the fellowship ended, the inaugural team went on to create a company,
IntuiTap Medical. IntuiTap Medical has now gone on to win five business plan
competitions and has been a finalist in numerous others. It has also raised $2.4M of angel
investments and participated in seven startup accelerators. The company has hired two
additional employees, conducted IRB-approved studies and cadaver studies, and has built
multiple versions of their prototype, approaching a design freeze. IntuiTap has applied for
one utility patent for the design of their device and has additional provisional patents filed.
The device is on track to be FDA cleared by 2019.
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APPENDIX E: RESULTS FROM IRB STUDY

OVERVIEW
Our initial study was designed to explore the feasibility of a new technology aimed at improving spinalneedle placements (i.e. for lumbar punctures, spinal anesthesia, and epidurals). The current method used
for identifying an entry site for proper needle insertion into the spinal canal is very difficult and
inaccurate, particularly in patients with high BMI. Physicians must palpate the lower back and estimate
the location of the vertebral gap. This often requires multiple needle insertion attempts and results in
physician frustration, patient pain, and ER bottleneck.
Our non-invasive, tactile-imaging solution consists of a sensor array, which senses underlying bony
landmarks when placed against the patient’s lower back. This information is presented to physicians as
a real-time pressure map, allowing them to better identify an entry site.
Having tested our system on spine models, we were hoping to evaluate its feasibility (particularly, as a
function of BMI) on human subjects. In doing so, we recruited healthy subjects, over the age of 18, to
undergo three common, non-invasive clinical techniques for spinous process localization (manual
palpation, tactile imaging, and ultrasound).
A ruled tegaderm dressing was used to allow investigators to identify coordinates for each determined
entry site. For each technique, investigators found one gap while being timed, and then went on to find
as many other gaps in the lumbar region as possible.
First, we compared the entry sites identified by a physician using palpation to those identified by a coinvestigator using tactile sensing. We then used ultrasound as the gold standard, to verify the entry site
identified by tactile imaging, and provide true data on underlying landmarks and anatomic
measurements (e.g. depth and midline location).
Additionally, we collected basic subject demographics to provide additional data-points to correlate with
study outcomes (e.g. how technique accuracy compares with BMI or weight status).
Finally, a feedback questionnaire related to the comfort and speed of each technique was administered
to obtain qualitative information on potential patient outcomes related to the localization component of
our device.
RESULTS

Subject demographics
6 males and 9 females took part in this study. The average age was 27, with an average BMI of 24. Figure
1a breaks down subject age and BMI by gender; 1b depicts the breakdown of weight status among
subjects. It should be noted that we did not specify BMI as an in/exclusion criterion for this study; rather,
we anticipated enrolling a range of BMIs, such that we could better extrapolate the results to outcomes
for our target, higher-BMI population.
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a.

b.

Age and BMI with gender

Subject weight status

35
30

Units

25
20

Normal

15

Overweight

10

Obese

5
0
Female

Male

Figure 1. Subject demographics, including a. age and BMI; b. weight status.

Localization time
To evaluate the effects of our technology on localization time, a correlated, one-way ANOVA was
performed. Results demonstrated that the times required for each localization method did not
statistically differ (p = 0.9). Figure 2a depicts the average and standard error for time across techniques;
2b demonstrates the trend in time with increased subject BMI.
a.

b.

Average localization time

Localization time with BMI
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5

0
0

20
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Ultrasound

Tactile

25

30

35

BMI

Figure 2. Localization time, a. mean and standard error; b. trends with BMI.

Interestingly, while the null hypothesis was not rejected in this case, there were some distinguishing
characteristics across methods. Namely, palpation was found to have the greatest variation in localization
time, largely due to its having been most strongly affected by increased BMI. It should be noted that we
did not anticipate providing timesaving value with our localization component; rather, we aim to
indirectly standardize procedure times through a reduction in required needle-insertion attempts, and
with the ease-of-use components of our system.

Midline detection
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To verify that our technology could adequately detect the midline of subjects’ spines, a correlated, oneway ANOVA was performed on the midline coordinates identified by each investigator. Results
demonstrated that the techniques did not statistically differ (p = 0.55) in lateral localization.
As depicted in figure 3a, observations of the mean absolute error with respect to the gold standard—
ultrasound—suggest greater deviations with palpation, as well as larger standard error with that method,
overall. As per figure 3b, initial regression attempts suggest that there may be an inverse correlation
between accuracy and BMI; however, a greater amount of data (particularly for subjects with higher
BMI) will be necessary to lend confidence to this observation.
a.

b.
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Figure 3. Mideline-detection data, showing a. mean absolute error (with standard error); b. trends with BMI.

Gap detection
A critical endpoint of this study was the comparison of our platform to the existing techniques in
identifying insertion sites along the midline. We were able to analyze >2 gaps per subject, given that
investigators were instructed to identify >1 potential sites. Gap locations were sorted and subsequently
matched to identify corresponding sites across methods.
A correlated, one-way ANOVA was performed on all gaps identified by all three investigators (n = 22).
Results suggested that the means across the three techniques statistically differed (p < 0.05); a Tukey HSD
test confirmed that while palpation statistically differed from both ultrasound and tactile sensing, tactile,
there was no significant difference observed between tactile sensing and ultrasound.
Sites were then compared using mean absolute and percent errors. As shown in figure 4a, when
compared to coordinates based on ultrasound, the mean absolute error with tactile sensing was found to
be less than half of that with palpation, falling well within the investigator’s stated experimental error.
Related to this, mean percent error was found to be 6.44% for palpation, versus 1.94% for tactile sensing.
As shown in figure 4b, palpation error was relatively high at all BMIs, but was especially so with
overweight and obese weights statuses.
a.

b.
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Gap-detection error with BMI
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Figure 4. Gap-detection data, showing a. average absolute error; b. trends with BMI.

Feedback
On a more qualitative note, the feedback questionnaires demonstrated that subjects ranked tactilesensing the highest for comfort and overall preference (at nearly 75%); and found both palpation and
tactile-sensing to be quicker than ultrasound. It should be noted that, in going into this study, there was
an understanding that substantial, quantitative value propositions for patients will likely not be achieved
until efficacy testing of the integrated system.
The study also gave us the opportunity to receive additional important feedback on our imaging platform,
user interaction, and algorithms.

Future
At a later stage, we aim to return to the collected ultrasound data, in an effort to improve our needleprojection algorithm. We also hope to use the collected datasets in order to run a usability study with
physicians, to optimize the signal-processing schemes used in visualization (e.g. colors; interpolation), in
an effort to arrive at an ideally readable and intuitive interface. Finally, having considered the output of
this study, we have identified additional metrics that may be important to collect and/or demonstrate in
future clinical studies (e.g. patient positioning).

